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ABSTRACT 
ABSTRACT (english)  
Preclinical tools in PET-tracer development: 
Automatisation and biopharmaceutical evaluation with special 
emphasis on the adenosine A3 receptor 
Positron Emission Tomography (PET) is the first choice technology for the visualization and 
quantification of receptors and transporters, enabling examination of e.g. neurological, 
psychiatric and oncological diseases on a molecular level. Therefore, new and innovative 
PET-radiopharmaceuticals need to be developed to get further insights into the biochemical 
mechanisms involved in pathological changes. PET-tracer development starts with the idea 
or modelling of the chemical structure of a (new) molecule with (hopefully) good binding 
characteristics to the desired target site. As next steps, the compound needs to be 
synthesized and radiolabelled with a suitable PET-nuclide. Then it has to be evaluated 
regarding its parameters in various preclinical experimental settings. Hence, two major tools 
are crucial in the development-process of new PET-tracers:  
1) a fast and reliable production method –most desirable and optimal in an automated set-
up, and 
2) proof of tracer suitability (high affinity, high selectivity and specificity, beside low 
unspecific binding) through preclinical evaluation in an animal model, prior to human 
application.  
Both aspects, the radiochemical preparation and automatisation, as well as the 
biopharmaceutical evaluation are presented in the thesis in 5 different manuscripts. In 
detail, the development and preclinical evaluation of 4 different PET-tracers ([11C]DASB, 
[18F]FE@SUPPY, [18F]FE@SUPPY:2, and [18F]FE@CIT) for 3 targets, the serotonin transporter 
(SERT), the adenosine A3 receptor (A3R) and the dopamine transporter (DAT), respectively, 
are covered in the present thesis.  
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The first manuscript presents a method for a fast, reliable and fully-automated 
radiosynthesis of [11C]DASB (a tracer for the imaging of the SERT in human brain in e.g. 
depression patients) will facilitate further clinical investigations (e.g. for the department of 
psychiatry and psychotherapy of the medical university of Vienna) with this tracer.  
[18F]FE@SUPPY was introduced as the first A3R PET-tracer recently. The adenosine A3 
receptor is expressed in high levels in tumor cells, but not in the majority of normal cells. 
Potential application of a tracer for the A3R will be inflammation processes, oncological 
diseases as solid tumors; breast-, colon-, lung-, pancreas-, prostate-, melanoma- and brain 
metastases, as well as ischemia (brain and heart) and neurological pathologies as glaucoma 
and epilepsy.  
[18F]FE@SUPPY:2, a completely new potential 18F-fluoroethylated radiotracer for the A3R, is 
presented in the thesis. The thesis covers the radiochemical preparation of [18F]FE@SUPPY:2 
and the automation of the radiosyntheses of both radiotracers in manuscript 2 and 3. 
Moreover, preclinical evaluations (affinity, selectivity, unspecific binding, biodistribution, 
logP, autoradiography and in-vitro and ex-vivo metabolic stability) of the two tracers were 
conducted, and also a comparison of these parameters are given in manuscripts 3 and 4. 
[18F]FE@CIT, a potential new tracer for imaging of the DAT for e.g. Parkinson patients, was 
successfully further evaluated in terms of metabolic stability against CES and 
autoradiographic distribution on rat brain slices. The high selectivity of [18F]FE@CIT over 
SERT and NET was confirmed in this study, and furthermore, it was even significantly higher 
than the selectivity of the well known tracers [123I]ß-CIT and [123I]FP-CIT. Based on these 
results, we aim for the future diagnostic application of [18F]FE@CIT in humans with 
neurological and psychiatric diseases caused by changes in the dopaminergic system (e.g. 
Parkinson’s disease, depression, drug abuse). 
 
This project was partly sponsored by the Austrian Academy of Sciences (DOC-fFORTE Nr. 
22347) awarded to D. Haeusler and by the Austrian Science Fund (FWF P19383-B09) 
awarded to M. Mitterhauser. 
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ABSTRACT (deutsch)  
Präklinische Aspekte in der Entwicklung von PET-Tracern: 
Automatisierung und biopharmazeutische Evaluierung mit 
Schwerpunkt auf dem Adenosin A3 Rezeptor 
PET (Positronen Emmissions Tomographie) ist eine innovative Technik zur Visualisierung und 
Quantifizierung von Rezeptoren und Transportern in-vivo und erlaubt dadurch die 
Untersuchung von z.B. neurologischen, psychiatrischen und onkologischen Erkrankungen auf 
molekularem Level. Daher ist es notwendig, (neue) PET-Radiopharmaka zu entwickeln, um 
nähere Einblicke in die biochemischen Mechanismen pathologischer Veränderungen zu 
bekommen. Die Entwicklung eines PET-Tracers beginnt mit der Idee für ein Molekül mit 
geeigneter chemischer Struktur und mit guten Bindungseigenschaften zum gewünschten 
Target. Wenn das Molekül diese Voraussetzungen erfüllt, wird es synthetisiert, und mit 
einem PET-Nuklid radioaktiv markiert. Dann folgen verschiedene Untersuchungen zur 
Evaluierung der präklinischen Parameter des Radiopharmakons. Zwei Hauptaspekte im 
Entwicklungsprozess von neuen Radiopharmaka sind: 
1) eine einfache und verlässliche Produktionsmethode für den PET-Tracer -im Optimalfall 
automatisiert- als Voraussetzung für alle weiteren Schritte 
2) die präklinischen Evaluierungsparameter des Tracers zur Untersuchung auf dessen 
Eignung für eine gewünschte humane Applikation in der Zukunft. 
Beide Aspekte, die radiochemische Herstellung bzw. Automatisierung und die 
biopharmazeutische Evaluierung, werden im Rahmen von 5 verschiedenen Studien in dieser 
Doktorarbeit präsentiert. Die Entwicklung und präklinische Evaluierung von 4 verschiedenen 
PET-Tracern ([11C]DASB, [18F]FE@SUPPY, [18F]FE@SUPPY:2, und [18F]FE@CIT) für 3 
unterschiedeliche Zielregionen: den Serontonintransporter (SERT), den Adenosin A3 
Rezeptor (A3R) und den Dopamintransporter (DAT), sind wie folgt beschrieben:  
Die erste Studie präsentiert eine schnelle und voll-automatisierte Methode, die die 
verlässliche radiochemische Herstellung von [11C]DASB (ein Tracer für das Imaging des SERT 
z.B. bei Depressionspatienten) für klinische Untersuchungen (z.B. für die Universitätsklinik 
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für Psychiatrie, Arbeitsgruppe Neuroimaging, der MedUni Wien) mit diesem Tracer in 
Zukunft vereinfachen wird. 
[18F]FE@SUPPY wurde kürzlich von der Arbeitsgruppe Radiopharmazeutische 
Wissenschaften als der erste PET-Tracer für den A3R vorgestellt. Der Adenosin A3 Rezeptor, 
der erst vor kurzem entdeckt worden ist, wird besonders hoch in verschiedenen 
pathologischen Prozessen, jedoch fast nicht in Zellen von gesunden Geweben exprimiert. 
Mögliche Einsatzgebiete von Tracern des A3R umfassen somit Entzündungsprozesse, 
onkologische Gegebenheiten wie solide Tumore und Brust-, Dickdarm-, Lungen-, Pankreas-, 
Prostata-, Melanom- und Hirnmetastasen; Herzkrankheiten wie Ischämie, und neurologische 
Erkrankungen wie zerebrale Ischämie, Glaukom und Epilepsie.  
[18F]FE@SUPPY:2 ist ein ganz neues 18F-radiomarkiertes Molekül, das als zusätzlicher 
potentieller Radiotracer für den A3R im Rahmen der These vorgestellt wird.  In der Arbeit (in 
den Manuskripten 2 & 3) ist sowohl die radiochemische Herstellung von [18F]FE@SUPPY:2, 
die Optimierung der Radiosynthese von [18F]FE@SUPPY, und die Automatisierung von 
beiden A3R-Tracern enthalten. Weiters werden auch die präklinischen Parameter wie 
Affinität, Selektivität, unspezifische Bindung, Biodistribution, logP, Autoradiographien, in-
vitro und ex-vivo Metabolitenstudien dieser neuen Radiopharmaka in der Arbeit 
(Manuskripten 3 und 4) untersucht.  
Der Tracer [18F]FE@CIT (ein potentieller Tracer für den DAT zum Imaging von z.B. Parkinson) 
wurde erfolgreich bezüglich seiner metabolischen Stabilität und autaradiographischen 
Verteilung in einem Tiermodell im Rahmen der fünften Studie evaluiert. Die hohe Selektivität 
von [18F]FE@CIT gegenüber dem SERT und dem NET (Norepinephrintransporter) konnte 
bewiesen werden und war sogar signifikant höher als die Selektivität der etablierten 
Radiopharmaka  [123I]ß-CIT and [123I]FP-CIT. Basierend auf diesen Daten, soll [18F]FE@CIT in 
Zukunft zur Diagnose von neurologischen und psychiatrischen Erkrankungen des Menschen 
(z.B. Parkinson, Depression, Drogenmissbrauch, etc.) angewendet werden. 
 
Dieses Projekt wurde teilweise von der Österreichischen Akademie der Wissenschaften (ÖAW: DOC-fFORTE Nr. 
22347 von D. Häusler) und dem Österreichischen Wissenschaftsfonds (FWF: P19383-B09 von M. Mitterhauser) 
gesponsert. 
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1. INTRODUCTION 
 
1.1. RECEPTOR AND TRANSPORTER 
TARGETS 
 
1.1.1. GENERAL ON ADENOSINE AND ITS RECEPTORS 
Adenosine is an ubiquitous nucleoside consisting of the purinebase adenine and the 
monosaccharide ß-D-ribose (see figure 1). It is an essential component of biological 
molecules, as for example NAD+, ATP, ADP, AMP, cAMP, Coenzyme A and nucleic acids. 
Therefore, adenosine and these related compounds are important for the regulation of 
many aspects of cellular metabolism and energy supply1. 
 
Figure 1: Chemical structure of adenosine 
Adenosine is present in all cells and body fluids and acts on four well defined receptors, 
called A1, A2A, A2B and A3, respectively (A1R, A2AR, A2B, A3R). These receptors differ in their 
affinity concerning adenosine, their tissure distribution and their pharmacological skills. 
Adenosine itself displays high affinity towards the A1 and A2A recptors (Ki=10-30nM), 
whereas it shows only low affinity towards the A2B and A3 receptors (Ki=~1µM)
2.  
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The adenosine receptors belong to the superfamily of G protein-coupled receptors (GPCR´s), 
and are located at the surface of the external cell membrane. As stated by Susan R. George 
in 2004, “GPCR´s are the largest family of cell-surface receptors, and transduce their signals 
mediated by a diverse range of signalling molecules, including ions, biogenic amines, 
peptides and lipids, as well as photons, to mediate alterations of intracellular function”3.  
 
SIGNALTRANSDUCTION  
Generally, GPCR´s can be divided into different families based on their structural and genetic 
characteristics. The adenosine receptors belong to the family 1, the largest subgroup within 
the GPCR´s, also called rhodopsin-like family.  
GPCR´s induce their signals according to different G proteins, Gs (stimulates the 
adenylatcyclasis), Gi (inhibits the adenylatcyclasis), Gq (activates the phospholipase C) and 
G12/13 (influences ionchannels e.g. of Cl
-), respectively4. Signaltransduction of GPCRs can be 
very complex; as shown in figure 2.  
 
 
Figure 2: Signaltransduction pathways of GPCRs  
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All four adenosine receptors are monomeric proteins with seven transmembrane domains 
(see figure 3) and alpha helical secondary structure with approximately 21-28 amino acids in 
each. The extracellular domains of the receptor proteins comprise the N-terminus and three 
extra-cellular loops. The intracellular domains of the receptor proteins comprise a C-
terminus with a palmitoylation site near the C-terminus (except of the A2A subtype) and 
three intracellular loops5. 
 
Figure 3: Typical scheme of a GPCR with 7 transmembrane domains 6 
As shown in figure 4, activation of the Gi proteins via A1 and A3 receptors causes classical 
second-messenger pathways, such as inhibition of adenylatecyclase, resulting in inhibition of 
neurotransmission. Activation of the Gs proteins via A2A and A2B receptors causes stimulation 
of adenylatecyclase activity, resulting in the stimulation of neurotransmission.  
 
 
 
 
 
 
 
 
Figure 4: Scheme of the 4 adenosine receptor subtypes (A1, A2A, A2B, A3) 
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The two main sources of extracellular adenosine are its transport from the intracellular 
compartment via the equilibrative nucleoside transporter (ENT) and the extracellular 
conversion of adenosine triphosphate (ATP) by action of ectonucleotidases (EctoN) (see 
figure 5)7.  
 
Figure 5: Main features of adenosine signalling in the CNS 
 
CLONING AND CLASSIFICATION OF THE ADENOSINE RECEPTORS  
So far, all four adenosine subtypes, have been cloned from several mammalian species -
including human- and some non-mammalian species (see figure 6)8.  
 
Figure 6: Subtype based structural sequence similarity between cloned adenosine receptors8 
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As shown in the dendrogram in figure 6, in mammals, there is a very close similarity in 
structure between the adenosine receptors within each sub-type. Only the adenosine A3 
receptor showed a large variability between the species: there is almost 30% difference of 
the amino acid level between the human and the rabbit A3R. This difference is in fact larger 
than the one between human and chick for the A1 subtype
8. Furthermore, there is also a 
large difference between A3 receptors from different species with regard to ligand 
specificity9. Even the distribution of the A3 subtype is different in man and rodents
10.  
 
The concept of the nomenclature and classification as “adenosine receptors” precedes the 
later concept of purinoceptors11,12 by Burnstock in 1978 (see figure 7). As stated and 
recommended by the NC-IUPHAR (=International Union of Basic and Clinical Pharmacology 
Committee on Receptor Nomenclature and Drug Classification) subcommittee on adenosine 
receptors, these receptors are nowadays named after their unique physiological ligand and 
agonist adenosine13.  
 
 
Figure 7: Classification of the nucleoside and nucleotide receptors by G. Burnstock  
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PHARMACOLOGICAL AND CLINICAL RELEVANCE 
Adenosine, although often referred to as a neurotransmitter, is not a classical 
neurotransmitter, because it is not principally produced and released vesicularly in response 
of neuronal firing. Generally, it modulates many important physiologic functions within the 
human body, involving the heart14 and the cardiovascular system, brain15, kidneys, 
gastrointestinal-tract, lungs, inflammation and the immune system16.  
Adenosine can be found in basal levels of 100nM in the heart and of 20nM in the brain, 
whereas in severe ischemic stress situations it can rise to levels of a micromolar range. In 
detail, adenosine acts as a cytoprotective modulator in response to stress in organs or 
tissues, both under physiological and pathophysiological conditions17:  
it increases the blood supply (e.g. by vasodilatation and angiogenesis), contributes to 
ischemic preconditioning (in the heart, brain and skeletal muscle) and suppresses 
inflammation (through activation and infiltration of inflammatory cells and furthermore 
through production of cytokines and free radicals). As a consequence, it promotes wound 
healing and protects tissues against ischemic damage. Moreover, it suppresses cytotoxic 
processes and acts as a local modulator of other neurotransmitters as glutamate and 
dopamine. Interestingly, the stimulating effect of the methylxanthine caffeine, which is the 
most widely used psychoactive drug in the world, is mainly due to its activity as an 
adenosine receptor antagonist18 (see figure 8). 
 
 
 
 
 
 
 
 
Figure 8: Stimulating effect of caffeine19 
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All in all, adenosine is involved in many different functions of the nervous system, e.g. it acts 
as an endogenous anticonvulsant, neuroprotectant and sleep-inducing factor. Adenosine is 
therefore one of the most important neuromodulators in the central and peripheral nervous 
system20. Therefore, therapeutic applications, both, in the central nervous system and in the 
periphery, are being explored for selective and affine adenosine receptor ligands.  
The clinical relevance of adenosine receptor agonists and antagonists, which were already 
tested in humans in clinical trails, are given in the following section17: 
Agonists for the A1R were tested in humans for cardiac arrhythmias, type 2 diabetes and 
angina. Antagonists of this subtype were tested in clinical trials for acute decompensated 
heart failure with renal impairment, cystic fibrosis and asthma. Positron emission 
tomography (PET)-ligands ([18F]CPFPX and [11C]MPDX) for the A1R are used for brain 
visualization to gain insights into sleeping disorders and neurodegenerative disorders as 
Parkinsons disease (PD). Agonists for the A2AR were tested in clinical trials for myocardial 
perfusion imaging and wound healing; antagonists are in phase 2 testing for PD. PET-ligands 
for the visualization of the A2A receptors in brain ([
11C]TMSX and [11C]KW-6002) were used to 
gain insights in PD, psychiatric disorders and (maybe) drug addiction. An antagonist for the 
A2BR was tested in humans with asthma. A3R agonists were in clinical trials for rheumatoid 
arthritis, dry eye syndrome, psoriasis, liver cancer, hepatitis and liver regeneration. A3R 
antagonists were tested for glaucoma treatment, cancer, stroke and inflammation. Some 
A3R antagonists are in biological testing as therapeutic targets for asthma, COPD, glaucoma, 
cancer and stroke treatment. The first PET-ligand of the A3R ([18F]FE@SUPPY) will be 
presented more detailed in the following chapter and in the scientific topic section in paper 
2, 3 and 4. Adenosine itself, which is quite short-lived in circulation, is used in clinical 
treatment of paroxysmal supraventricular tachycardia and in radionuclide myocardial 
perfusion imaging21. 
Figure 9 summarizes the most important –so far known- pharmacological effects of the 4 
adenosine receptor subtypes in the human body.  
In conclusion, adenosine receptors are widespread on virtually every organ and tissue and 
according to all the mentioned actions of them, they represent promising drug targets for 
pharmacological intervention in many patho-physiological conditions that are believed to be 
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associated with changes of adenosine levels such as asthma, neurodegenerative disorders, 
psychosis and anxiety, chronic inflammatory diseases, and cancer22.  
This short overview shows the need for suitable pharmacological substances for the further 
exploration in the field of adenosine and its receptors.  
 
Figure 9: Overview over the pharmacological relevance of the adenosine receptors22. 
K.A. Jacobson stated pointedly “It is hoped that new agents in development will avoid the 
undesirable sideffects that have impeded the clinical development of adenosine receptor 
ligands in the past. Selective agonists are well advanced in clinical trials for the treatment of 
atrial fibrillation, pain, neuropathy, pulmonary and other inflammatory conditions, and 
cancer. Selective antagonists have entered clinical trials for the treatment of Parkinson´s 
disease and congestive heart failure. Both, in the case of diseases such as stroke, where 
there is an unmet need, and for diseases that already have pharmacological intervention 
options, the introduction of adenosine-based drug therapy will provide novel mechanisms 
for therapy”22.  
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1.1.2. ADENOSINE A3 RECEPTOR 
 
CLONING, DISTRIBUTION AND GENOMIC STRUCTURE  
The adenosine A1 and A2A receptors have been known for a very long time, whereas the 
adenosine A3 receptor was discovered recently. It was originally isolated as an orphan 
receptor from rat testis in 199123. Further clones were obtained from rat striata, sheep 
hypophysial pars tuberalis and human striatum and heart24,25,26. cDNA sequences of the 
other adenosine receptor subtypes are highly similar between rat and human. As mentioned 
before, the A3R shows large interspecies differences in its structure. Rat A3Rs reveal only 
72% sequence homology with that of human and sheep. Interestingly, between sheep and 
human there is 85% homology. Therefore, different pharmacological profiles, especially in 
antagonist binding have to be expected and kept in mind. Furthermore, peripheral A3R 
mRNA expression is similar between human and sheep, but not between human and rat. 
Generally, A3 receptors have been identified and sequenced in testes, brain, lung, liver, 
kidney, and heart of various species, including mouse, rat and human27.  
In detail, distribution patterns of the A3R mRNA were found as following: in rat (testes, lung, 
kidneys, heart and brain), sheep (lung, spleen, pars tuberalis, pineal gland) and human (high 
amounts in lung and liver, moderate amounts in heart, kidney, placenta and brain). 
The gene which encodes the human A3 subtype is called ADORA3 and is located on the 
chromosome 1 in the location 1p13.327,28 (see figures 10 and 11) and constists of 318 amino 
acid residues. The genomic structure seems to be similar for all human adenosine receptors. 
 
Figure 10: Genomic regions of the human A3 receptor: Homo sapiens chromosome 1, GRCh37 
primary reference assembly29 
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Figure 11: Genetic linkage map of part of human chromosome 1p from 8 to 17 cM distal from 
centromere27  
 
PHARMACOLOGICAL AND THERAPEUTIC RELEVANCE 
Signalling pathways of the A3R include, for example, inhibition of adenylatsyclasis and PKA, 
and, stimulation of PLC, IP3, Ca
++, KATP (heart), RhoA, PLD, MAK-activity, ERK1/2. Therefore, it 
is important to be aware of the fact, that several intracellular mechanisms are involved in 
the A3R stimulation, which is important for explaining all the different aspects of its actions 
and functions: 
The A3R is highly expressed on the cell surface of tumor cells30, 31, 32, 33, 34, 35 and in human 
enteric neurons36, but not in the majority of normal tissues37. In addition, A3R protein 
expression was studied in fresh tumors and was correlated with that of the adjacent normal 
tissue. The authors concluded, that primary and metastatic tumor tissues highly express A3R 
indicating that high receptor expression is a characteristic of solid tumors. These findings 
suggest the A3R as a potential target for tumor growth inhibition and imaging.  
The A3Rs are known to be involved in many other diseases, such as cardiac38 and cerebral 
ischemia39, glaucoma40, stroke41 and epilepsy42. Western blot analysis showed that A3 
receptors are present in rat hippocampal nerve terminal membranes43 and it has been 
shown, that the A3R plays a role in the brain neurotransmitter system by directly influencing 
for instance serotonin44, 45, 46, dopamine47 or glutamate48.  
Furthermore, the A3R plays a critical role in the modulation of inflammatory and 
autoimmune pathologies. At the present, A3R compounds are used in brain and heart 
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ischemia, asthma, sepsis, glaucoma and rheumatoid arthritis. An overview of the various 
different roles of the A3R in the human body is given in figure 12.  
 
Figure 12: Synopsis of the different actions of the A3R in the human body 
In conclusion, molecular in-vivo visualization and quantification of the A3R in the human 
brain, as well as in periphery, would be very attractive and important according to all the 
above mentioned roles of the A3R in disease conditions and its therapeutic potential.  
Interestingly, some A3R antagonists have been patented concerning tumor growth, 
treatment of cardiac hypoxia, allergic diseases, cerebral ischemia, cancers with high 
concentrations of the A3R. Other papants concern their use for cognitive disorders, multiple 
sclerosis, neurodegeneration, PD, stroke, traumatic brain injury, asthma, COPD, glaucoma 
and arthritis49. 
 
RADIOLABELLED LIGANDS FOR THE A3R 
Although the number of synthesized A3R ligands, both, agonists and antagonists with 
different pharmacological characteristics is increasing, the availability of highly potent and 
selective ligands is not yet satisfactory. In addition, regarding radiolabelled ligands for the 
A3R, there is still a great need for further investigations.  
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Radiolabelled agonists for the A3R 
The main number of agonist radioligands for the adenosine A3 receptors are tritiated 
compounds, which are used for preclinical testings in cell-lines or animal models. The two 
commercially available agonist radioligands for the A3R are [3H]-NECA and [125I]AB-MECA. 
[3H]-NECA is quite unspecific and only useful if no other subtypes of the adenosine receptors 
are present. The second radiolabeled agonist, [125I]AB-MECA, displays high affinity towards 
the A3R and its high specific radioactivity allows the detection of even low levels of the 
adenosine A3 receptors. However, the latter mentioned radioligand displays also significant 
affninity at the adenosine A1 receptors
50, which makes it only useful for imaging of the A3 
receptor in experiments when the other subtypes (especially the A1) are blocked or not 
available. 
Radiolabelled antagonists for the A3R 
The advantage of antagonist radioligands over agonist radioligands is, that they label all 
receptors present in the cell membrane, independently of the activation state and the 
coupling to G-proteins. Therefore, they are preferable for the use of the determination of 
receptor density and other information about the target receptor. One major drawback 
concerning most of the so far available and developed antagonists for the adenosine A3 
receptors is their high lipophilicity and, thus, tendency for nonspecific binding. Natural 
antagonists such as the methylxanthines caffeine and theophylline show generally low 
affnitiy for the A3 subtype. Concerning the chemistry of A3R antagonists, xanthines, 1,4-
dihydropyridines, pyridines, pyrazolo-triazolo-pyrimidines, isoquinoline and quinazoline urea 
analogues have been developed. For a long time, there was no antagonist radioligand 
available for the A3R at all. In 2000, the compound MRE3008F20 was introduced as a 
tritiated compound51.  
The Jacobson group published a series of A3R antagonists52, one amongst them was 
compound Nr. 7, displaying high affinity (Ki=4.2nM) and selectivity (rA1/hA3= 2700) towards 
the human A3R. Since this compound comprised a fluoroethylester function, it was obvious 
that our group chose this compound for radiolabelling with F-18. Hence, in 2008, the first 
PET-tracer for the A3R, [18F]FE@SUPPY, was introduced by our group53. 
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In the meantime, [76Br]-4´truncated nucleoside compounds were developed as A3R PET-
tracers by Dale Kisewetter and his coworkers. Compound Nr. 4 (MRS 3581) was introduced 
as an A3R agonist and compound Nr. 6 (MRS 5147) was introduced as an A3R antagonist. 
Binding studies were conducted, and, as the authors state, 60-70% of total binding was A3 
specific. Furthermore, in-vitro metabolism in hepatocytes, in vitro tissue binding (on rat 
brain and testis slices) and biodistribution in rats has been conducted.  
 
[18F]FE@SUPPY 
[18F]FE@SUPPY, (5-(2-[18F]fluoroethyl)2,4-diethyl-3-(ethylsulfanylcarbonyl)-6-phenylpyridine-
5-carboxylate), is a pentasubstituted pyridine-derivative comprising two ester functions (one 
carboxylic and one thiocarboxylic), with the F-18 label on the carboxylic ester function (see 
figure 13).  
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Figure 13: Chemical structure of [18F]FE@SUPPY 
Since, the radiochemical preparation of [18F]FE@SUPPY was introduced in 2008, first 
bioevaluation studies have been conducted with this molecule54. Prior to the potential 
future application of [18F]FE@SUPPY in humans, further preclinical evaluations have to be 
performed to prove tracer safety. Moreover, the automatisation of the radiochemical 
preparation, to guarantee routine preparation of this tracer for these evaluations was 
conducted. Both, the automation and further preclinical evaluations are presented in detail 
in the papers 3 and 4 in the scientific topic section. 
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[18F]FE@SUPPY:2  
Based on the high affinity of [18F]FE@SUPPY for the A3R, and the knowledge, that 
pharmaceuticals often improve their chemical characteristics through allosteric changes, we 
developed the counterpart [18F]FE@SUPPY:2 (5-ethyl 2,4-diethyl-3-((2-
[18F]flourethyl)sulfanylcarbonyl)-6-phenylpyridine-5-carboxylate) as an additional potential 
ligand for the A3R. [18F]FE@SUPPY:2 is a pyridine-derivative with the F-18 label on the 
thioester moiety (see figure 14), and should also display characteristics as an A3R antagonist. 
It could therefore display a comparable or even improved affinity, blood-brain-barrier 
permeability, selectivity and/or stability. 
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Figure 14: Chemical structure of [18F]FE@SUPPY:2 
The radiosynthesis of [18F]FE@SUPPY:2 is described in detail in paper 2, and the 
automatisation of the radiochemical preparation is presented in paper 3 in the specific topic 
section. Results concerning first preclinical evaluations of [18F]FE@SUPPY:2 are given in 
papers 3 and 4.  
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1.1.3. DOPAMINE TRANSPORTER  
 
GENERAL 
Dopamine (see figure 15) is biosynthesized from tyrosine with the rate-limiting step, being 
catalysed by tyrosine hydroxylase. Then, it is packaged into synaptic vesicels, and released 
into the synaptic space on nerve firing. There, it can activate postsynaptic receptors (D1-5) or 
presynaptic dopamine autoreceptors. Dopamine receptors are GPCR´s that either increase 
(D1, D5) or inhibit (D2,3,4) the activity of adenylyl cyclase. The dopamine transporter (DAT) 
regulates the dopamine concentration in the synaptic cleft through reuptake of dopamine 
into presynaptic neurons. Therefore, it plays a central role in the spatial and temporal 
buffering of the released dopamine. 
 
Figure 15: Chemical structure of dopamine 
The DAT was first described more than 30 years ago, and is composed of 12 transmembrane 
spanning regions with the carboxyl and amino termini residing intracellularly (see figure 16). 
The gene of the human DAT is located on chromosome 5 at the region 5p15.3. The DAT 
belongs to the neurotransmitter/sodium symporter family (NSS, solute carrier 6) together 
with the closely related monoamine transporters SERT (serotonin transporter) and NET 
(norepinephrin transporter)55. The DAT is located on the plasma membrane of nerve 
terminals in a small number of neurons in the brain, especially in the axonal membranes of 
nigrostriatal dopaminergic neurons and nucleus accumbens, but can also be found in the 
globus pallidus, cingulate cortex, olfactory tubercle, amygdale and midbrain.  
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Figure 16: schematic representation of the human dopamine transporter55 
Physiologically, the DAT displays vital influence on dopamine function by modulating 
locomotor activity, cognition and the reward system. From a pharmacological point of view, 
is serves as a binding site of stimulants and drugs (e.g. amphetamine and cocaine). Hence, 
the density of this transporter can be used as a marker for dopamine terminal innervation56.  
In contrast to the early developing status of the A3R-concept, great efforts have been taken 
over the past decades, towards the investigation of suitable DAT imaging agents and 
radiotracers:  
Quantitative neuroimaging of the dopamine transporter is a state-of-the-art method to 
evaluate changes of presynaptic DAT expression and occupancy in neurological and 
psychiatric diseases using SPECT or PET. Striatal dopamine transporter density is frequently 
used as a specific marker of dopaminergic degeneration in patients suffering from 
Parkinson’s disease57,58,59. Changes of DAT binding potential have been found in depression 
60 and drug abuse including cocaine61,62,63,64, alcohol65 and methylphenidate66. Therefore, the 
measurement of DAT binding potential has been used in various fields of drug research67,68. 
In addition, alterations of the DAT can be associated with neurodegenerative and 
neuropsychiatric disorders, including attention deficit-hyperactivity disorder, Huntington´s 
chorea and schizophrenia. Therefore, the development and evaluation of ameliorated DAT 
ligands is of great practical relevance for neuroimaging of neurological and psychiatric 
disorders.  
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[18F]FE@CIT 
Radiolabelled cocaine analogues based on ß-CIT have proven undisputable for the imaging of 
the dopamine transporter69,70,71,72,73,74,75. Among these, the so called WIN-compounds 
exhibit a 2-200-fold higher affinity for the DAT than cocaine. Some of these compounds have 
been labeled with carbon-11 or fluorine-18, and were used for positron emission 
tomography. However, further improvements in their pharmacodynamic and 
pharmacokinetic features were aimed for. An important improvement, yielding in a 1.5 
times higher affinity to the dopamine transporter, a 10 fold increased selectivity DAT over 
SERT and a 59 times increased selectivity DAT over NET72, was achieved by a simple 
replacement of the carboxylic methyl ester group in ß-CIT by a fluoroethyl ester73.  
Looking at the metabolic pattern of ß-CIT and methylester-analogues, enzymatic ester 
cleavage appears to be the major degradation route76,77,78. There is evidence for a higher 
metabolic stability of esters when the alkyl-rest was replaced by a fluoroalkyl-chain79,80. 
Furthermore, ester cleavage results in a non-radioactive tropane acid compound and 2-
[18F]fluoroethanol as the only labelled metabolite, which is washed out of the brain and 
cleared hepatobiliary. Therefore, no disturbing interaction of radioactive metabolites is 
concluded in neuroimaging with the compound called [18F]FE@CIT (2-[18F]fluoroethyl 3ß-(4-
iodophenyl)tropane 2ß-carboxylate) (see figure 17).  
The successful radiochemical preparation and biodistribution of this tracer was presented by 
our group in 200581. Since the results of the first studies with this tracer were successfull and 
promising, further evaluations were performed, and will be given in detail in paper 5 in the 
scientific topic section. 
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Figure 17: Chemical structure of [18F]FE@CIT 
A further cocaine-derivative, N-(3-iodopro-2E-enyl)-2-beta-carbomethoxy-3beta-(4`-
methylphenyl)nortropane (PE2I) has been proved to be a very potent radiopharmaceutical 
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to image the DAT. Therefore, this compound has been labelled with iodine -123 or -125, as 
well as with tritium and carbon-1182. DAT radiotracers, which are already widely used in 
humans, (some of them even have reached phase III or IV of clinical applications), are 
[11C]cocaine, [123I]ß-CIT, [123I]FE-CIT, [123I]/[18F]/[11C]FP-CIT, [18F]/[11C]CFT, 
[123I]/[11C]altropane, [123I]/[11C]PE2I, [11C]methylphenidate and [99mTc]TRODAT-183,84. A 
recently presented compound [123I]-4-(2-(bis(4-fluorophenyl)methoxy)ethyl)-1-(4-
iodobenzyl)piperidine proved selective for imaging the DAT, but didn´t show sufficient brain 
uptake in rats due to P-gp washout, and is therefore not suitbable for in vivo DAT imaging85.  
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1.1.4. SEROTONIN TRANSPORTER 
 
GENERAL 
Serotonin (5-hydroxy-tryptamine, 5-HT, see figure 18) is an important modulatory 
neurotransmitter, and, although only about 1% of the body's serotonin is localized in the 
brain, serotonin has profound effects on brain function.  
 
Figure 18: Chemical structure of serotonin 
Despite serotonin's effects are complex and yet incompletely understood, alterations of the 
serotonergic expression have been frequently shown in psychiatric and neurological diseases 
such as depression, anxiety disorders, attention deficit hyperactivity disorder (ADHD), 
Alzheimer’s disease (AD) and epilepsy. Following the release of 5-HT, a portion is re-uptaken 
by the presynaptic serotonergic neuron in a manner similar to that of the reuptake of 
dopamine or norepinephrine: it makes use of a specific transporter protein, called serotonin 
transporter (SERT, 5-HTT). The function of serotonin is exerted upon its interaction with 
specific receptors. More than 20 serotonin receptor subtypes have been identified as 5HT
1A
-
5HT
7. 
Most of these receptors are coupled to G-proteins that affect the activities of either 
adenylate cyclase or phospholipase C, while the 5HT
3 
belongs to the class of ion-channels. 
Some serotonin receptors are predominantly expressed presynaptically and others 
postsynaptically86.  
The serotonin transporter is a monoamine transporter protein with 12 transmembrane 
segments, 5 extracellular and 5 intracellular loops. As evident from figure 19, both, the 
amino, and the carboxyterminal tail are located intracellularly.  
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Figure 19: Schematic picture of the SERT protein87. 
The serotonergic neurotransmission is mainly regulated by the major inhibitory (5-HT1A) and 
excitatory (5-HT2A) serotonergic receptor subtypes and the serotonin transporter, which 
transports the neurotransmitter serotonin from synaptic spaces into presynaptic neurons. 
The transport of serotonin terminates the action of serotonin and recycles it in a sodium 
dependant manner.  
The gene that encodes the serotonin transporter (see figure 20) is called solute carrier family 
6 member 4 (SLC6A4). In humans, this gene is located on chromosome 17 in the area 
17q11.1-q12. The structure of the SLC6A4 gene includes the sites of the major functional 
variants: the serotonin-transporter-gene-linked polymorphic region (5-HTTLPR), the variable 
number of tandem repeats (VNTR) (between 9 and 12 repeats can be found in intron 2 
(STin2)) and the single nucleotide polymorphisms (SNPs).  
 
 
 
 
 
 
Figure 20:  Organization of the human serotonin transporter gene (SLC6A4)87  
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Mutations associated with this gene may result in changes in the function of the 5-HTT. 
Based on evidences in molecular neuroimaging, postmortem and genetic studies, the 
serotonin transporter plays a pivotal role in the treatment of affective disorders88,89. The 
serotonin transporter is involved in the pathophysiology of psychiatric disorders, e.g. 
schizophrenia90, mood disorders91, depression92,93,94,95,96 and anxiety disorders97. Hence, the 
SERT is an important site for the so called selective serotonin reuptake inhibitors (SSRIs), 
which reduce the activity of 5-HTT, therefore increase the serotonin level in extracellular 
space, and decrease binding of specific displaceable radioligands to 5-HTT. For the 
visualisation and quantification of the SERT, highly selective carbon-11 (and fluorine-18 
labelled) PET-tracers have been developed and synthesised.  
The most prominent and clinically used 11C-tracers  are: [11C]McN525698, [11C]DASB99, 
[11C]MADAM100, [11C]DAPP99 (see figure 21).  
 
 
 
 
 
Figure 21: Chemical structure of a selection of clinically used 11C-SERT tracers. 
 
[11C]DASB 
The best established and explored SERT ligand for PET-imaging in the brain is, so far, 
[11C]DASB  (3-amino-4-[N-methyl-N-[11C]methyl-amino-methylphenylsulfanyl]-benzonitrile) 
(see figure 21). Its promising properties (Ki= 1.1nM, high specific binding; reversible, high 
brain uptake, signal/noise ratio 7.9; cerebellar clearance 15.6min; logP7.4 2.7, excellent 
selectivity (NET/SERT= 1230 and DAT/SERT= 1300) make it a suitable PET-tracer99.  
Since, [11C]DASB provides all the prerequisites for a reliable quantification of the SERT 
binding potential in-vivo, there is a great need for this specific SERT-tracer. The 
radiosynthesis of [11C]DASB was described already in 2000, converting the secondary amine 
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precursor (MASB = desmethyl-DASB) with freshly prepared [11C]methyliodide into the 
derived dipenyl-sulfid-molecule99. Later, an evaluation of the reaction parameters was 
performed101. Several PET-studies have demonstrated the excellent imaging quality of this 
radioligand, suggesting [11C]DASB as the first choice for measurement of SERT binding in 
studies focused on SSRI-dependent changes in SERT binding in patients in-vivo102,103,104,105,106. 
Therefore, the development of the radiochemical preparation of this tracer into a rapid fully-
automated set-up was conducted by our group. Details are given in paper 1 in the scientific 
topic section. 
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1.2. PET-TRACER DEVELOPMENT 
PET is the first choice technology for the visualization and quantification of receptors and 
transporters enabling examination of e.g. neurological, psychiatric and oncological diseases 
on a molecular level. New and innovative PET-radiopharmaceuticals need to be developed to 
get further insights into the biochemical mechanisms involved in pathological changes.  
At the very beginning, PET-tracer development starts with the idea or modelling of the 
chemical structure of a (new) molecule with (hopefully) good binding characteristics to the 
desired target site. Then, as next steps, the compound needs to be radiolabelled with a 
suitable PET-nuclide, and then, it has to be evaluated regarding its parameters in various 
preclinical experiment settings.  
Hence, two major tools are crucial in the development process of new PET-tracers:  
1) a reliable production method –most desireable and optimal in an automated set-up, and 
2) proof of tracer suitability (high affinity, high selectivity and specificity, beside low 
unspecific binding) through preclinical evaluation in an animal model prior to human 
application.  
In the next chapters these tools (both: the reliable radiochemical preparation/ 
automatisation, and the preclinical evaluation) are described in detail theoretically, whereas 
the results of 5 different investigations with respect to this focus are given in the scientific 
topic section (manuscripts 1-3 deal with the radiochemical preparation and automatisation, 
manuscripts 3-5 deal with the preclinical evaluation).  
 
1.2.1. RADIOCHEMICAL ASPECTS 
Positron emitters can be found throughout the entire chart of nuclides, but only few display 
suitable physical properties combined with the possibility of being produced under simple 
conditions. The most important PET-nuclides for clinical applications are summarized in table 
1. The two most widely used PET radoinuclides are 11C and 18F, and the focus of the thesis lies 
upon this two nuclides. 
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nuclide production half-life 
F-18 (F-) 18O  (p,n)  18F 109.7 min 
F-18 (F2) 
20Ne (d,α)  18F 109.7 min 
C-11 14N  (p, α)  11C 20.4 min 
N-13 16O  (p, α)  13N 10.0 min 
O-15 14N  (d,n)  15O 2.0 min 
Cu-64 64Ni  (p,n)  64Cu 12,7 h 
Y-86 86Sr  (p,n)  86Y 14,7 h 
Br-76 76Se  (p,n)  76Br 16,0 h 
Ga-68 68Ge / 68Ga generator 67.6 min 
 
Table 1: Important PET-nuclides for clinical application 
 
[11C]RADIOCHEMISTRY 
Carbon-11 is commonly prepared as carbon dioxide in the cyclotron. Subsequently, this 
active precursor is converted either into [11C]CH3I for methylations, into [
11C]HCN, [11C]COCl2 
or [11C]CHO for special applications, or it is used directly for the synthesis of carbonyls or 
carboxyls via corresponding Grignard reactions. The major radiosynthetic pathways are 
illustrated in figure 22. 
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Figure 22: Labelling techniques with C-11 
Methylations 
[11C]Methyl iodide may be prepared from [11C]carbon dioxide by reduction to [11C]methanol 
and then treatment with a source of HI. The reduction is carried out either by catalytic 
hydrogenation, or more often, by lithium aluminium hydride (LiAlH4). As the carbon dioxide, 
methanol, and methyl halide are all volatile, separation from non-volatile impurities is easily 
achieved by distillation or gas chromatography. [11C]CH3I has also been prepared from 
[11C]methane through substitution by iodine107. Larsen et al108 have reported the automated 
on-line preparation of [11C]methyl iodide in 1.0 Ci quantities. [11C]methane and iodine in 
helium were recirculated through a tube at 700–750°C, removing the iodomethane being 
formed. Methyl triflate has been introduced as an even faster methylating agent109,110. 
Radiolabelled methyl triflate is generally obtained by the reaction of methyl halide with 
silver triflate; for example, a gas stream containing [11C]methyl iodide impinges upon silver 
triflate absorbed upon graphite at loadings as high as 50% at 170–200°C. An excellent review 
on this topic was presented by R. Bolton72. In table 2 an overview of the most commonly 
used [11C]methylated PET-radiopharmaceuticals is given, including [11C]DASB. In the scientific 
topic section, in paper 1, a detailed description about an automated method for the rapid 
and reliable preparation of this tracer via [11C]methyl iodide is given.  
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PET-tracer Abbrevation Target 
[S-methyl-11C]-L-methionine MET Brain tumours 
[11C]metomidate MTO 
11ß-hydroxylase 
(adrenal cortex) 
[11C]flumazenil 
FMZ,  
Ro 15-1788 
central benzodiazepine 
receptors (GABAA) 
[11C]Patrick-Emond-substance 2I PE2I Dopamine transporter 
[11C]raclopride RAC D2 receptor 
[11C]N,N-Dimethyl-2-(2-amino-4-
cyanophenylthio)-benzylamine  
DASB Serotonin transporter 
[11C]carfentanyl CFN µ-opioid receptor 
[N-Methyl-11C]-6-OH-BTA-1 PIB ß-amyloid plaques (AD) 
 
Table 2: Important [11C]methylated PET-radiopharmaceuticals 
 
[18F]RADIOCHEMISTRY 
Figure 23 illustrates possible labelling techniques with F-18. Depending on the starting 
material, e.g. [18F]fluoride or [18F]F2-gas, respectively, nucleophilic and electrophilic reactions 
are possible. Complementary to the direct radiofluorination reactions, fluorinated synthons 
can be produced, which are subsequently bound to the target molecules. Fluoroalkylations – 
and especially fluoroethylations – represent the most important class for this indirect 
labelling technique. 
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Figure 23: Labelling techniques with F-18 
Fluoroalkylations  
Since many biologically active compounds contain alkylic side chains, e.g. methyl- and ethyl-
groups, these structural units may be targets for the affixation of a radiolabel. In fact, many 
compounds have been labelled with a [11C]methyl-group for PET. Thus, the development of 
[18F]fluoroalkylated tracers was the logical consequence. A variety of different 
fluoroalkylating agents have been developed so far:  
[18F]bromofluoromethane111,112, [18F]fluoroiodomethane113, 2-[18F]bromofluoroethane114,69, 
2-[18F]tosyloxyfluoroethane115,116, 3-[18F]bromofluoropropane117,118,119, 3-[18F]fluoroiodo-
propane120 and 3-[18F]tosyloxyfluoropropane121. The thus labelled synthons are restricted to 
small alkyl-chains to avoid too large structural differences.  
Fluoroethylations 
Fluoroethylations represent the most important class amongst the fluoroalkylations, since 
fluoroethylating agents can be easily produced from commercially available substances, and 
the fluoroethyl-group is sterically close to methyl- and ethyl-groups. Targets for 
fluoroethylations are amine122,123,124,125,126,127, hydroxylic128,129, mercapto130,131 and carboxylic 
moieties. 2-[18F]Tosyloxyfluoroethane is widely used, since it is easy to prepare, very stable 
and suitable for a variety of compounds132.  
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On the other hand, it is not as reactive as 2-[18F]fluoroethyltriflate133,134; sensitive to some 
solvents and bases133; not a selective agent135 and intricate to purify – a semi preparative 
HPLC is unavoidable. Hence, microwave enhanced conditions were proposed that increased 
the selectivity and the radiochemical yields136. 
2-[18F]Bromofluoroethane can also be produced rapidly, because no preparative HPLC is 
necessary, but the distillation is very tricky. Thus, a lot of effort was put into investigations to 
optimize yields and quality of this intermediate compound by addition of sodium iodide and 
application of solid phase extraction for purification137,138.  
Three of the introduced tracers in this thesis, [18F]FE@SUPPY, [18F]FE@SUPPY:2 and 
[18F]FE@CIT, respectively, are fluoroethylated tracers, and, therefore, prepared via this kind 
of synthetic route. The explanation of their similar and special sounding names ([18F]FE@...) 
lies partly in their preparation methods: the [18F]FE refers to the fluorine-18 fluoroethylation 
method, and the @ is a trademark for the newly developed tracers by our group. 
 
ADVANTAGES OF [18F]LABELLED PET-TRACERS  
Rationales for the development of [18F]labelled radiotracers bear the advantages of the 18F 
nuclide: the relatively long half-life of fluorine-18 (109.7min) as compared to carbon-11 
(20.3min), and a hypothesised higher stability of the [18F]fluoroethyl-esters as compared to 
their parent C-11 methyl or ethylesters. 
The longer half-life leads to the advantage of longer patient protocols, especially necessary 
for radiopharmaceuticals reaching late equilibriums at the receptors or enzymes, or enables 
the imaging of sore consecutive patients. A longer half-life also supports the concept of 
distribution of these valuable radiopharmaceuticals to PET-centres without on-site cyclotron 
(satellite principle) and commercial exploitation. The the higher stability reduces the 
demanded amount of applied radiotracer (to bring intact radiotracer to the 
bindingsite/target), thus, reduces the radiation burden for the patients and simplifies kinetic 
models for the quantification of receptor or enzyme binding of the tracers. Therefore, our 
group introduced a method for the development of [11C]-tracers into their respective [18F]-
tracers139.  
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In the following chapter, details about the so called “cold” chemistry (precursor and 
reference standard preparation) of the radiotracers described and presented in this thesis 
([11C]DASB, [18F]FE@SUPPY, [18F]FE@SUPPY:2 and [18F]FE@CIT) are given. 
 
“COLD” CHEMISTRY 
Precuror Chemistry 
As a prerequisite for a successful radiochemical preparation, a suitable precursor molecule 
with an efficient leaving group has to be prepared. Due to the short halflife of F-18, saving 
time for this [18F]fluorination steps, is essential for effective radiolabelling. It is better to 
spend time for suitable precursors than waste time and yield in the subsequent labeling 
step. In this thesis, for the [18F]flouroethylated radiotracers, the widely used leaving group p-
toluene-solfonate (=tosylate, =OTs) was used for aliphatic nucleophilic displacement.  
A) [18F]FE@SUPPY-Derivatives 
The precursors of the two A3R tracers, are called Tos@SUPPY (5-(2-tosyloxyethyl)2,4-diethyl-
3-(ethylsulfanylcarbonyl)-6-phenylpyridine-5-carboxylate) and Tos@SUPPY:2 (5-ethyl2,4-
diethyl-3-((2-tosyloxyethyl)sulfanylcarbonyl)-6-phenylpyridine-5-carboxylate). The reaction 
scheme for the preparation of both precursor molecules is presented in figure 24.  
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Figure 24: Preparation scheme of Tos@SUPPY and Tos@SUPPY:2 starting from OH@SUPPY and 
OH@SUPPY:2, respectively. 
B) [18F]FE@CIT 
ß-CIT (3-ß-(4-idophenyl)tropane-2-ß-carboxylic acid) (see figure 25), the precursor for the 
preparation of [18F]FE@CIT, was prepared as described elsewhere, yielding in about 61% of ß-
CIT81.  
(R)
N
(S)
I
H3C
O
O
CH3
 
Figure 25: Chemical structure of ß-CIT 
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C) [11C]DASB  
MASB (=desmethyl-DASB=N-Methyl-2-(2-amino-4-cyanophenylthio)-benzylamine) (see 
figure 26), the precursor for the preparation of [11C]DASB, is a commercially available 
compound, and was therefore purchased from the company ABX, in Germany140.  
S
HN
CH3
NH2
CN
 
Figure 26: Chemical structure of MASB 
 
Reference Standards 
A) [18F]FE@SUPPY-Derivatives 
The reference standards FE@SUPPY (5-(2-fluoroethyl) 2,4-diethyl-3-(ethylsulfanylcarbonyl)-
6-phenyl-pyridine-5-carboxylate) and FE@SUPPY:2 (5-ethyl 2,4-diethyl-3-((2-
fluoroethyl)sulfanylcarbonyl)-6-phenyl-pyridine-5-carboxylate) were prepared as shown in 
figure 27.  
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R2R1
Compound   R1  R2
OH@SUPPY   -H  -OH
OH@SUPPY:2  -OH  -H
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 FE@SUPPY:2
DAST 
      dichloromethane 
             -78°C --> r.t.
DAST 
       dichloromethane 
               -78°C --> r.t.
N
O
O
S
O
F
 FE@SUPPY
 
Figure 27: Reaction scheme for the preparation of the standard compounds FE@SUPPY and 
FE@SUPPY:2. 
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Briefly, OH@SUPPY or OH@SUPPY:2, respectively, was dissolved in water-free 
dichloromethane at -78°C under inert gas. Then, diethylaminosulfur trifluoride (DAST) was 
slowly added dropwise to obtain crude FE@SUPPY or FE@SUPPY:2. The reaction was kept at 
-78°C for half an hour and then slowly heated to room temperature. After completion of the 
reaction, the mixture was cooled to 0°C and hydrolysis was performed by addition of 10mL 
of water. The organic phase was separated and the aqueous phase was extracted 3-times 
with diethylether. The combined organic phases were dried over magnesium sulphate and 
the solvent was evaporated under reduced pressure. Subsequent purification was 
performed using again combined straight phase and reversed-phase column 
chromatography. The method is described in detail elsewhere 141.  
B) [18F]FE@CIT 
FE@CIT (3-ß-(4-idophenyl)tropane-2-ß-carboxylic acid 2-fluoroethylester) was prepared from 
ß-CIT and analyzed by spectroscopic methods, resulting in 42% yield81 (see figure 28).  
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Figure 28: Scheme of the synthesis of FE@CIT 
Reagents and conditions: 
a) 6N HCl, reflux for 24 hours 
b) standard synthesis: 2-fluoroethanol, DMAP, EDCI and dichloromethane 
 
C) [11C]DASB 
DASB reference standard (see figure 31) was obtained from the company ABX, in 
Germany142.  
 
RADIOSYNTHESES 
For the radiochemical preparation of the radiotracers, described in this thesis, three 
different routes of radiolabelling were selected: a direct radiolabelling method 
 46 
([18F]FE@SUPPY-Derivatives), an indirect radiolabelling method via synthon ([18F]FE@CIT) 
and a C11-methylation method ([11C]DASB). 
A) Radiochemical preparation via direct radiolabelling: [18F]FE@SUPPY-Derivatives 
Radiosyntheses of [18F]FE@SUPPY and [18F]FE@SUPPY:2 were performed in simple and 
straight forward one-step, one-pot procedures, each. The radiosynthesis of [18F]FE@SUPPY 
was presented recently by our group143. The radiosynthesis of [18F]FE@SUPPY:2 will be 
explained in detail in the scientific topic section in paper 2.  
Briefly, preparation for both tracers started from cyclotron-produced [18F]fluoride. After 
addition of potassium carbonate and aminopolyether (Kryprofix 2.2.2.), aceotropic drying 
assisted by repeated addition of acetonitrile was performed at 100°C. The activated, dried 
[18F]fluoride-aminopolyether complex was converted to [18F]FE@SUPPY by addition of 
Tos@SUPPY, or to [18F]FE@SUPPY:2 by addition of Tos@SUPPY:2, in acetonitrile at elevated 
temperature (see figure 29). 
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Tos@SUPPY -H -OTos
Tos@SUPPY:2 -OTos -H
[18F]fluoride
acetonitrile
75°C; 20min
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[18F]FE@SUPPY:2[18F]FE@SUPPY  
Figure 29: Reaction scheme for the radiochemical preparation of [18F]FE@SUPPY and 
[18F]FE@SUPPY:2. 
The crude reaction mixture was passed online over two consecutive anion-exchange 
cartridges (PS-HCO3), thereby reducing the amount of unreacted [18F]fluoride. Thereafter, 
purification was conducted by using semi-preparative RP-HPLC and subsequent solid phase 
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extraction to separate residual solvents. Then, the respective product ([18F]FE@SUPPY or 
[18F]FE@SUPPY:2) was eluated with 2mL ethanol and formulated with saline and phosphate 
buffer. Finally, sterile filtration (0.22µm) under aseptic conditions (laminar air flow hot cell, 
class A) was performed to avoid microbial contamination. 
B) Indirect radiolabelling method via synthon: [18F]FE@CIT 
Radiochemical preparation of [18F]FE@CIT (see figure 30) was conducted via destillation of 
[18F]bromofluoroethane ([18F]BFE) and reaction with (1R-2-exo-3-exo)8-methyl-3-(4-iodo-
phenyl)-8-azabicyclo[3.2.1]octane-2-carboxylic acid. After 10 minutes at 150°C the product 
was purified using a C-18 SepPak. The radiosynthesis evinced radiochemical yields of >90% 
(based on [18F]BFE), the specific radioactivity was >416 GBq/µmol. An average 30µAh 
cyclotron irradiation yielded in more than 2.5GBq [18F]FE@CIT81.  
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Figure 30: Scheme of the synthesis of [18F]FE@CIT. 
 
C) C11-metylation method: [11C]DASB 
Radiosynthesis of [11C]DASB via [11C]methyl iodide (see figure 31) was first described in 2000 
by Wilson and his co-workers99. Details about the developmemt into a fully-autpmated set-
up are given in paper 1 in the specific topic section. Briefly, freshly prepared [11C]methyl 
iodide was trapped online in the reaction mixture containing 1 mg of precursor (MASB; 
desmethyl-DASB) in 500 µL of DMSO. The reaction mixture was heated at 100°C for 2min, 
diluted with 1 mL of mobile phase and subsequently transferred to the semi-preparative 
HPLC system. Purification was achieved using RP-HPLC with a mobile phase consisting of 40% 
acetonitrile and 60% 0.1 mol/L ammonium acetate at a flow rate of 8mL/min. Then, the 
product fraction was diluted and subjected to solid phase extraction to reduce contents of 
residual solvents. After washing with water the purified product was eluted with ethanol. 
Finally, the ethanolic product solution was formulated with saline and phosphate buffer and 
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sterile filtrated under aseptic conditions. Typically, 2-9 GBq of [11C]DASB were prepared 
within 35±3min (n=60) 
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Figure 31: Scheme of the synthesis of [11C]DASB 
 
AUTOMATISATION 
Up-scaling and automatisation of radiosyntheses are useful tools, if the tracers shall or will 
be prepared on a routine basis for preclinical and/or clinical applications. Furthermore, the 
automatisation of a radiosynthetic procedure keeps the radiation burden for the operators 
to a minimum. 
A) [18F]FE@SUPPY-Derivatives 
The syntheses for the two A3R tracers were automated in a GE Tracerlab Fx synthesizer, 
remotely controlled by a standard laptop with dedicated processing software. Generally, the 
main steps of the automation process included: [18F]fluoride fixation on an anion exchange 
column regenerating [18O]water; azeotropically supported drying and activation of 
[18F]fluoride; substitution of the precursor’s leaving group by activated [18F]fluoride ions; 
purification of the crude reaction mixture using semi-preparative reversed-phase HPLC 
and/or solid phase extraction (SPE) techniques; and formulation and sterile filtration of the 
purified product. Details about the automatisation of [18F]FE@SUPPY and [18F]FE@SUPPY:2 
are given in paper 3 in the specific topic section. 
B) [18F]FE@CIT 
The automated preparation of [18F]FE@CIT was not yet implemented. 
C) [11C]DASB 
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As mentioned before, the automated procedure of the preparation of [11C]DASB is given in paper 1 
in the scientific topic section. 
Quality control  
Radiochemical purities always exceeded 95% for all four described PET-tracers ([11C]DASB, 
[18F]FE@SUPPY, [18F]FE@SUPPY:2 and [18F]FE@CIT), in accordance with the regulations of 
the European pharmacopoeia144. Radiochemical identity and purity were determined by 
analytical HPLC for all tracers and by TLC (except for [11C]DASB) by comparison of retention 
times (or retention factors, respectively) with an authentic sample of the investigated 
tracers. Sterility, presence of endotoxines, pH, osmolality and residual solvents were 
assessed by standard procedures routinely performed at the PET Centre of the Vienna 
General Hospital, all in accordance with the European Pharmacopoeia144. 
 50 
1.2.2. PRECLINICAL EVALUATION 
In the process of PET-tracer development the first prerequisite is the successfull production 
of the radiopharmaceutical. The automatisation of the radiochemical preparation of the PET-
tracer is a second very valuable prerequisite, especially, if further investigations with this 
tracer are planned. Then, as a next step, is the preclinical evaluation process, which is a 
crucial tool prior to the clinical application of the tracer. M. Bergström stated in 2003: “the 
process of development of new PET-tracers requires use of a range of preclinical methods. 
The purposes of these studies are to qualify a tentative labelled molecule for further testing 
in more labor intensive and more complex models, up to human validation studies. Because 
typically nine tentative tracers out of 10 would fail to show the desired property in vivo, it is 
essential to reject failures at an early stage, so as not to delay the utilization of PET in clinical 
trials. There is no single method today that can adequately predict the in-vivo behaviour of a 
tracer, and therefore, combinations of assays are needed to increase the propability of 
success”145.  
According to the stated need of combination of methods, the present thesis presents several 
evaluation methods: biodistribution testing, metabolic stability experiments and last but not 
least, autoradiography, to get a first estimate of the in-vitro and in-vivo behaviour of the 
dedicated tracers. 
 
BIODISTRIBUTION 
Biodistribution testing is a very important tool in the preclinical evaluation process, since it 
gives a first estimate of the in-vivo distribution of the tracer in an animal model. One can 
divide organs with high, mediate and low uptake of the tracer, and see, for example, if there 
is uptake of the tracer in bones, which is important to know especially for [18F]tracers. In 
case of high bone uptake of [18F]tracers, one would have to consider a high degree of 
defluorination. Furthermore, the biodistribution model can give hints of the excretion 
pathways of the tracer, whether it is cleared hepatobilliary, or renally. Moreover, it is 
important to compare given mRNA data about the desired target with the data resulting 
from the biodistribution, and checking if there is analogy or not.  
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A) [18F]FE@SUPPY-Derivatives 
Biodistribution experiments were conducted for [18F]FE@SUPPY:2 and were planned in a 
similar manner as performed in various preceding tracer-evaluations at the Austrian Institute 
of Technology (AIT, Seibersdorf)146, 54, 147. 
Briefly, male wild-type rats were injected with 1-2.5 MBq of [18F]FE@SUPPY:2 in ~200 µl 
physiological phosphate buffer through a tail vein. Subsequently, the rats were sacrificed by 
exsanguination from the abdominal aorta in ether anaesthesia after 5, 15, 30, 60 and 120 
minutes. Organs were removed, weighed and counted with a Canberra Packard Cobra II 
auto-gamma counter. % Doses were calculated using two calibration curves (high and low 
activity) with known activities and decay corrected for the injection time. Preparation of the 
doses was done on a Capintec CRC15R dose calibrator and the rest body was counted on a 
planar NaI crystal assembled with Ortec Maestro 32MCA emulator data acquisition software.  
Remaining activity in the rest body was calculated by correlation of the counts with a 
calibration curve acquired with known activities in the same geometry and decay corrected 
for the injection time. Radioactivity was expressed as percentage injected dose per gram 
tissue (% ID/g). All biodistribution studies performed at the AIT Austrian Institute of 
Technology GmbH, in Seibersdorf, followed a protocol of the NIH Animal Care and Use 
Committee and were in accordance with the national legislation on animal experiments 
(“Österreichisches Tierschutzgesetz”).Results are given in the scientific topic section in paper 
3. 
B) [18F]FE@CIT & C) [11C]DASB 
No biodistribution experiments were conducted for these two tracers.  
 
METABOLIC STABILITY 
In the living organism, PET-tracers may undergo biotransformation reactions, including 
oxidation, hydrolysis or decarboxylation, as well as conjugation processes, as any other 
xenobiotics and drugs do. In consequence, the measured PET-signal in a PET-scan reflects 
the total of all radiolabelled compounds, including the parent tracer and possibly formed 
labelled metabolites148. Therefore, metabolic stability testing of new potential PET-tracers is 
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crucial regarding their possible future application in humans. Since, those tracers get applied 
intravenously, and enter the normal metabolisation process inside the body, it is important 
to know what happens to them. So, distinct information concerning the stability and 
degradation, as well as the amount of formation of radioactive metabolites, is needed. 
Radioactive metabolites – if present in the target tissue – could interfere with the signal of 
the intact molecule, which would lead to misinterpretation of the resulting PET-scans by the 
physicians. Addidionaly, tracer metabolism affects the arterial input function used for 
quantitative analysis of the resulting images. As a consequence, metabolite analysis in 
plasma is an essential prerequisite for determination of the exact arterial input functions149. 
Metabolic stability can be tested both, in-vitro and ex-vivo: 
In-vitro metabolite analysis 
A first estimate of the metabolic characterisation of a PET-tracer can be gained by simulation 
of the typical reactions in-vitro. Carboxylesterases (CES) are considered to contribute 
significantly to cleavage and degradation of carboxylester- and thioester-functions. In-vitro 
assays of the biotransformations mediated by enzymes are performed to obtain detailed 
information of the substrate hydrolyis. Therefore, enzyme kinetic studies using CES were 
conducted to obtain information about ester cleavage of the unlabeled substrates of 
[18F]FE@SUPPY, [18F]FE@SUPPY:2 and [18F]FE@CIT.  
In general, kinetic studies were performed using carboxylesterase from a stock solution (500 
µg/ml = 10 I.U.in distilled water). The determination of Michaelis-Menten kinetic 
parameters, Km and Vmax, were performed with constant enzyme concentration (2.5 I.U) and 
various concentrations of unlabelled substrate under physiological conditions at given time 
points (1 minute to 6 hours). A linear regression analysis of the concentration versus time 
plot yielded a steady state velocity represented by the slope k. The same time points were 
used to determine steady-state kinetics for a range of increasing substrate concentrations. 
Substrate incubation took place at 37°C, in a final volume of 1 ml phosphate buffer. For 
quantification of the esterase experiments an HPLC (high performance liquid 
chromatography) system, containing of a diode array UV detector at 248nm and 250nm and 
a Nal Socket was used. Figure 32 shows a typical progression of enzymatic cleavage over a 
time period of 6 hours.  
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Figure 32: Degradation of a dedicated substrate in dependence of CES 
A) [18F]FE@SUPPY-Derivatives 
Details and results of in-vitro behavior of FE@SUPPY and FE@SUPPY:2 concerning CES are 
given in the specific topics section, in Paper 4.  
B) [18F]FE@CIT  
Details and results of in-vitro behavior of FE@CIT concerning CES are given in the specific 
topics section, in Paper 5. 
C) [11C]DASB 
In-vitro experiments with CES have not been conducted with this tracer by our group.  
Ex-vivo metabolite analysis 
A next step towards a complete metabolic characterization, is the examination of potential 
metabolites of the dedicated tracer in an animal model. Hence, one has to establish an 
appropriate experimental setting, to allow simulation of the typical reactions in-vivo, and to 
detect the possible respective radiolabelled metabolites. Separation techniques for the 
detection of possible metabolites are e.g. radio-HPLC, radio-TLC (thin layer chromatograohy) 
or SPE (solid phase extraction). Therefore, samples have to be prepared immediately after 
explant of e.g. blood and brain from the animal.  
Progression of enzymatic cleavage 
injection 
product after 6h 
product after 1h 
substrate after 0h 
substrate after 6h cleaved 
cleaved 
peak 
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In our case, we analyzed the tracers according to standart protocols via radio-HPLC. For 
quantification of the respective radioactive metabolites, the HPLC system was equipped with 
a lead-shielded high-sensitivity-radiodetector with a BGO crystal as detection device. 
Recovery was performed by comparing peak areas from spiked biological samples with those 
from samples of fluoroethyl-esters in aqueous solution. Aqueous and biological samples 
were processed under identical conditions.  
A) [18F]FE@SUPPY-Derivatives 
Results of ex-vivo metabolite studies in rat plasma and rat brain of [18F]FE@SUPPY and 
[18F]FE@SUPPY:2 are given in the specific topics section, in Paper 4.  
B) [18F]FE@CIT  
Ex-vivo experiments have not yet been conducted with this tracer.  
C) [11C]DASB 
Ex-vivo experiments have not been conducted with this tracer by our group.  
 
AUTORADIOGRAPHY 
Autoradiography is a method of self reproduction of radioactive sources by means of 
modified photographic techniques. The basis of autoradiography is the recording of 
radioactivity distribution in slices of various tissues. This can be performed with radioactivity 
added to premade tissue slices (in-vitro autoradiography), or administered to animals, which 
are thereafter sacrificed and sliced (ex-vivo autoradiography). Autoradiography experiments 
allow a range of frozen tissues to be sectioned and incubated with the dedicated PET-tracer, 
and additionally, with selective blocking agents. Hence, quantitative values can be obtained 
with respect to tracer binding and its regional distribution.  
Nowadays, recording of radioactivity is typically made with an Instant Imager or with a 
Phosphor Imager, using imaging plates, being the most sensitive devices for the 
measurement of radioactivity from PET tracers145. Most frequently used nuclides for 
autoradiography are 3H, 14C and 125I. Differences in the resulting pictures derive from the 
emitted radioation sources, for example 3H emits ß-radiation with particle energy of 
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18.5KeV, whereas 125I emits auger electrons with 35keV. Additionaly, also the half-life, as 
well as the ionisation degree of the nuclide show impact on the resulting images.  
For autoradiographic experiments, different steps have to be processed one after the other, 
as explained and listed in the following. The exact preparation of the tissue sections 
(commonly rat tissues, if available also human brain or tumor tissues) is a prerequisite for 
autoradiographic studies: 
Step 1: Preparation of Tissue Sections for in-vitro autoradiography 
In our autoradiographic experiments, the PET-tracers were examined in rat brain, so far. 
Hence, male wild-type rats, weighing 200 to 300g were deeply anesthetized by diethylether 
and rapidly decapitated. Since, freezing of the various tissues promotes blockage of all 
biological processes, including protein degradation and tissue hardening, rat brains were 
removed and subsequently quick-frozen in isopentane, which was cooled over dry ice to –
45°C.  
Then, brains were stored at –80°C and transferred to –20°C the night before cutting in a 
cryostat. A cryostat is a microtome placed in a refrigerating compartment (see figure 33a). 
Frozen samples were left in the chamber of the cryostat to warm the slices to optimum 
temperature of -20°C before cutting (see figure 33b).  
 
Figure 33: (a) Cryo-microtome for sectioning frozen tissues 
             (b) inside view of the cutting chamber of the cryostat 
Then, frozen brains were fixed upon dedicated chucks (see figure 34) and immediately 
sectioned into 20µm thick coronal slices as schematically shown in figure 35. Sections were 
a b
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thaw-mounted onto superfrost slides, and after drying at room temperature, the slides were 
stored at –40°C until processing. 
 
Figure 34: Chucks for fixation of the rat brains  
 
 
Figure 35: Scheme of a coronal rat brain slice  
Step 2: Autoradiographic set-up 
Approximately 20 minutes before starting the experiment, the frozen tissue sections were 
preincubated for 2 minutes in a container with a TRIS-HCl buffer solution (pH 7.4) (see figure 
36) to adjust the sections to the medium and to room temperature.  
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Figure 36: Typical container filled with buffer solution for preincubation of frozen tissues150 
Subsequently, parallel slices were directly incubated with a solution containing the PET-
tracer in a specific concentration expressed in nM of cold compound, and selective blocking 
agents for the various receptor subtypes, which might interfere with the signal of the tracer 
(scheme see in figure 37). Incubation time was chosen to fit optimal binding equilibrium with 
respect to the half-life of the tracer. After incubation, slides were washed in buffer twice, 
rinsed with ice-cold water, and dried. 
 
 
 
 
Figure 37: Scheme of a tissue slide covered with the incubation mixture151 
 
Thereafter, samples were put in an Instant Imager, or placed on Phosphor Imager plates for 
exposure. According to the research question, it might be sufficient to observe the 
radioactivity distribution ([18F]FE@SUPPY and [18F]FE@SUPPY:2), while other studies might 
demand quantitative estimates ([18F]FE@CIT).  
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1.3. AIM OF THE PRESENT THESIS 
The technology of PET bases on radioactive molecules, the PET-tracers, which accumulate 
selectively at target binding sites, e.g. receptors, enzymes and transporters. Hence, these 
targets can be visualized and quantified non-invasively.  
In case of the presented PhD-thesis, three different receptor and transporter targets are 
described: the dopamine and serotonin transporter -both well known targets since many 
decades, and, the recently identified adenosine A3 receptor, as a completely new target. For 
the DAT and SERT, there exists already a wide range of excellent PET- tracers, which is not 
yet true for the A3R. But, since the A3R is involved in a variety of pathologies, especially 
neurological, psychiatric, cardiac and oncological diseases (such as solid tumors and 
metastases), the in-vivo visualisation and quantification of the A3R with PET would be of 
immense clinical and scientific interest.  
In general, the successful and feasible preparation of radiopharmaceuticals, is the first 
prerequisite for their application in patients. Therefore, it is crucial to develop automated 
radiosynthetic procedures, to guarantee save and continuous availability of the tracers. 
Furthermore, in order to have the chance to realize application of newly developed 
radiopharmaceuticals in humans, a series of preclinical evaluations have to be performed. 
These evaluations should guarantee tracer safety, and give a first estimate of the in-vivo 
behaviour of these substances.  
The publications, included in this thesis, aimed to contribute to these various aspects of the 
development and evaluation of the 4 different PET-tracers: The completely new compound 
[18F]FE@SUPPY:2 was aimed to be introduced as a second potential A3R PET-tracer. 
Radiochemical procedures of [11C]DASB, [18F]FE@SUPPY and [18F]FE@SUPPY:2 were aimed 
to be developed into fully-automated settings; and [18F]FE@SUPPY, [18F]FE@SUPPY:2 and 
[18F]FE@CIT were aimed to be preclinically evaluated. 
The first major aim was the optimization of the radiosynthesis of [11C]DASB for routine 
application for psychiatric and scientifically demanding clinical trials. Thus, this radioligand 
has to be available on a routine basis in accordance to highest quality requirements. 
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Hence, we aimed to establish a fully-automated procedure for the synthesis and purification 
of [11C]DASB with a high degree of reliability; to reduce overall synthesis time, while 
conserving high yields and purity; and to develop a suitable and fast quality control assay to 
assure safe application. Details and results about these improvements are given in the 
scientific section in paper 1. 
The second principal aim was the development and evaluation of suitable PET-tracers for the 
visualisation and quantification of the adenosine A3 receptor. In this context, it was first 
aimed, to radiochemically prepare [18F]FE@SUPPY:2, the structural analogue of 
[18F]FE@SUPPY, as a second potential A3R PET-tracer. Moreover, it was aimed to automate 
the radiosyntheses for both potential PET-tracers, and, in addition, as a consequential next 
step in the development procedure, to evaluate them preclinically. Comparisons of the 
resulting parameters of both tracers, and, in consequence, the decision upon their suitability 
as A3R PET-tracers, were the objective of these investigations. 
The third main focus was the further preclinical evaluation of the fluoroethylated ß-CIT 
analogue, [18F]FE@CIT, which was introduced by our group as a novel potential DAT PET-
tracer in 2005. Since the preparation and first evaluation revealed promising results, this 
study aimed to further prove the suitability of the tracer (for future human application), 
regarding its in-vitro metabolic and autoradiographic characterisation.  
Taken together, for researchers, working in the field of preclinical sciences, it is the major 
aim to bring new and improved molecules from bench to bedside. 
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2. SPECIFIC TOPICS 
 
2.1. GENERAL 
The thesis aimed in general for PET-tracer development and preclinical evaluation with 
special emphasis on novel [18F]labelled ligands for the adenosine A3 receptor. In the 
following chapters the results of the different investigations are presented in 5 manuscripts.  
The first paper describes the optimization and automatisation of the radiochemical 
preparation of the well known and widely used SERT tracer [11C]DASB. The radiosynthesis 
was modified into a rapid and simple set-up for an automated high-quality production for 
routine application of this tracer for various studies in cooperation with the department of 
psychiatry and psychotherapy. 
The second paper deals with the radiochemical preparation of a completely new potential 
[18F]labelled PET-tracer for the A3R, called [18F]FE@SUPPY:2. This tracer was developed as a 
functional isomer of [18F]FE@SUPPY, the first PET-tracer for the A3R.  
The third paper shows the results of the automation of the radiosyntheses of the new 
potential A3R PET-tracers [18F]FE@SUPPY and [18F]FE@SUPPY:2. Furthermore, it also 
includes first preclinical evaluation parameters of [18F]FE@SUPPY:2, and a comparison of the 
results with those of [18F]FE@SUPPY. 
The forth manuscript deals with the metabolic characterisation of the A3R PET-tracers 
[18F]FE@SUPPY and [18F]FE@SUPPY:2 in-vitro and in-vivo.  
The fifth paper includes the metabolic and autoradiographic characterisation of the DAT 
PET-tracer [18F]FE@CIT.  
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2.2. SCIENTIFIC PAPERS 
 
2.2.1. AUTHOR´S CONTRIBUTION 
I hereby declare to have significantly contributed to the realization of each of the five studies 
included in the present thesis.  
In the first manuscript (Simple and rapid preparation of [11C]DASB with high quality and 
reliability for routine applications), I participated in the study design and performed all the 
radiosyntheses. Additionally, I participated in the analysis and interpretation of the data, as 
well as in the conception and writing of the manuscript. 
Regarding the second manuscript (Radiosynthesis of a novel potential adenosine A3 receptor 
ligand, 5-ethyl 2,4-diethyl-3-((2-[18F]fluoroethyl)sulfanylcarbonyl)-6-phenylpyridine-5-
carboxylate ([18F]FE@SUPPY:2)), I conceived of the study and was involved in the  
radiosyntheses. Moreover, I carried out the analysis and interpretation of the data, as well 
as the drafting of the manuscript. 
Concerning the third study (Automatisation and first evaluation of [18F]FE@SUPPY:2, an 
alternative PET-Tracer for the Adenosine A3 Receptor: A Comparison with [
18F]FE@SUPPY), I 
participated in the study design and was involved in the radiosyntheses. Furthermore, I took 
part in the planning of the bioevaluation study and fully participated in the experiments at 
the AIT Seibersdorf. Additionally, I took a significant part in the writing of the manuscript.  
In the fourth paper ([18F]FE@SUPPY and [18F]FE@SUPPY:2 - Metabolic considerations), I 
conceived of the study, contributed to the preparation of the radiotracers, and performed 
the ex-vivo metabolite experiments at the AIT. Moreover, I participated in the 
carboxylesterase experiments and carried out the data analysis and interpretation of the 
results, as well as the drafting of the manuscript.  
Regarding the fifth study (Metabolism and autoradiographic evaluation of [18F]FE@CIT: a 
Comparison with [123I]ß-CIT and [123I]FP-CIT), I participated in the study design and 
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performed the autoradiographic experiments. Additionally, I took part in the analysis and 
interpretation of the data, as well as in the drafting of the manuscript.  
 
Mag. Daniela Häusler      Vienna, 03.03.2010 
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Abstract 
[11C]DASB combines all major prerequisites for a successful SERT-ligand, providing excellent 
biological properties and in-vivo behaviour. Thus, we aimed to establish a fully-automated 
procedure for the synthesis and purification of [11C]DASB with a high degree of reliability 
reducing the overall synthesis time while conserving high yields and purity. The optimized 
[11C]DASB synthesis was applied in more than 60 applications with a very low failure rate 
(3.2%). We obtained yields up to 8.9GBq (average 5.3 ± 1.6GBq). Time consumption was kept 
to a minimum, resulting in 43 minutes from end of bombardment to release of the product 
after quality control.  
Form our data, it is evident that the presented method can be implemented for routine 
preparations of [11C]DASB with high reliability. 
Key words: serotonin, SERT, PET, carbon-11, radiosynthesis, DASB 
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1. Introduction 
The serotonin transporter (SERT) influences and controls extracellular serotonin levels in the 
synaptic cleft by decreasing the serotonin level through reuptake and is involved in the 
pathophysiology of psychiatric disorders, e.g. schizophrenia (Joyce et al., 1993), mood 
disorders (Ichimiya et al., 2002), depression (Meyer et al., 2001, Meyer et al., 2004a, 
OwensNemeroff, 1994, Parsey et al., 2006a, Reivich et al., 2004) and anxiety (Jarret et al., 
2007). Hence, it is one of the main targets for antidepressant drugs, the so called SSRIs 
(selective serotonin reuptake inhibitors) (Meyer et al., 2001, Meyer et al., 2004b, Reivich et 
al., 2004, Spindelegger et al., 2008). Consequently, the imaging of the SERT before and after 
medication with SSRIs would be of great value for a deeper and further understanding of 
psychiatric disorders (Hesse et al., 2004, Meyer, 2008), the way of action of newly developed 
anti-psychotics, and could help to improve diagnosis and the planning of treatment.  
Imaging with Positron Emission Tomography (PET) allows in vivo measurement of receptors 
and transporters in humans non-invasively. For the visualisation and quantification of the 
SERT, highly selective carbon-11 and fluorine-18 labelled PET-tracers have been developed 
and synthesised, such as [11C]McN5256 (Suehiro et al., 1993), [11C]DASB (Wilson et al., 
2000b), [11C]ADAM (Vercouillie et al., 2001) [11C]MADAM (Tarkiainen et al., 2001), [11C]DAPP 
(Wilson et al., 2000b), [11C]DAPA (Huang et al., 2002), [11C]AFM (Huang et al., 2004a), 
[11C]AFA (Huang et al., 2004b), [11C]AFE (Zhu et al., 2004), [18F]ACF (Oya et al., 2002) and 
[18F]F-ADAM (Shiue et al., 2003a, Shiue et al., 2003b), respectively. Structures are given in 
Figure1. So far, only, [11C]McN5256 (Frankle et al., 2004, McCann et al., 2005, Parsey et al., 
2000, Parsey et al., 2006a, Szabo et al., 1995), [11C]DASB (Frankle et al., 2004, Houle et al., 
2000, McCann et al., 2005, Meyer et al., 2001, Meyer et al., 2004b, Meyer, 2007, Parsey et 
al., 2006b, Praschak-Rieder et al., 2008), [11C]DAPP (Houle et al., 2000) and [11C]MADAM 
(Chalon et al., 2003, Jovanovic et al., 2008, Lundberg et al., 2005, Lundberg et al., 2006, 
Lundberg et al., 2007a, Lundberg et al., 2007b) have found their way into clinical 
measurements.  
The best established and explored SERT ligand for PET-imaging is [11C]DASB (3-amino-4-[N-
methyl-N-[11C]methyl-amino-methylphenylsulfanyl]-benzonitrile). It was firstly introduced 
and synthesised by Wilson et al. in 2000 (Wilson et al., 2000a, Wilson et al., 2000b) and 
 67 
showed promising properties (Ki= 1.1nM, signal/noise ratio 7.9; cerebellar clearance 
15.6min; logP7.4 2.7) (Wilson et al., 2000b).  
DASB combines several advantages which makes it an excellent SERT-tracer for clinical use:  
(1) high affinity (1.1nM);  
(2) excellent selectivity (NET/SERT= 1230 and DAT/SERT= 1300);  
(3) high specific binding; 
(4) reversible, high brain uptake; and  
(5) binding equilibrium within a reasonable timeframe. 
Since, DASB provides all the prerequisites for a reliable quantification of the SERT binding 
potential in vivo, there is a great need for this specific SERT-tracer.  
The radiosynthesis of [11C]DASB was described already in 2000 (Wilson et al., 2000b) 
converting the secondary amine precursor (MASB) with freshly prepared [11C]methyliodide 
into the derived dipenyl-sulfid-molecule. (Reaction scheme, see figure 2) A short time later, 
an evaluation of the reaction parameters was performed. (Solbach et al., 2004) Additionally, 
a synthetic procedure using [11C]methyl triflate was described in 2004 (Belanger et al., 2004). 
Nevertheless, for routine application, the production has to fulfil even more requirements 
than just high yields and purity. Full-automation to reduce the radiation burden for the 
operator, a low probability of failed syntheses and a short overall production time are also of 
great importance.  
Thus, we aimed  
(1) to establish a fully-automated procedure for the synthesis and purification of [11C]DASB 
with a high degree of reliability; 
(2) to reduce overall synthesis time while conserving high yields and purity; and 
(3) to develop a suitable and fast quality control assay to assure safe application in a routine 
setting.  
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Hence, our investigation should provide a simple method for the quick preparation of 
[11C]DASB with high quality and reliability.  
 
2. Experimental 
2.1. Materials 
All chemicals and solvents were obtained from commercial sources with analytical grade and 
used without further purification.  
Iodine (sublimated grade for analysis; ACS, Pharm.Eur.) was purchased from Merck 
(Darmstadt, Germany; product number: 1.04761). MASB precursor (N-Methyl-2-(2-amino-4-
cyanophenylthio)-benzylamine) and DASB reference compound (3-amino-4-(2-dimethyl-
amino-methylphenylsulfanylbenzonitrile) were obtained from ABX (ABX- Advanced 
Biochemical Compounds Radeberg, Germany). Dimethylsulfoxide (DMSO, >99.9%, 
anhydrous) was obtained from Sigma Aldrich (Vienna, Austria). Acetonitrile, ammonium 
formate, ammonium acetate and ethanol (absolute) were purchased from Merck 
(Darmstadt, Germany). C18plus SepPak® cartridges were purchased from Waters (Waters® 
Associates Milford, MA, USA). Low-protein binding Millex GS® 0.22 µm sterile filters were 
pruchased from Millipore® (Bedford, MA, USA). Semipreparative HPLC (High performance 
liquid chromatography) column (Supelcosil LC-ABZ+; 5µm, 250mm x 10mm; Nr. 59179) was 
purchased from Supelco (Bellfonte, PA, USA). Analytical HPLC-column (Prodigy 5µ Phenyl-3 
(PH-3); 250 x 4.6mm) was obtained from Phenomenex (Aschaffenburg, Germany). GC 
capillary column (HP-Innowax 30m x 0.32mm x 0.25µm; Nr. 19091N-113) was from Agilent 
(Santa Clara, CA, USA).  
2.2. Instruments 
For the fully automated preparation of [11C]DASB, a C11-methylation PET-synthesizer 
(formerly: Nuclear Interface®, now: General Electric Medical Systems, Uppsala, Sweden) was 
used and remotely controlled via GINAstar software (Raytest Isotopenmessgeräte GmbH, 
Straubenhardt, Germany) installed on a standard PC. 
Semipreparative HPLC was performed using the original Nuclear Interface® PET synthesizer 
chromatographic equipment. Analytical HPLC was performed with a Merck-Hitachi LaChrom 
 69 
system consisting of a L-7100 pump, a Merck-Hitachi LaChrom L-7400 UV detector (operated 
at 254nm) and a lead shielded NaI-radiodetector (Berthold technologies, Bad Wildbach, 
Germany) for radiation detection. Gas chromatography was performed using an HP 6890 
series system (Agilent, Santa Clara, CA, USA) with flame ionisation detector (FID).  
2.3. Fully automated radiosynthesis 
A scheme of the synthesis module is presented in Figure 3. All details given in the following 
section refer to this figure.  
2.3.1. Preparation of the synthesis module 
All parts prior to HPLC-purification (reactor, HPLC injector, tubing) were rinsed with DMSO or 
acetone and then dried with a stream of helium. Parts after HPLC (SPE, product collection 
vial, product outlet tubing) were cleaned using ethanol and physiological saline.  
Vessels were filled as followed: 
Vial 2: 1mL of HPLC solvent for quenching of the reaction; 
Flask 3: 100mL of sterile water for dilution of the lipophilic HPLC fraction; 
Vial 4: 5mL of saline solution 0.9% for final rinsing of the SPE cartridge and dilution of the 
eluate; 
Vial 5: 1.5mL ethanol for elution of the SPE cartridge; 
Vial 6: 10mL sterile water for washing the SPE cartridge. 
A C18plus SepPak® cartridge was preconditioned using ethanol and sterile water, dried and 
connected to its designated position. The product collection vial was filled with 4mL 0.9% 
saline, 1mL 3% saline and 1mL phosphate buffer (125mM). The reactor was filled with 1mg 
MASB dissolved in 0.5mL DMSO and subsequently placed into the heating block.  
2.3.2. Production of [11C]CH3I 
[11C]CO2 was produced at the GE PETtrace cyclotron (General Electric Medical Systems, 
Uppsala, Sweden) by irradiation of a gas target containing N2 and 0.5% O2 using the 
14N(p,α)11C nuclear reaction with 16.5MeV protons. Typical beam currents were 50-60 µA 
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and irradiation was stopped as soon as the desired activity level was reached (e.g. 70-90 
GBq). [11C]CH3I was produced using the gas phase conversion described by Larsen et al. in 
1997 in an automated synthesis module (MeI-Microlab, General Electric Medical Systems). 
(Larsen et al., 1997) Briefly, [11C]CO2 was trapped on molecular sieve (4Å) and converted to 
[11C]CH4 within 120 seconds in presence of Ni catalyst (Shimalilte Ni reduced, Shimadzu) and 
hydrogen at 360°C. Subsequently, [11C]CH4 was reacted with elemental iodine at 720°C to 
[11C]CH3I and recirculated for 300 seconds. [
11C]CH3I was trapped online on Porapak N in a 
small glass column and finally released by heating to 190°C in a stream of helium (45 
mL/min) within 160 seconds.  
2.3.3. Preparation of [11C]DASB 
Gaseous [11C]methyl iodide produced by the MeI-Microlab module was delivered through 
V10 into the reactor of the previously prepared synthesizer system and trapped on-line in 
the reaction mixture containing 1mg MASB in 500µL of DMSO at 22°C. The reactor was 
heated to 100°C and kept at this temperature for 2min to achieve conversion of MASB to 
[11C]DASB. After cooling down to room temperature, the reaction mixture was quenched by 
addition of 1mL HPLC-eluent (through V2) and subsequently transferred to the 5mL injection 
loop of the HPLC-system through V11 passing the fluid detector.  
 
2.3.4. Product purification  
Injection of the crude reaction mixture to the semi-preparative RP-HPLC column was 
controlled by an automated fluid detector. Semi-preparative HPLC was performed with 
acetonitrile and 0.1M ammonium acetate (40/60; v/v) as mobile phase with a flow of 
8mL/min. Chromatograms were registered using an UV-detector (254nm) and a NaI 
radioactivity detector in series. An example is given in Figure 4. 
The [11C]DASB fraction was cut into flask (3) through V7 and diluted with 100mL water. The 
resulting solution was then pushed over a C18plus SepPak®. After washing with 10mL water 
(Vial 6) the pure product was completely eluted with 1.5mL ethanol (Vial 5) and 5mL 0.9% 
saline (Vial 4). Formulation was done with a further 4mL saline solution 0.9%, 1mL saline 
solution 3% and 1mL physiological phosphate buffer (125mM) in the product collection vial. 
 71 
This final solution was transferred to a shielded laminar-air-flow hot cell and, there, sterile-
filtered (0.22µm) into a sterile 25mL vial containing another 5 mL of saline solution 0.9%.  
2.4. Quality control 
Chemical and radiochemical impurities were detected using radio-HPLC according to the 
monograph in the European Pharmacopoeia (2005b). 
Quality was assessed with analytical RP-HPLC; acetonitrile and 0.1M ammonium formate 
(55/45; v/v) were used as the mobile phase with a flow rate of 2mL/min. The whole quality 
control was completed within 8 minutes, the retention time of the precursor (MASB) was 
4.4-4.8min (k´=2.2-2.7) and the product [11C]DASB was eluted with a retention time of 6.7-
7.2min (k´=3.8-4.6). The chemical identity of [11C]DASB was determined by co-injection of 
the unlabeled reference compound, [12C]DASB. To check for contaminations with higher 
retention factors, we investigated the RP-HPLC chromatograms for 20 min but did not find 
any substance eluting from the HPLC after 8 min.  
Residual solvents were analyzed by gas chromatography (GC) (carrier gas: He, flow 
2.7mL/min, 45°C (2.5min); 20°C/min to 110°C; 30°C/min to 200; 200°C (10min); FID: 270°C). 
Osmolality and pH were determined to assure safe administration using standard methods. 
Radionuclidic purity was assessed by recording of the corresponding gamma spectrum 
(annihilation radiation at 511keV and sum peak at 1022keV) and additional measurement of 
the physical half-life (20.2 ± 1.5min).  
Testing of sterility and concentration of bacterial endotoxines was performed using standard 
protocols at the Department of Microbiology (General Hospital of Vienna). 
 
3. Results 
So far, we performed 60 successful radiosyntheses of [11C]DASB using the optimum reaction 
conditions. We obtained high average yields of 5.3 ± 1.6 GBq (arithmetic mean ± SD; range: 
2.6 - 8.9GBq). Radiochemical yields based on [11C]CH3I, (corrected for decay) were 66.3 ± 
6.9% with a specific radioactivity (As) of 86.8 ± 24.3 GBq/µmol (both at the end of synthesis, 
EOS). Overall, the whole synthetic procedure – including [11C]methyl iodide production, 
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radiosynthesis, HPLC and SPE purification, formulation and sterile filtration - took 35 ± 3 min. 
Semi-preparative HPLC revealed excellent separation of MASB and DASB: retention times 
were 2.9–3.4min (k`= 0.9–1.3) for MASB and 6.4–7.1min (k`= 3.3–3.7) for DASB, respectively 
(Figure 4). SPE purification resulted in a recovery of >98% using 1.5 mL of ethanol followed 
by 5 mL of saline solution. Typical loss during sterile filtration was 200-350 MBq (4-8% of the 
product activity). From a total of 62 preparations for patient routine, we observed two 
failures, both due to problems with the HPLC injection valve. 
The product was obtained as a sterile solution (total volume: 17.5mL) ready for application. 
Radiochemical purity always exceeded 98% as determined by radio-HPLC. Residual solvents 
as determined by GC were found to be 4ppm DMSO and 20ppm acetonitrile. Typical HPLC 
and GC chromatograms are given in Figure 5. MASB content was 0.06 ± 0.04µg/mL; pH was 
7.54 ± 0.16 and osmolality was 286 ± 20mosmol/kg. Endotoxines were found to be below 
0.5EU/ml and all samples passed the test for sterility.  
 
4. Discussion 
Given, that a successful PET tracer requires more than high affinity to the binding site, also 
high selectivity, high specific to non-specific binding ratio, suitable pharmacokinetics and, 
moreover, a good synthetic availability are essential for application in a routine setting. 
[11C]DASB combines excellent biological properties (high affinity and selectivity to the SERT) 
with distinguished in-vivo behaviour (low non-specific binding, suitable pharmacokinetical 
profile). Since it is used in PET-centres all over the world for routine applications, e.g. for PET 
imaging of psychiatric disorders, it is crucial to have a reliable, simple and quick 
radiosynthesis at hand, providing high yields with high purity.  
Set-up of the preparation was straight forward and needed only 10 runs prior to productions 
for human use. Since the short half-life of carbon-11 (20.4min) requires a rapid preparation 
and purification in the radiochemical process, we were interested in a significant reduction 
of the overall synthesis time. We were able to reduce it from 45min to 35min. Furthermore, 
we were able to further optimize the amount of precursor used in the synthesis as compared 
to the literature (Solbach et al., 2004). A 50% reduction, from 4mg/mL to 2mg/mL, was 
applied without loss of reactivity. Radiochemical yields in our presented work were 66.3 ± 
6.9%, overall, using a fully automated set-up. This is a significant improvement as compared 
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to previously published data (Solbach et al., 2004) where 43 ± 3%, overall yield, was reported 
in the case of automation. Absolute yields were also improved by 30%.  
As shown in Figure 4, the separation of precursor and product was excellent. In the final 
product solution, we observed only 0.06µg/mL MASB. Furthermore, separation of residual 
solvents (e.g. acetonitrile, DMSO) was satisfying, resulting in contaminations far below the 
limits set by the European Pharmacopoiea (2005a). Consequently, all of our product 
solutions could be used in human PET applications. Set-up of the quality control (QC) was 
simple, using only standard methods and equipment. The whole QC procedure was 
performed within 8 minutes.  
The fully-automated synthesis and purification of [11C]DASB was performed with extremely 
high reliability. The failure rate was only 3.2% (2 out of 62). These two failed syntheses were 
both due to technical problems with the injection valve of the semi-preparative HPLC 
(attenuator did not switch from load to inject). No failure was observed due to lack in 
chemical reactivity or operator mishandling.  
Overall, we were able  
(1) to establish a fully-automated procedure for the synthesis and purification of [11C]DASB 
with a high degree of reliability; 
(2) to reduce overall synthesis time while conserving high yields and purity; and 
(3) to develop a suitable and fast quality control assay to assure safe application in a routine 
setting.  
Hence, our investigations provide the basis for a simple and quick preparation of [11C]DASB 
with high reliability for routine PET applications.  
5. Conclusion 
We established the rapid preparation and purification of [11C]DASB on a commercial 
synthesizer module. The presented method was applied in more than 60 applications with a 
very low failure rate (3.2%). Time consumption was kept to a minimum, resulting in 43 
minutes from EOB to release of the product after QC. Thus, the presented work should 
provide the basis for routine preparations of [11C]DASB with high reliability. 
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8. Figure Captions 
 
Figure 1: Chemical structures of various important SERT-tracers. 
Figure 2: Reaction scheme of the radiosynthesis of [11C]DASB. 
Figure 3: Illustration of the automated procedure for the radiosynthesis and purification of 
[11C]DASB with a commercial C11-synthesizer. For details in set-up and processing refer to 
section 2.3. 
Figure 4: Typical chromatograms of the product purification via semi-preparative RP-HPLC: 
(a) Radioactivity detector and (b) UV detector @ 254nm. 
Figure 5: Typical chromatograms of the quality control (QC) of [11C]DASB: 
(a) reference compounds: MASB (1µg/ml) and DASB (1µg/ml) in acetonitrile – HPLC (UV 
detector, 254nm):  
(b) final product solution: HPLC (Radioactivity detector) showing radiochemical purity (>98%) 
(c) final product solution: HPLC (UV detector, 254nm) showing chemical purity and content 
of unlabelled DASB 
(d) final product solution: GC (FID detector) showing residual solvents. Acetone peak results 
from the initial washing procedure of the synthesizer parts. 
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Summary 
 
Since, to date very limited information on the distribution and function of the adenosine A3 
receptor is available, the development of suitable radioligands is needed. Recently, we 
introduced [18F]FE@SUPPY (5-(2-[18F]fluoroethyl) 2,4-diethyl-3-(ethylsulfanylcarbonyl)-6-
phenylpyridine-5-carboxylate) as the first PET-ligand for the A3R. Regarding the metabolic 
profile – this class of dialkylpyridines comprises two ester functions within one molecule, 
one carboxylic and one thiocarboxylic – one could expect carboxylesterases significantly 
contributing to cleavage and degradation. Therefore, our aim was the development of 
[18F]FE@SUPPY:2 (5-ethyl 2,4-diethyl-3-((2-[18F]fluoroethyl)sulfanylcarbonyl)-6-
phenylpyridine-5-carboxylate), the functional isomer containing the label at the 
thiocarboxylic moiety. 
For satisfactory yields in high scale radiosyntheses, a reaction temperature of 75°C has to be 
applied for at least 20 minutes using 20 mg/mL of precursor. So far, 6 complete high-scale 
radiosyntheses were performed. Starting from an average of 51.2 ± 21.8GBq (mean ± SD) 
[18F]fluoride, 5.8 ± 4.1GBq of formulated [18F]FE@SUPPY:2 (12.0 ± 5.4%, based on 
[18F]fluoride, not corrected for decay) were prepared in 75 ± 8 minutes.  
 
 
Key words: Adenosine / PET / Receptor / Fluorine-18 / Radioligand
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Introduction 
Adenosine is one of the key modulators in humans and exhibits its mechanism of action 
through four different receptor subtypes, namely the A1, A2A, A2B, and A3 receptors, 
respectively (A1R, A2AR, A2BR, and A3R). The most recently identified receptor subtype was 
the A3R, and, so far, there is little known regarding its distribution and density in vivo. PET 
(positron emission tomography) is a suitable technique to collect these lacking data. As a 
prerequisite for successful molecular imaging with PET, there is demand for suitable 
radioligands. Such a suitable receptor-radioligand is characterized by high affinity, high 
selectivity, low nonspecific binding and the absence of interfering radioactive metabolites in 
the target tissue. Beside these prerequisites, the most important premise for a successful 
PET-tracer is its broad availability and reliable preparation.  
Recently, we introduced [18F]FE@SUPPY (5-(2-[18F]fluoroethyl) 2,4-diethyl-3-
(ethylsulfanylcarbonyl)-6-phenylpyridine-5-carboxylate) as the first PET-ligand for the A3R. 
[1, 2] The preparation followed a simple one-pot one-step reaction with good and reliable 
radiolabelling yields. So far, [18F]FE@SUPPY is the most suitable radioligand for the A3R 
amongst the well characterized family of 3,5-diacyl-2,4-dialkylpyridines with all derivatives 
showing considerable affinity for the adenosine receptor system. [3] FE@SUPPY was shown 
to display a Ki of 4.2nM to human A3R and a selectivity of 2700 (ratio A1R/A3R). [3] 
Regarding the metabolic profile – these dialkylpyridines all comprise two ester functions 
within one molecule, one carboxylic and one thiocarboxylic – one could expect 
carboxylesterases significantly contributing to cleavage and degradation. Carboxylesterases 
are known to attack mainly carboxylic and thiocarboxylic functions. [4, 5] To the best of our 
knowledge, there is no conclusive data regarding the stability differences of carboxylic and 
thiocarboxylic esters within one molecule. Since Azema et al. [6] in a comparative study even 
presented evidence for increased stability of the thioester function compared to carboxylic 
esters, we translated the fluoroethyl ester [18F]FE@SUPPY into the fluoroethyl - thioester 
[18F]FE@SUPPY:2 (5-ethyl 2,4-diethyl-3-((2-[18F]fluoroethyl)sulfanylcarbonyl)-6-
phenylpyridine-5-carboxylate; see figure 1). Therefore, we expect a better metabolic profile 
of [18F]FE@SUPPY:2 as compared to [18F]FE@SUPPY. Preliminary binding studies and 
blocking experiments demonstrated high affinity for the A3R (even higher than for 
[18F]FE@SUPPY and for the standard A3-selective compound MRS1523) and excellent 
selectivity against the other adenosine receptor subtypes. 
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Aims of the present study were (1) the preparation of the suitable labelling precursor and 
reference standard for [18F]FE@SUPPY:2, (2) the establishment of a radiosynthetic 
procedure for the preparation of the fluorine-18 labelled analogue, [18F]FE@SUPPY:2, (3) the 
evaluation and optimization of the reaction conditions to allow the large scale production of 
[18F]FE@SUPPY:2 and (4) the comparison of the results with those obtained with 
[18F]FE@SUPPY. 
Both, [18F]FE@SUPPY and [18F]FE@SUPPY:2, will finally serve as radioligands for the 
determination of Kd and Bmax on human A3R.  
 
Materials and Methods 
General 
1H- and 13C-NMR spectra were recorded on a Bruker Avance DPX-200 spectrometer at 27 °C 
(200.13MHz for 1H, 50.32MHz for 13C). Mass spectra were obtained on a Shimadzu QP 1000 
instrument (EI, 70eV). IR spectra were recorded on a Perkin-Elmer FTIR spectrum 1000 
spectrometer. Melting points were determined on a Reichert-Kofler hot-stage microscope. 
Elemental analyses were performed at the Microanalytical Laboratory, University of Vienna 
(Austria). Analysis of radio-TLC plates was performed using a digital autoradiograph (Instant 
Imager, Canberra-Packard, Rüsselsheim, Germany). Analytical high-performance liquid 
chromatography (HPLC) was performed using a Merck-Hitachi LaChrom system equipped 
with an L-7100 pump, an L-7400 UV detector (operated at 248 nm) and a lead-shielded NaI-
radiodetector (Berthold Technologies, Bad Wildbach, Germany). The semi-preparative HPLC 
system consisted of a Sykam S1021 pump, and an UV detector (254 nm) and a radioactivity 
detector in series. 
Solid phase extraction (SPE) cartridges (SepPak® C18plus) were purchased from Waters 
Associates (Milford, MA). [18F]Fluoride was produced via the 18O(p,n)18F reaction in a GE 
PETtrace cyclotron (16.5MeV protons; GE medical systems, Uppsala, Sweden). H2
18O (>98%) 
was purchased from Rotem Europe (Leipzig, Germany). Anion exchange cartridges (PS-HCO3) 
for [18F]fluoride separation were obtained from Macherey-Nagel (Dueringen, Germany). 
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If not stated otherwise, all starting materials for precursor and reference standard syntheses 
as well as for radiosyntheses were obtained from Merck (Darmstadt, Germany), Fluka or 
Sigma-Aldrich (Vienna, Austria). All reagents were at least of analytical grade and used 
without further purification.  
5-ethyl 2,4-diethyl-3-((2-hydroxyethyl)sulfanylcarbonyl)-6-phenylpyridine-5-carboxylate 
(OH@SUPPY:2; 1) was prepared as described previously in detail. [7] (see Figure 2)  
Precursor chemistry – 5-ethyl 2,4-diethyl-3-((2-tosyloxyethyl)sulfanylcarbonyl)-6-
phenylpyridine-5-carboxylate (Tos@SUPPY:2; 2) 
A reaction scheme is presented in Figure 3. A solution of toluene-4-sulfonyl chloride (1.64g, 
8.59mmol) in THF (15mL) was added drop wise to a stirred mixture of OH@SUPPY:2 (1; 
1.69g, 4.36mmol) and triethylamine (1.18g, 1.6ml, 11.67mmol) in THF (40mL) at 0°C. Then 
the reaction mixture was refluxed for 62h and the solvent was evaporated in vacuo. Finally, 
the residue was purified via column chromatography (length: 55.5cm; diameter: 2.5cm): 
combined straight phase silica gel (KG60 Merck; 70-230 mesh ASTM) with ligroin/ethyl 
acetate 3/1 as mobile phase and RP-18 (Merck LiChroprep RP-18; 40-63 µm) with 
acetonitrile/water as mobile phase were used.  
Reference standard – 5-ethyl 2,4-diethyl-3-((2-fluoroethyl)sulfanylcarbonyl)-6-phenyl-
pyridine-5-carboxylate (FE@SUPPY:2; 3) 
OH@SUPPY:2 (1; 1.00g, 2.58mmol) was dissolved in water-free dichloromethane (30mL) at -
78°C under inert gas. Diethylaminosulfur trifluoride (DAST; 0.69g, 5.17mmol) was slowly 
added dropwise to obtain crude FE@SUPPY:2. The reaction was kept at -78°C for half an 
hour and then slowly heated to room temperature. After completion of the reaction, the 
mixture was cooled to 0°C and hydrolysis was performed by addition of 10mL of water. The 
organic phase was separated and the aqueous phase was extracted 3-times with 
diethylether. The combined organic phases were dried over magnesium sulphate and the 
solvent was evaporated under reduced pressure. Subsequent purification was performed 
using again combined straight phase and reversed-phase column chromatography (for 
details see previous section).  
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Radiosynthesis – 5-ethyl 2,4-diethyl-3-((2-[18F]fluoroethyl) sulfanylcarbonyl)-6-phenyl-
pyridine-5-carboxylate ([18F]FE@SUPPY:2; 3a) 
No-carrier-added (n.c.a.) aqueous [18F]fluoride was fixed on an anion exchange cartridge 
(carbonate form) on-line and separated from excess water. Subsequently, [18F]fluoride was 
eluted with a solution containing the aminopolyether Kryptofix 2.2.2. (4,7,13,16,21,24-
hexaoxo-1,10-diaza-bicyclo[8.8.8]hexacosane; 20mg, 53.2µmol; for synthesis; Merck) and 
potassium carbonate (4.5mg, 32.6µmol; 99.9%+, Sigma-Aldrich) in acetonitrile/water (70/30 
vol/vol; V=1.0mL). This solution was heated to 100°C and azeotropic drying was performed 
by subsequent addition of at least four 250µL portions of acetonitrile (DNA grade, <10ppm 
water, Merck). 
To the dried [18F]fluoride-aminopolyether complex, 0.1-4.0mg of Tos@SUPPY:2 (0.2-
7.4µmol) in 500µL of acetonitrile was added, the vial was sealed and heated up to 120°C for 
1-60min. The mixture was cooled to room temperature and the radiochemical yield was 
determined using analytical radio-HPLC (column: Merck Chromolith® Performance RP18e 100 
x 4.6mm; mobile phase: acetonitrile/water/acetic acid (60/38.8/1.2 v/v/v; 2.5g/L ammonium 
acetate; pH 3.2); flow 2mL/min) and radio-TLC (plate: Merck TLC aluminium sheets RP-18 
F254s; mobile phase: acetonitrile/water 95/5 (v/v)).  
Purification of [18F]FE@SUPPY:2 
After cooling to ambient temperature, the crude reaction mixture was subjected to semi-
preparative reversed-phase HPLC (HPLC: column: Merck Chromolith® SemiPrep RP-18e, 
100x10mm; mobile phase: acetonitrile/water/acetic acid (60/38.8/1.2 v/v/v; 2.5g/L 
ammonium acetate; pH 3.2); flow: 10mL/min). Product peak of [18F]FE@SUPPY:2 eluted after 
4.0-4.9min, all other radioactive impurities were observed to elute clearly separated and 
accounted only for minor amounts of radioactivity. Tos@SUPPY:2 showed a retention time 
(tR) of 6.2-8.5min and was also completely removed from the product fraction.  
The [18F]FE@SUPPY:2 fraction was cut and diluted with 80mL water (Aqua ad injectabilia; 
Meditrade, Kufstein, Austria) to reduce lipophilicity of the solvent and subjected to SPE. This 
additional purification was performed in order to avoid potential contamination of the 
formulated product solution with toxic solvents. It is noteworthy that inadequate dilution 
resulted in partial breakthrough of [18F]FE@SUPPY:2. The resulting solution was then fixed 
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on a C18plus SepPak®. Solid phase extraction was shown to have significant advantages in 
the preparation of radiopharmaceuticals compared to evaporation using a rotary evaporator 
[8]. Time needed is decreased, technical requirements are kept to a minimum and potential 
radiolytic processes are diminished. After washing with 10mL water (Aqua ad injectabilia; 
Meditrade, Kufstein, Austria), the pure product was eluted with 2.0mL ethanol (100%, 
Pharm.Eur. grade, Merck), sterile filtered (0.22µm Millipore GS®) and formulated with 0.9% 
sodium chloride solution (15mL; for injection; Fresenius-Kabi, Graz, Austria). 
Quality control of [18F]FE@SUPPY:2 
Chemical and radiochemical impurities were detected using radio-HPLC and radio-TLC (for 
conditions see Radiochemistry section). Quality control systems revealed excellent 
separation and quantification properties: HPLC retention times were 8.9 ± 0.3min (range: 
8.5-9.2min) for [18F]FE@SUPPY:2 and 15.0 ± 0.5min (range: 14.4-15.6min) for Tos@SUPPY:2, 
respectively; Radio-TLC Rf-values were 0.0-0.1 for [
18F]fluoride and 0.63 ± 0.03 (range: 0.58-
0.68) for [18F]FE@SUPPY:2. All values were verified by the corresponding inactive reference 
substances.  
Residual solvents were analyzed by GC (carrier gas: He; flow: 2.7mL/min; 45°C (2.5min) – 
20°C/min to 110°C – 30°C/min to 200°C – 200°C (10 min);  FID: 270°C). Residuals of Kryptofix 
2.2.2 were analyzed using a dedicated test kit obtained through Rotem GmbH (Leipzig, 
Germany); semi-quantitative analysis was performed in accordance with the regulations laid 
down in the FDG monograph within the European Pharmacopoeia [9]. pH and osmolality 
were checked with dedicated equipment. Specific radioactivity was determined by dividing 
the activity of the final product (GBq) by the amount of “cold” FE@SUPPY:2 (µmoles) within 
this final product solution. A calibration curve was determined using different amounts of 
FE@SUPPY:2 standards in the previously given HPLC assay.  
 
Results and Discussion 
General 
Herewith, we present the successful preparation of [18F]FE@SUPPY:2 as a consequential 
close analogue of [18F]FE@SUPPY, which was presented recently. [2, 1] The two tracers were 
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selected according to Li et al. [3] who evaluated a series of adenosine A3 receptor 
antagonists. Amongst these antagonists, FE@SUPPY displayed favourable properties making 
it a promising candidate compound for a PET tracer. As evident from figure 1, 
[18F]FE@SUPPY and [18F]FE@SUPPY:2 are isomers with exchanged carboxylic and 
thiocarboxylic substituents. Having these two ester-moieties within one molecule, ester-
cleavage is expected as one of the primary metabolic routes. There is evidence in literature, 
that – as a general trend – thioesters are seemingly hydrolytically more stable than their 
corresponding oxy analogues [10]. However, for the hydrolysis of two different ester 
functions within one single molecule, to the best of our knowledge, there is no stability data 
available. In first preliminary kinetic experiments with carboxylesterases we observed the 
trend towards a higher stability of FE@SUPPY:2 as compared to FE@SUPPY (data not 
shown).  
On the other hand, beside these exciting metabolic features, knowing, that the A3R is 
according to Gessi et al. such an “enigmatic player in cell biology”, and there is still strong 
need for suitable antagonists or agonists for this receptor subtype [11], we could provide a 
second antagonist for the imaging of the A3R.  
So far, for autoradiography and binding studies, the well known and commercially available 
[125I]AB-MECA is the most used radioligand for the A3R. However, it is undisputed, that 
[125I]AB-MECA also displays considerable affinity for the A1R and A2AR. [12] Since the A3R is 
known to be the adenosine receptor subtype with the lowest density in most tissues, 
significance of the quantification of the A3R beside the other subtypes with [125I]AB-MECA is 
limited.  
Hence, additionally to the application as in-vivo radiotracers for PET, [18F]FE@SUPPY and 
[18F]FE@SUPPY:2 could serve as selective and high affinity radiotracers for quantitative 
autoradiography and binding studies. 
Precursor chemistry  
2.10 g purified Tos@SUPPY:2 was obtained (89%) as yellowish oil. For NMR-analysis, the 
solvent signal was used as an internal standard which was related to TMS with δ = 7.26ppm 
(1H in CDCl3) and δ = 77.0ppm (
13C in CDCl3), respectively. 
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1H-NMR (200 MHz, CDCl3): δ (ppm) 7.82 (m, 2H), 7.58 (m, 2H), 7.38 (m, 4H), 4.26 (t, 2H, J = 
6.30 Hz), 4.09 (q, 2H, J = 7.18 Hz), 3.39 (t, 2H, J = 6.20 Hz), 2.77 (q, 2H, J = 7.44 Hz), 2.64 (q, 
2H, J = 7.82 Hz), 2.44 (s, 3H), 1.28 (t, 3H, J = 7.56 Hz), 1.17 (t, 3H, J = 6.94 Hz), 0.98 (t, 3H, J = 
7.06 Hz).  
13C-NMR (50 MHz, CDCl3): δ (ppm) 194.2, 168.2, 159.2, 157.3, 148.0, 145.1, 139.6, 132.6, 
132.3, 129.9, 128.9, 128.3, 127.9, 126.6, 67.7, 61.5, 29.1, 28.8, 24.1, 21.6, 15.6, 14.0, 13.5.  
IR (KBr): ν (cm-1) 2978, 2938, 2878, 1724, 1678, 1598, 1556, 1495, 1463, 1447, 1403, 1362, 
1278, 1250. 
MS: m/z (%) 543 (M+ + 2, 1), 542 (1), 311 (24), 310 (100), 282 (17), 264 (4), 236 (3), 155 (3), 
91 (9). 
Elemental analysis: calculated for C28H31NO6S2: C, 62.08; H, 5.77; N, 2.59. found: C, 61.92; H, 
5.77; N, 2.57. 
The preparation and purification of the precursor molecule were accomplished straight 
forward without any significant problems. Surprisingly, the tosylation reaction was 
unexpectedly sluggish (62 hours under refluxing in THF). 
Reference standard  
0.37 g FE@SUPPY:2 was obtained after purification (37%) as yellowish oil.  
1H-NMR (200 MHz, CDCl3): δ (ppm) 7.60 (m, 2H), 7.42 (m, 3H), 4.76 (t, 1H, J = 5.92 Hz), 4.53 
(t, 1H, J = 5.94 Hz), 4.10 (q, 2H, J = 7.06 Hz), 3.50 (t, 1H, J = 5.94 Hz), 3.39 (t, 1H, J = 5.92 Hz), 
2.86 (q, 2H, J = 7.44 Hz), 2.72 (q, 2H, J = 7.58 Hz), 1.34 (t, 3H, J = 7.46 Hz), 1.23 (t, 3H, J = 7.44 
Hz), 0.98 (t, 3H, J = 7.06 Hz).  
13C-NMR (50 MHz, CDCl3): δ (ppm) 194.4, 168.2, 159.2, 157.2, 148.0, 139.6, 132.6, 126.6, 
81.3 (d, J = 170.5 Hz), 61.5, 30.0 (d, J = 21.8 Hz), 29.1, 24.1, 15.6, 14.0, 13.5.  
IR (KBr): ν (cm-1) 3061, 2978, 2939, 2902, 2879, 1726, 1678, 1557, 1465, 1448, 1405, 1380, 
1279, 1251, 1175, 1144, 1091, 1076, 1014, 973. 
MS: m/z (%) 389 (M+, 3), 343 (4), 311 (20), 310 (100), 282 (14), 236 (7),105 (20), 77 (12). 
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High-resolution mass spectroscopy (HRMS): m/z calculated for C21H24NO3SF: 389.1461; 
found: 389.1473. 
Radiosynthesis 
The general reaction scheme of the radiochemical preparation of [18F]FE@SUPPY:2 is given 
in Figure 3. Distinct temperature dependence was observed. Maximum yields were obtained 
at 100°C with no conversion at 120°C (Figure 4a). However, at temperatures above 75°C, we 
observed disproportional thermal load for the septa of the reaction vials. With focus for 
future automation we decided to keep this mechanical risk for the synthesizer module at a 
minimum and decided to perform the radiosynthesis at 75°C, below the boiling point of 
acetonitrile (~82°C). Additionally, possible leakage in the stressed septa could result in 
evaporation of solvent. Regarding the reaction kinetics, our data indicate that a minimum 
reaction time of 20 minutes is required to achieve satisfactory conversion results (Figure 4b). 
The slightly higher yields after 60 minutes are clearly outweighed by the decay of fluorine-
18. As evident from the present data, a continuous increase in the radiochemical yields is 
observed using increasing amounts of Tos@SUPPY:2 (Figure 4c). Interestingly, we observed 
the demand of drastically elevated amounts of precursor for the preparation of 
[18F]FE@SUPPY:2 as compared to [18F]FE@SUPPY (Figure 4c). Obviously, the SUPPY:2 
derivative is more sluggish than the SUPPY molecule. Scaling up the radiosynthesis, we found 
that a larger amount of precursor was needed for satisfactory conversion (20mg/mL) using 
starting activities up to 85.5GBq. Hence, optimum reaction conditions for large scale 
preparation of [18F]FE@SUPPY:2 were found to be 75°C with 20mg/mL of precursor for at 
least 20 minutes. 
So far, 6 complete high-scale radiosyntheses were performed. Starting from an average of 
51.2 ± 21.8GBq (mean ± SD; range: 10.8-85.5 GBq) [18F]fluoride, 5.8 ± 4.1GBq (range: 1.7-
14GBq) of formulated [18F]FE@SUPPY:2 (12.0 ± 5.4%, based on [18F]fluoride, not corrected 
for decay) was prepared in 75 ± 8 minutes (range: 61–84 min). Total recovery of radioactivity 
from SPE was higher than 97%. 
In comparison, we found for [18F]FE@SUPPY 32.3 ± 12.4% radiochemical yield, which is 
almost a threefold higher than for [18F]FE@SUPPY:2. [1] Once again, the sluggishness of the 
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reaction in the preparation of [18F]FE@SUPPY:2 due to the different position of the 
fluoroethyl-ester in the molecule seems to be the reason for this drastic change.  
Quality control of [18F]FE@SUPPY:2 
Radiochemical purity as determined via the given radio-TLC and radio-HPLC methods always 
exceeded 98%. Specific radioactivity was determined via HPLC and found to be 344 ± 133 
GBq/µmol; range: 187-575 GBq/µmol (9300 ± 3600 Ci/mmol; range: 5050-15500 Ci/mmol) at 
the end of synthesis (EOS). [18F]FE@SUPPY:2 was found to be stable for at least 10 hours 
(checked by chromatography).  
In comparison, we found for [18F]FE@SUPPY a specific radioactivity of 70.4 ± 26.1 GBq/µmol 
at EOS which is approximately a fifth of the value of [18F]FE@SUPPY:2. [1] For this fact, we 
are left without an explanation.  
 
Conclusion 
[18F]FE@SUPPY:2, a potential PET-ligand for the adenosine A3 receptor, was successfully 
prepared in a feasible and reliable manner. Purification using RP-HPLC and subsequent SPE 
methodology lead to high radiochemical purities and specific radioactivities. Compared with 
[18F]FE@SUPPY, the preparation of [18F]FE@SUPPY:2 demanded higher amounts of 
precursor and overall radiochemical yields were lower.  
The preparation of [18F]FE@SUPPY:2 will enable a direct comparison with [18F]FE@SUPPY in 
preclinical tests to select the optimum molecule for further applications.  
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Captions 
 
Figure 1 – Structural differences in fluoroethylated SUPPY and SUPPY:2 compounds and their 
precursor molecules. 
 
Figure 2 – Reaction scheme for the preparation of OH@SUPPY:2 (1, according to [7]).  
 
Figure 3 – Reaction scheme for the preparation of Tos@SUPPY:2, FE@SUPPY:2 and 
[18F]FE@SUPPY:2 starting from OH@SUPPY:2. 
 
Figure 4 – The dependence of the radiochemical yield of [18F]FE@SUPPY:2 on  
(a) reaction temperature (6 mg/mL precursor conc., 20 min);  
(b) reaction time (6 mg/mL precursor conc., 75°C); and  
(c) amount of precursor (75°C, 20 min) including data for [18F]FE@SUPPY. 
Bold data points represent arithmetic means ± SD for n≥4. Additionally, all single values are 
presented as light coloured crosses. 
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Figure 3  
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Figure 4 
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Abstract 
Introduction Since the Adenosine-A3-receptor was identified in the late 1990´s, there is little 
data available describing its distribution in vivo. Recently, we introduced [18F]FE@SUPPY as 
the first PET-tracer for this receptor. In the present investigation we translated this 
fluoroethyl-ester into the fluoroethyl-thioester [18F]FE@SUPPY:2 (5-ethyl 2,4-diethyl-3-((2-
[18F]fluoroethyl) sulfanylcarbonyl)-6-phenylpyridine-5-carboxylate). Aims of the present 
study were the evaluation of (1) the automatized preparation of both [18F]FE@SUPPY-
derivatives, (2) the biodistribution of [18F]FE@SUPPY:2, (3) the lipophilicity and (4) the 
comparison of the findings of [18F]FE@SUPPY and [18F]FE@SUPPY:2. Methods The 
automated preparations of both [18F]FE@SUPPY-analogues were performed on a GE 
TRACERlab FxFN synthesizer using suitable precursors. Biodistribution experiments were 
performed using Sprague-Dawley rats/Him:OFA. Lipophilicity of the compounds was 
determined using an HPLC assay. Results 22 automated radiosyntheses were performed for 
both radiotracers. Specific radioactivity was 70±26GBq/µmol for [18F]FE@SUPPY and 
340±140GBq/µmol for [18F]FE@SUPPY:2. Biodistribution experiments evinced bowels and 
liver as organs with highest uptake and intermediate uptake in kidney, lung and heart. LogP 
values of both molecules ranged from 3.99 to 4.12 at different pH. Conclusion From a 
radiopharmaceutical perspective, drastically better specific radioactivities would militate in 
favour of [18F]FE@SUPPY:2; preclinical evaluations, so far, do not permit the decision upon 
the selection of the optimum [18F]FE@SUPPY-derivative. With [18F]FE@SUPPY:2, we are able 
to provide a second potential tracer that could help to further characterize the still quite 
unexplored Adenosine-A3-receptor. 
Key words: Adenosine, PET, Adenosine A3 Receptor, Fluorine-18, Radioligand, SUPPY 
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Introduction 
Adenosine is one of the key modulators of the human body and acts through four different 
receptor subtypes: the A1, A2A, A2B, and A3 receptors, respectively (A1AR, A2AAR, A2BAR, and 
A3AR). The A3AR was identified in the late 1990´s, and, so far, there is little data available 
describing its distribution and density in vivo. The most suitable technique to collect these 
lacking data in the living organism would be PET (positron emission tomography). As a 
premise for molecular PET imaging with high quality, there is need for suitable radioligands 
displaying high affinity, high selectivity and low unspecific binding. Also, the absence of 
interfering radioactive metabolites in the target tissue is of importance. Beside these 
prerequisites, the most important premise for a successful PET-tracer is its widespread 
availability and reliable preparation. Additionally, to keep radiation burden for the operators 
as low as possible, a fully automated preparation would be beneficial. 
Recently, we introduced [18F]FE@SUPPY (5-(2-[18F]fluoroethyl) 2,4-diethyl-3-
(ethylsulfanylcarbonyl)-6-phenylpyridine-5-carboxylate) as the first PET-tracer for the A3AR. 
[1, 2] The radiosynthesis was performed in a simple one-pot one-step reaction with good 
and reliable radiolabelling yields and good specific radioactivities. [18F]FE@SUPPY was 
selected due to its favourable binding characteristics for the A3AR out of the well 
characterized chemical family of 3,5-diacyl-2,4-dialkylpyridines – with all derivatives showing 
considerable affinity for the adenosine receptor system [3]. Regarding the metabolic profile 
– these diacyl-derivatives all carry two ester moieties within one molecule, one carboxylic 
and one thiocarboxylic – enzymes derived from the family of carboxylesterases would be 
expected to significantly contribute to cleavage and degradation [4, 5]. To the best of our 
knowledge, there is no conclusive data regarding differences in stability of carboxylic and 
thiocarboxylic esters within one molecule. In a comparative study, Azema et al. [6] even 
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presented evidence for increased stability of the thioester function compared to carboxylic 
esters. Hence, we translated the fluoroethyl ester [18F]FE@SUPPY into the fluoroethyl-
thioester [18F]FE@SUPPY:2 (5-ethyl 2,4-diethyl-3-((2-[18F]fluoroethyl) sulfanylcarbonyl)-6-
phenylpyridine-5-carboxylate; see figure 1). Being close structural analogues, even 
lipophilicity of both molecules could be expected to be comparable. 
Thus, aims of the present study were  
(1) the fully automated preparation of both [18F]FE@SUPPY:2 and [18F]FE@SUPPY,  
(2) the evaluation of the biodistribution of [18F]FE@SUPPY:2 in rats,  
(3) the characterisation of the lipophilicity using standardized methods and  
(4) the comparison of the findings of [18F]FE@SUPPY and [18F]FE@SUPPY:2.  
 
Materials and Methods  
General  
Mass spectra were obtained on a Shimadzu QP 1000 instrument (EI, 70 eV; Shimadzu, Kyoto, 
Japan). IR spectra were recorded on a Perkin-Elmer FTIR spectrum 1000 spectrometer 
(Perkin Elmer, Watford, UK). Elemental analyses were performed at the Microanalytical 
Laboratory at the University of Vienna, Austria 
(http://www.univie.ac.at/Mikrolabor/ind_eng.htm). 1H- and 13C-NMR spectra were recorded 
on a Bruker Avance DPX-200 spectrometer at 27°C (200.13 MHz for 1H, 50.32 MHz for 13C; 
Bruker AXS GmbH, Karlsruhe, Germany). High resolution mass spectroscopy was performed 
on a Finnigan MAT 8230 (EI; 70eV; Thermo Finnigan Waltham, MA, USA). Radio-analytical 
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thin-layer chromatography (radio-TLC) was performed using silicagel 60F254 plates from 
Merck (Darmstadt, Germany). Analysis of radio-TLC plates and autoradiography were 
performed using a Canberra-Packard Instant Imager (Perkin Elmer, Watford, UK). Analytical 
high-performance liquid chromatography (HPLC) was performed using a Merck-Hitachi 
LaChrom system with a NaI-radiodetector from Berthold Technologies (Bad Wildbach, 
Germany). The semi-preparative HPLC system (as part of the GE TRACERlab Fx FN synthesizer) 
consisted of a Sykam S1021 pump (Sykam GmbH, Eresing, Germany) and a UV detector (254 
nm) and a radioactivity detector in series. 
Solid phase extraction (SPE) cartridges (SepPak® C18plus) were purchased from Waters 
Associates (Milford, USA). All starting materials for precursor and reference standard 
syntheses were commercially available and used without further purification. [18F]Fluoride 
was produced via the 18O(p,n)18F reaction in a GE PETtrace cyclotron (16.5MeV protons; GE 
Medical systems, Uppsala, Sweden). H2
18O (>98%) was purchased from Rotem Europe 
(Leipzig, Germany). Anion exchange cartridges (PS-HCO3) for [
18F]fluoride fixation were 
obtained from Macherey-Nagel (Dueringen, Germany).  
Precursor chemistry – 5-(2-tosyloxyethyl) 2,4-diethyl-3-(ethylsulfanylcarbonyl)-6-
phenylpyridine-5-carboxylate (Tos@SUPPY)  
This precursor was prepared as described previously [1, 2, 7]. Briefly, OH@SUPPY, prepared 
according to [8] was reacted with toluene-4-sulfonyl chloride in THF and purified by 
recrystallization.  
5-ethyl 2,4-diethyl-3-((2-tosyloxyethyl)sulfanylcarbonyl)-6-phenylpyridine-5-carboxylate 
(Tos@SUPPY:2)  
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A solution of toluene-4-sulfonyl chloride (1.64g, 8.59mmol) in THF (15mL) was added to 
OH@SUPPY:2 [8] (1.69g, 4.36mmol) and triethylamine (1.18g, 1.6ml, 11.67mmol) in THF 
(40mL) at 0°C. Then the reaction mixture was refluxed and the solvent was evaporated in 
vacuo. The residue was purified via column chromatography. 
Reference standard – 5-(2-fluoroethyl) 2,4-diethyl-3-(ethylsulfanylcarbonyl)-6-phenyl-
pyridine-5-carboxylate (FE@SUPPY)  
The reference compound was obtained according to [1, 2, 7]. Briefly, OH@SUPPY [8] was 
treated with diethylaminosulfur trifluoride (DAST) at -78°C. Purification was performed using 
column chromatography.  
5-ethyl 2,4-diethyl-3-((2-fluoroethyl)sulfanylcarbonyl)-6-phenyl-pyridine-5-carboxylate  
(FE@SUPPY:2) OH@SUPPY:2 (1.00g, 2.58mmol, [8]) was reacted with DAST (0.69g, 
5.17mmol) in water-free dichloromethane at -78°C. After hydrolysis, purification was 
performed using column chromatography.  
Automated radiosynthesis – [18F]FE@SUPPY and [18F]FE@SUPPY:2  
The automated preparation of both fluorinated FE@SUPPY analogues was preformed on a 
GE TRACERlab FxFN synthesizer. A comprehensive overview of all components of the system 
is given in figure 2. The following preparation steps were performed prior to synthesis start: 
a C18plus SPE cartridge (360mg, SepPak® Waters) and a PS-HCO3 SPE cartridge (45mg, 
Macherey-Nagel) were placed on their designated spots and connected to the corresponding 
tubing. The vials were filled with the following solutions: vial 1 – Kryptofix K2.2.2 
(4,7,13,16,21,24-hexaoxo-1,10-diaza-bicyclo[8.8.8]hexacosane; 20mg, 53.2µmol) and 
potassium carbonate (4.5mg, 32.6µmol) in a mixture of 700µL acetonitrile and 300µL water; 
vial 2 – 1mL acetonitrile; vial 3 – 0.5mL acetonitrile; vial 4 – 1mL of precursor solution (e.g. 
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10mg Tos@SUPPY (18.5µmol) in acetonitrile for [18F]FE@SUPPY and 15mg Tos@SUPPY:2 
(27.8 µmol) in acetonitrile for [18F]FE@SUPPY:2, respectively); vial 5 – 0.5mL water; vial 7 – 
15mL physiological saline; vial 8 – 2mL ethanol and vial 9 – 10mL water. The round bottom 
flask was filled with 80mL water and the reactor was filled with 1mL acetonitrile. 
No-carrier-added aqueous [18F]fluoride was produced via the 18O(p,n)18F reaction in a GE 
Gen2-silver target filled with 2.4mL [18O]water (>98%) and delivered to a 5mL v-vial. This vial 
was placed on the designated spot of the synthesizer (left hand side, see figure 2) and 
connected. Then, vacuum was applied and [18F]fluoride was sucked over the anion exchange 
cartridge on-line (via V10 and V11) and separated from excess water. [18F]fluoride was 
eluted with a solution containing Kryptofix 2.2.2. and potassium carbonate in 
acetonitrile/water into the reactor (V1, V10, V11, V13). The resulting solution was heated for 
2 minutes at 60°C and acetonitrile was added (V2). Heating was continued for another 3min 
at 60°C and then for 5min at 120°C in a stream of helium (V20) while adding the final portion 
of acetonitrile (V3) to complete azeotropic drying. The dried [18F]fluoride-aminopolyether 
complex was cooled to 65°C, precursor was added (V4) and the mixture was heated to 75°C 
for 18min. After cooling to 35°C, the crude reaction mixture was quenched with water (V5) 
and transferred (V14) to the injector of the semi-preparative reversed-phase HPLC system 
(column: Merck Chromolith® SemiPrep RP-18e, 100x10mm, mobile phase: 
acetonitrile/water/acetic acid (60/38.8/1.2 v/v/v; 2.5 g/L ammonium acetate; pH 3.2); flow: 
10 mL/min). Triggered by the fluid detector, the injector automatically changed from the 
“load” to the “inject” position and the chromatographic plotting started. Using the pre-
settings from our evaluation runs, the desired peak was cut automatically and collected in 
the round bottom flask (V18). The diluted solution was transferred over a C18plus SepPak® in 
a stream of helium (V17, V21). After washing with water (V9), the purified product was 
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eluted with ethanol (V8) directly into a sterile vial within a laminar air-flow hot-cell (V15) and 
on-line sterile filtered (0.22µm). The product was diluted and formulated using physiological 
saline (V7).  
Biodistribution experiments  
The experiments were approved by the Austrian law on animal experiments and the 
procedure followed the protocol established in various previous studies of our group. Male 
Sprague-Dawley rats/Him:OFA (n=20, 271-346 g) were injected with 2.17–7.52 MBq (180-
225µL) through a tail vein. Subsequently, individuals were sacrificed by exsanguination from 
the abdominal aorta in ether anaesthesia after 5, 15, 30, 60 and 120 minutes (n=4 each). 
Organs were removed, dry weighed and counted. Results are expressed as percent injected 
dose per gram tissue (%I.D./g).  
Lipophilicity  
The lipophilicity of the title compounds was determined using an HPLC assay based on 
Donovan and Pescatore [9]. Briefly, a short octadecyl-poly(vinyl alcohol) HPLC column 
(Supelco ODP-50; 4.6 x 20mm) was eluted with a flow rate of 2mL/min. A linear gradient 
from 10 to 100% methanol (organic phase) within 7 min was applied and buffers for pH 2, 
7.4 and 10 (aqueous phase) were prepared; UV-detection was done at 270 nm. Toluene and 
triphenylene (dissolved in methanol) were used as internal standards and the injection 
volume was 20µL. Between consecutive HPLC runs, 5min for re-equilibration of the HPLC 
column were allowed. The HPLClogP of a compound was then determined using the following 
equation: 
( )
triRtolR
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where logPtol and logPtri are the logP values for toluene and triphenylene, respectively, from 
the literature [10] and tR,tol and tR,tri are the retention times for toluene and triphenylene, 
respectively, determined in the HPLC run. tR,x is the retention time of the compound.  
clogP-values were calculated based on the structural formulas of the compounds using the 
logP add-on within the ACD/chemsketch software (ACD labs; version 11.01; October 2007).  
 
Results 
Precursor chemistry  
1.7g Tos@SUPPY was obtained as white crystalline powder and fully characterized as 
presented recently [1, 2]. 
2.10g purified Tos@SUPPY:2 was obtained (89%) as yellowish oil. For NMR-analysis, the 
solvent signal was used as an internal standard which was related to TMS with δ = 7.26ppm 
(1H in CDCl3) and δ = 77.0ppm (
13C in CDCl3), respectively. 
1H-NMR (200 MHz, CDCl3): δ (ppm) 7.82 (m, 2H), 7.58 (m, 2H), 7.38 (m, 4H), 4.26 (t, 2H, J = 
6.30 Hz), 4.09 (q, 2H, J = 7.18 Hz), 3.39 (t, 2H, J = 6.20 Hz), 2.77 (q, 2H, J = 7.44 Hz), 2.64 (q, 
2H, J = 7.82 Hz), 2.44 (s, 3H), 1.28 (t, 3H, J = 7.56 Hz), 1.17 (t, 3H, J = 6.94 Hz), 0.98 (t, 3H, J = 
7.06 Hz).  
13C-NMR (50 MHz, CDCl3): δ (ppm) 194.2, 168.2, 159.2, 157.3, 148.0, 145.1, 139.6, 132.6, 
132.3, 129.9, 128.9, 128.3, 127.9, 126.6, 67.7, 61.5, 29.1, 28.8, 24.1, 21.6, 15.6, 14.0, 13.5.  
IR (KBr): ν (cm-1) 2978, 2938, 2878, 1724, 1678, 1598, 1556, 1495, 1463, 1447, 1403, 1362, 
1278, 1250. 
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MS: m/z (%) 543 (M+ + 2, 1), 542 (1), 311 (24), 310 (100), 282 (17), 264 (4), 236 (3), 155 (3), 
91 (9). 
Elemental analysis: calculated for C28H31NO6S2: C, 62.08; H, 5.77; N, 2.59. found: C, 61.92; H, 
5.77; N, 2.57. 
Reference standards  
136.8mg FE@SUPPY was obtained as yellowish oil and fully characterized as presented 
recently [1, 2]. 
0.37g FE@SUPPY:2 was obtained after purification as yellowish oil.  
1H-NMR (200 MHz, CDCl3): δ (ppm) 7.60 (m, 2H), 7.42 (m, 3H), 4.76 (t, 1H, J = 5.92 Hz), 4.53 
(t, 1H, J = 5.94 Hz), 4.10 (q, 2H, J = 7.06 Hz), 3.50 (t, 1H, J = 5.94 Hz), 3.39 (t, 1H, J = 5.92 Hz), 
2.86 (q, 2H, J = 7.44 Hz), 2.72 (q, 2H, J = 7.58 Hz), 1.34 (t, 3H, J = 7.46 Hz), 1.23 (t, 3H, J = 7.44 
Hz), 0.98 (t, 3H, J = 7.06 Hz).  
13C-NMR (50 MHz, CDCl3): δ (ppm) 194.4, 168.2, 159.2, 157.2, 148.0, 139.6, 132.6, 126.6, 
81.3 (d, J = 170.5 Hz), 61.5, 30.0 (d, J = 21.8 Hz), 29.1, 24.1, 15.6, 14.0, 13.5.  
IR (KBr): ν (cm-1) 3061, 2978, 2939, 2902, 2879, 1726, 1678, 1557, 1465, 1448, 1405, 1380, 
1279, 1251, 1175, 1144, 1091, 1076, 1014, 973. 
MS: m/z (%) 389 (M+, 3), 343 (4), 311 (20), 310 (100), 282 (14), 236 (7),105 (20), 77 (12). 
High-resolution mass spectroscopy (HRMS): m/z calculated for C21H24NO3SF: 389.1461; 
found: 389.1473. 
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Automated radiosynthesis – [18F]FE@SUPPY and [18F]FE@SUPPY:2  
The described automated preparation of both fluorinated FE@SUPPY analogues was set up 
using standard PET radiochemistry equipment. The whole preparation including 
radiosynthesis, purification, sterile filtration and formulation was completed within 70-
80min. Semi-preparative HPLC revealed consistent retention patterns for [18F]FE@SUPPY 
and [18F]FE@SUPPY:2 (retention times: 4.2-4.9min; k’: 2.8-3.5). SPE purification led to a 
recovery of more than 90% using 2.0mL of ethanol. 
So far, 15 complete high-scale radiosyntheses were performed for [18F]FE@SUPPY and 7 
preparations were conducted for [18F]FE@SUPPY:2. Starting from 51 ± 25 GBq of 
[18F]fluoride, 9.4 ± 3.6 GBq of formulated [18F]FE@SUPPY and 5.1 ± 4.2 GBq of formulated 
[18F]FE@SUPPY:2 were achieved. 
Radiochemical purity as determined using radio-TLC and radio-HPLC always exceeded 97%. 
The only radioactive contaminant was found to be [18F]fluoride. Specific radioactivity was 
determined via HPLC and found to be 70 ± 26 GBq/µmol for [18F]FE@SUPPY and 340 ± 140 
GBq/µmol for [18F]FE@SUPPY:2, respectively, at the end of synthesis (EOS).  
Biodistribution experiments  
All values are shown in Table 1. The organ with the lowest uptake was fat showing 
0.05±0.02%I.D./g after 5 minutes, followed by lung (0.07±0.05%I.D./g), spleen 
(0.07±0.03%I.D./g) and brain (0.07±0.01%I.D./g, all values after 120 minutes). Organs with 
highest uptake were bowels with 1.45±0.97%I.D./g after 15 minutes followed by the liver 
showing 1.08±0.39%I.D/g after 5 minutes. Other organs with pronounced uptake were 
kidney and heart. Blood activity was 0.12-0.18%I.D./g throughout the whole experiment. 
Remaining activity in the carcass was 0.15-0.39%I.D./g.  
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Lipophilicity  
We found retention times of 4.95-5.15min for toluene and 8.05-8.15min for triphenylene. 
Both [18F]FE@SUPPY and [18F]FE@SUPPY:2 eluted at 6.48-6.67min. Using 2.74 as logPtol and 
5.49 as logPtri [10], the HPLClogP values of [
18F]FE@SUPPY and [18F]FE@SUPPY:2 were 
calculated according to the equation given in the methods section. These HPLClogP values at 
three different pH values and the calculated clogP of [
18F]FE@SUPPY and [18F]FE@SUPPY:2 
are presented in table 2. All HPLC-experiments were repeated at least 4-times; given values 
are arithmetic means.  
 
Discussion 
General  
Collectively, adenosine receptors are widespread on virtually every organ and tissue and 
represent promising drug targets for pharmacological intervention in many 
pathophysiological conditions such as asthma, neurodegenerative disorders, chronic 
inflammatory diseases, and cancer. The A3AR is the most recently identified adenosine 
receptor and its involvement in tumors has recently been shown: the A3ARs are highly 
expressed on the cell surface of tumor cells [11-16] and in human enteric neurons [17] but 
not in the majority of normal tissues [15]. In a very comprehensive study, A3AR mRNA 
expression in various tumor tissues was tested using reverse transcription-PCR analysis and 
A3AR protein expression was studied in fresh tumors and was correlated with that of the 
adjacent normal tissue. The authors conclude that primary and metastatic tumor tissues 
highly express A3AR indicating that high receptor expression is a characteristic of solid 
tumors. These findings suggest the A3AR as a potential target for tumor growth intervention 
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or imaging [18]. The A3ARs are also known to be involved in many other diseases, such as 
cardiac [19] and cerebral ischemia [20], glaucoma [21], stroke [22] and epilepsy [23].  
Li et al [3] published a series of chemical structures, with most of them displaying 
reasonable affinities for the A3AR. Amongst all the investigated structures, FE@SUPPY (see 
figure 1) was the most affine compound for the A3AR (Ki 4.22 nM) and thus was selected 
and developed as [18F]FE@SUPPY, the first PET-tracer [1,2]. Hence, having developed a 
series of fluoroethyl-esters over the last five years [24-29], it was obvious for us to develop 
[18F]FE@SUPPY:2. 
Precursor and reference standard  
Organic chemistry of precursor and reference molecules were accomplished in 
straightforward procedures. Preparations and purifications were performed with good 
yields; unexpectedly the tosylation reactions for both precursors were time-consuming.   
Automated radiosynthesis – [18F]FE@SUPPY and [18F]FE@SUPPY:2  
Automation of the radiosyntheses of [18F]FE@SUPPY and [18F]FE@SUPPY:2 was straight 
forward using the GE TRACERlab FxFN synthesizer with minor modifications (shortcuts). No 
problems were encountered when implementing the “manual” radiosynthesis [1, 2] on this 
synthesizer platform and, so far, not a single failed preparation was observed.  
For the satisfying synthesis of [18F]FE@SUPPY:2, a higher amount of precursor was needed 
(+50%) in comparison to [18F]FE@SUPPY. Nevertheless, radiochemical yields were drastically 
lower for [18F]FE@SUPPY:2 – 16.4 ± 9.7 % compared to 32.3 ± 12.4 % for [18F]FE@SUPPY 
(values based on [18F]fluoride, corrected for decay). Nucleophilic substitution of the tosyl-
leaving group on a thiocarboxylic ester moiety therefore seems to be slower than on a 
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carboxylic ester. Interestingly, the found specific radioactivities were dramatically higher for 
[18F]FE@SUPPY:2.  
Biodistribution experiments  
As presented in Table 1, organs displaying highest uptake were the bowels, followed by liver. 
Initially, uptake in the kidneys was high, too, yet decreasing significantly after 15 minutes. 
Since our group has demonstrated recently that [18F]fluoroethyl esters are primarily 
metabolized by carboxylic esterases, high kidney uptake could be explained by the renal 
excretion route of the major expected metabolite, [18F]fluoroethanol [30, 31]. High liver 
uptake could be explained by metabolism taking place in the cytochrome P-450-rich 
hepatosomes.  
Comparing maximum uptake values over time of [18F]FE@SUPPY and [18F]FE@SUPPY:2, we 
found good correlations in brain, muscle and testes; all other organs showed pronounced 
uptake variations. Comparing mean uptake values over time, only muscle and testes showed 
some degree of correlation. Figure 3 shows a comparison of the six most expedient organs 
and tissues: liver, fat, colon, ileum/jejunum, femur and brain.  Interestingly - in contrast to 
[18F]FE@SUPPY - uptake of [18F]FE@SUPPY:2 increased over time in fat and femur. Increasing 
uptake in fat could be explained by the relatively pronounced lipophilicity of 
[18F]FE@SUPPY:2 (see table 2), whereas usually bone uptake is attributed to defluorination. 
Initially high uptake in ileum/jejunum associated with increasing uptake in colon over time 
could be due to potential hepatobiliary clearance of [18F]FE@SUPPY:2. This fact could not be 
observed for [18F]FE@SUPPY. Calculating brain to blood ratios, we observed a dramatic 
increase of the ratio for [18F]FE@SUPPY (2.73-18.33; see figure 4), whereas [18F]FE@SUPPY:2 
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remained constant over time. So far, we are left without an explanation for this 
phenomenon. 
Lipophilicity  
As a prerequisite for its successful application as a radiopharmaceutical, a molecule has to 
exhibit several properties: it should be widely available, it should accumulate in the target 
tissue in stable condition and within a reasonable time flow and it should bind to the desired 
structures (receptor sites, enzymes, transporters, proteins…) with high affinity, selectivity 
and specificity. Since logP is known to influence many of these pharmacokinetic and 
pharmacodynamic parameters, especially unspecific binding of radiopharmaceuticals and 
blood brain barrier permeability [32], we tried to pay specific deference to this measure 
although we are well aware of the fact, that logP is of limited value as a predictor for 
lipophilicity. Nevertheless, it is the most commonly used and prominent measure.  
LogP (or more precisely OWlogP where OW stands for octanol/water) is defined as the 
decadal logarithm of the partition coefficient between equal volumes of 1-octanol and 
water. Normally, an aliquot of the solid compound is dissolved directly in a mixture of 1-
octanol and water, the phases are separated and then the content is determined using e.g. 
chromatographic or spectroscopic methods. But in the case of radiopharmaceutical 
preparations, on the one hand, one has the advantage of using the radioactivity for very 
accurate measurement of the product concentration but, on the other hand, one rarely has 
access to solid compounds. Furthermore, the final preparation is always contaminated by 
small amounts of other radioactive species (e.g. by-products, educts…). Even these small 
amounts (1-3%) would significantly bias the outcome of the measurement of the OWlogP: if, 
for instance, the final product solution of a typical lipophilic compound displayed a 
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radiochemical purity of 99% and the remaining 1% could be attributed to a contamination 
with hydrophilic [18F]fluoride, the partition coefficient would never be higher than 99 to 1 
and therefore the OWlogP measurement would always give a result lower than 2! Thus, 
optimized methods have been proposed to overcome this problem [33]. In our mind, the 
most elegant solution to get an accurate and simple measure of the lipophilicity is using the 
HPLClogP instead of OWlogP. Since contaminations are separated within the HPLC run they do 
not interfere with the retention of the main compound. Additionally, the used HPLC method 
is very simple and inexpensive, it may be used both with radioactive and non-radioactive 
compounds and the pH of the aqueous phase may be adjusted easily to whatever value is 
desired. 
As shown in table 2, logP values for both [18F]FE@SUPPY-derivatives are comparatively high. 
It is known, that high lipophilicity significantly contributes to the amount of unspecific 
binding. However, HPLClogP values measured for well established PET-tracers such as 
[11C]DASB (HPLClogP: 3.81), [
11C]carfentanil (HPLClogP: 3.37) or [
11C]verapamil (HPLClogP: 3.35) 
are also high and found their way into scientific routine. Hence, although being in the upper 
range, logP values should not be an obstacle for further expedient application of 
[18F]FE@SUPPY-derivatives.  
 
Conclusion 
Aims of the present study were (1) the automatized preparation of both [18F]FE@SUPPY-
derivatives, (2) the biodistribution of [18F]FE@SUPPY:2 in rats, (3) the characterisation of the 
lipophilicity and (4) the comparison of the findings of [18F]FE@SUPPY and [18F]FE@SUPPY:2. 
Results show that 
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(1) [18F]FE@SUPPY:2, an alternative to [18F]FE@SUPPY, the first PET-ligand for the adenosine 
A3 receptor, was prepared in a reliable and feasible manner. Automation yields for both 
molecules were sufficient for further preclinical and clinical applications.  
(2) Biodistribution experiments evinced bowels and liver as organs with highest uptake, 
suggesting metabolic activity and hepatobiliary excretion. Intermediate uptake was found in 
kidney, lung and heart, all organs known to express A3AR. 
(3) LogP values are in the upper range but should not pose any hindrance for successful 
application of [18F]FE@SUPPY and [18F]FE@SUPPY:2 in future. 
(4) The uptake pattern of [18F]FE@SUPPY:2 differed from [18F]FE@SUPPY, especially brain to 
blood ratios are considerably higher for [18F]FE@SUPPY. 
Hence, from a radiopharmaceutical perspective, drastically better specific radioactivities 
would militate in favour of [18F]FE@SUPPY:2; preclinical evaluations, so far, seem to point in 
favour of [18F]FE@SUPPY. Taken together, our preliminary data do not yet permit the 
decision upon the selection of the optimum [18F]FE@SUPPY-derivative. With 
[18F]FE@SUPPY:2, we are able to provide a second potential tracer that could help to further 
characterize the still quite unexplored A3AR. 
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Captions 
 
Figure 1 – Structural differences in fluoroethylated SUPPY and SUPPY:2 compounds and their 
precursor molecules. 
Figure 2 – Graphical illustration of the automated set-up of the commercially available 
TRACERlab Fx FN module for [
18F]FE@SUPPY and [18F]FE@SUPPY:2 synthesis.  
Figure 3 – A comparison of the uptake of [18F]FE@SUPPY and [18F]FE@SUPPY:2 in several 
organs. Values represent %I.D./g, n=4, error bars represent standard deviation. 
Figure 4 – Brain to blood ratios of [18F]FE@SUPPY and [18F]FE@SUPPY:2 after various time 
points. Values represent arithmetic means of individually calculated ratios, n=4, error bars 
represent standard deviation. 
Table 1 – Biodistribution values of [18F]FE@SUPPY:2 in rats at different time points.  
Table 2 – Experimentally determined HPLClogP and calculated clogP values of [
18F]FE@SUPPY 
and [18F]FE@SUPPY:2. 
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Figure 1 – Structural differences in fluoroethylated SUPPY and SUPPY:2 compounds and their 
precursor molecules. 
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Figure 2 – Graphical illustration of the automated set-up of the commercially available 
TRACERlab Fx FN module for [
18F]FE@SUPPY and [18F]FE@SUPPY:2 synthesis.   
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 Figure 3 – A comparison of the uptake of [18F]FE@SUPPY and [18F]FE@SUPPY:2 in several 
organs. Values represent %I.D./g, n=4, error bars represent standard deviation.  
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Figure 4 – Brain to blood ratios of [18F]FE@SUPPY and [18F]FE@SUPPY:2 after various time 
points. Values represent arithmetic means of individually calculated ratios, n=4, error bars 
represent standard deviation.  
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Table 1 – Biodistribution values of [18F]FE@SUPPY:2 in rats at different time points.  
 
Tissue 5min 15min 30min 60min 120min 
blood 0,18 ± 0,05 0,15 ± 0,05 0,18 ± 0,05 0,14 ± 0,02 0,12 ± 0,03 
liver 1,08 ± 0,39 0,76 ± 0,34 0,79 ± 0,24 0,40 ± 0,06 0,21 ± 0,04 
femur 0,27 ± 0,10 0,20 ± 0,10 0,31 ± 0,10 0,48 ± 0,08 0,67 ± 0,10 
lung 0,48 ± 0,14 0,31 ± 0,11 0,25 ± 0,06 0,12 ± 0,04 0,07 ± 0,05 
heart 0,85 ± 0,24 0,40 ± 0,07 0,31 ± 0,08 0,15 ± 0,03 0,10 ± 0,03 
thyroid 0,41 ± 0,13 0,24 ± 0,09 0,30 ± 0,13 0,21 ± 0,03 0,14 ± 0,09 
kidney 1,06 ± 0,37 0,56 ± 0,16 0,61 ± 0,13 0,43 ± 0,11 0,26 ± 0,05 
testes 0,10 ± 0,04 0,08 ± 0,04 0,13 ± 0,05 0,11 ± 0,02 0,09 ± 0,03 
fat 0,05 ± 0,02 0,08 ± 0,04 0,18 ± 0,17 0,19 ± 0,03 0,25 ± 0,08 
muscle 0,26 ± 0,10 0,15 ± 0,09 0,18 ± 0,08 0,12 ± 0,04 0,08 ± 0,04 
colon 0,19 ± 0,09 0,21 ± 0,15 0,66 ± 0,84 0,69 ± 1,00 0,16 ± 0,11 
ileum/jejunum 0,78 ± 0,41 1,45 ± 0,97 0,50 ± 0,32 0,45 ± 0,28 0,21 ± 0,11 
spleen 0,33 ± 0,13 0,18 ± 0,05 0,17 ± 0,05 0,09 ± 0,02 0,07 ± 0,03 
brain 0,34 ± 0,13 0,18 ± 0,02 0,21 ± 0,06 0,09 ± 0,02 0,07 ± 0,01 
carcass 0,31 ± 0,09 0,39 ± 0,13 0,33 ± 0,13 0,26 ± 0,05 0,15 ± 0,05 
 
Values represent percentage of injected dose per gram of tissue (% I.D./g; arithmetic means 
± standard deviation) 
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Table 2 – Experimentally determined HPLClogP and calculated clogP values of [
18F]FE@SUPPY 
and [18F]FE@SUPPY:2. 
 
 
HPLClogP  
pH 2 pH 7.4 pH 10 
clogP 
[18F]FE@SUPPY 3.99 4.04 4.06 5.81 
[18F]FE@SUPPY:2 4.12 4.05 4.10 5.81 
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Abstract 
Introduction: Recently, [18F]FE@SUPPY and [18F]FE@SUPPY:2 were introduced as the first 
PET-tracers for the adenosine A3 receptor. Thus, aim of the present study was the metabolic 
characterisation of the two adenosine A3 receptor PET tracers. Methods: In-vitro 
carboxylesterase experiments were conducted using incubation mixtures containing of 
different concentrations of the two substrates, porcine carboxylesterase and phosphate 
buffered saline. Enzymatic reactions were stopped by adding acetonitrile/methanol (10:1) 
after various timepoints, and analyzed by a HPLC standard protocol. In-vivo experiments 
were conducted in male wild type rats; tracers were injected through a tail vein. Rats were 
sacrificed after various timepoints (n=3) and blood and brain samples were collected.  
Sample clean-up was performed by a HPLC standard protocol. Results: The rate of enzymatic 
hydrolysis by carboxylesterase demonstrated Michaelis-Menten constants in a µM range 
(FE@SUPPY: 20.15µM and FE@SUPPY:2: 13.11µM) and limiting velocities of 0.035µM/min 
and 0.015µM/min for FE@SUPPY and FE@SUPPY:2, respectively. Degree of metabolism in 
blood showed: 15min p.i. 47.7% of [18F]FE@SUPPY were intact compared to 33.1% of 
[18F]FE@SUPPY:2; 30min p.i. 30.3% intact [18F]FE@SUPPY were found compared to 15.6% 
[18F]FE@SUPPY:2. In brain [18F]FE@SUPPY:2 formed an early hydrophilic metabolite, 
whereas metabolism of [18F]FE@SUPPY was not observed before 30 minutes p.i. Conclusion: 
Knowing, that metabolism in rats is several times faster than in human, we conclude that 
[18F]FE@SUPPY should be stable for the typical time span of a clinical investigation. As a 
consequence, from a metabolic point of view, one would tend to decide in favour of 
[18F]FE@SUPPY. 
Keywords: PET, Adenosine A3 Receptor, Fluorine-18, SUPPY, Metabolism, Carboxylesterase 
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Introduction 
Adenosine is an important regulatory molecule which activates four receptors named A1, A2A, 
A2B, and A3 (A1R, A2AR, A2BR, A3R), respectively, which all belong to the G-protein–coupled
 
superfamily of receptors. There exists a lot of information about the A1 and A2A receptors, 
because good pharmacological tools - including radioligands - are available. In the case of 
the A3 receptors,
 these tools have been presented lately, but there is still little information in 
literature regarding the distribution and density of these receptors in humans. 
Yet, A3R agonists and antagonists are discussed for the treatment of pathophysiological 
conditions, such as asthma, neurodegenerative disorders and inflammatory diseases [1]. 
Moreover, it was repeatedly shown that A3Rs are highly expressed on the cell surface of 
various tumor cell lines [2, 3]. Hence, the A3R may also serve as a potential target for tumor 
growth inhibition and tumor imaging. The most suitable and accurate technique to gain 
information about receptors in the living organism is PET (positron emission tomography). As 
a prerequisite for molecular PET imaging, there is need for suitable radioligands displaying 
high affinity, high selectivity and low nonspecific binding.  
The fluoroethylester FE@SUPPY (5-(2-fluoroethyl) 2,4-diethyl-3-(ethylsulfanyl-carbonyl)-6-
phenylpyridine-5-carboxylate), which was evaluated by Li et al., displays high affinity 
(Ki=4.22nM) as well as excellent selectivity for the A3R (ratio A1/A3=2700) [4]. Recently, we 
introduced [18F]FE@SUPPY as the first PET-tracer for the A3R [5, 6]. Meanwhile, a second 
potential PET-radiotracer has been presented, radiolabelled with the radionuclide bromine-
76 [7].  
Regarding possible metabolic pathways for [18F]FE@SUPPY, it has to be pointed out that this 
diacyl-derivative carries two ester moieties, one carboxylic and one thiocarboxylic ester. 
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Enzymes derived from the family of porcine carboxylesterases EC 3.1.1.1 (CES) would be 
expected to significantly contribute to cleavage of the ester function and thus to the 
degradation of this molecule [8]. [18F]FE@SUPPY carries the [18F]fluoroethyl-substituent on 
the carboxylic function, whereas the thiocarboxylic moiety carries an ethyl-ester group. It 
appeared promising to exchange these fluoroethyl and ethyl substituents within the 
molecule to generate a structural analogue which could be evaluated as a second potential 
PET-tracer. 
Hence, we translated the fluoroethyl-ester [18F]FE@SUPPY into the fluoroethyl-thioester 
[18F]FE@SUPPY:2 (5-ethyl 2,4-diethyl-3-((2-[18F]fluoroethyl) sulfanylcarbonyl)-6-
phenylpyridine-5-carboxylate) [9, 10]. As far as assessable from literature, there is no 
conclusive data regarding differences in stability of carboxylic and thiocarboxylic ester 
moieties within one molecule. Interestingly, Azema et al. presented evidence for increased 
stability of a thioester function compared to a carboxylic ester group [11].  
The radiosyntheses of both molecules were performed in simple one-pot, one-step reactions 
with good and reliable radiolabelling yields and good specific radioactivities [5, 9]. 
Biodistribution experiments revealed that the uptake pattern of the two tracers mainly 
followed the distribution pattern of the A3R mRNA [6, 10].  
As a next step in the preclinical evaluation of these two radioligands, their metabolic profiles 
had to be examined to gain further information regarding their stability and degradation in-
vitro and ex-vivo. Since radioactive metabolites – if present in the target tissue – could 
interfere with the signal of the intact molecule, distinct information regarding the amount of 
possible formation of these metabolites is crucial before application in humans. Thus, aims 
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of the present study were the metabolic characterisation and the comparison of the two 
A3R PET tracers, [18F]FE@SUPPY and [18F]FE@SUPPY:2.  
In detail we aimed for, 
(1) the assessment of the in-vitro stability of FE@SUPPY and FE@SUPPY:2 against  
 Carboxylesterase and the metabolites;  
(2) the determination of the extent of metabolisation of [18F]FE@SUPPY and 
[18F]FE@SUPPY:2 in rodents; and  
(3) the comparison of the metabolic behaviour of both tracers. 
 
Materials and Methods  
General 
Radioanalytical thinlayer chromatography (radio-TLC) was performed for determination of 
radiochemical purity using TLC Silicagel 60 F254 plates from Merck (Darmstadt, Germany). 
Analyses of radio-TLC plates were performed using a Canberra-Packard Instant Imager 
(Perkin Elmer, Watford, UK). Analytical high-performance liquid chromatography (HPLC) 
system was used for determination of specific radioactivity and identity consisting of a 
Merck-Hitachi LaChrom pump and UV-detector, as well as a NaI-radiodetector from Berthold 
Technologies (Bad Wildbach, Germany). The semi-preparative HPLC system (as part of the 
GE TRACERlab FxFN synthesizer) consisted of a Sykam S1021 pump (Sykam GmbH, Eresing, 
Germany), an UV detector and a radioactivity detector. 
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Solid phase extraction cartridges (SepPak® C18plus) were purchased from Waters Associates 
(Milford, USA). Anion exchange cartridges (PS-HCO3) for [
18F]fluoride fixation were obtained 
from Macherey-Nagel (Dueringen, Germany). All starting materials for precursor and 
reference standard syntheses were commercially available and used without further 
purification. Acetonitrile was purchased from Merck; methanol and carboxylesterase (E-
3019) were purchased from Sigma Aldrich (Steinheim, Germany).  
HPLC System1: Autosampler 1100, quaternary pump 1200 (at a flow rate of 1ml/min) and 
diode array detector 1100 (248 and 255nm) were purchased from Agilent (Böblingen, 
Germany). LiChrospher®100 (RP-18 LiChroCART® 125-4mm) and LiChrospher®100 pre-column 
(RP-18 LiChroCART® 4-4mm) as well as chemicals for mobile phase (0.034M sodium citrate 
tribasic dihydrate, pH 2.5 and acetonitrile) were purchased from Merck. Mobile phase: 
citrate buffer/acetonitrile 1:1.  
HPLC System2: Pump L-6220 (at a flow rate of 2ml/min) and UV-detector L-4000 were 
purchased from Merck-Hitachi. Radiomatic Flo-One Beta Flow Scintillation Analyzer was 
purchased from Packard, Radiomatic FlowBeta FSA 150 detector cell from PerkinElmer. 
Columns (Cromolith® Performance RP-18e 100-4.6mm) and chemicals for mobile phase (60% 
acetonitrile and 40% water/acetic acid 97.5/2.5, 32mM ammonium acetate, pH 3.5) were 
purchased from Merck. 
Chemistry and Radiochemistry 
The preparations of the precursors, Tos@SUPPY and Tos@SUPPY:2, as well as the 
productions of the reference standards FE@SUPPY, FE@SUPPY:2, SUPPY:0, FE@SUPPY:11, 
FE@SUPPY:21, DFE@SUPPY and DFE@SUPPY:2 were described in detail elsewhere [9, 10, 
12, 13] (for chemical structures see figure 1). 
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The automated preparations of both [18F]fluorinated FE@SUPPY analogues were performed 
on a GE TRACERlab FxFN synthesizer by radiofluorination of the corresponding tosylated 
precursor in a one-step, one-pot reaction, as already described [5, 9]. 
Enzyme reactions 
Experiments (n=3) were performed using several pre-tested concentrations of the two 
tracers to get reasonable Michaelis-Menten kinetics. For FE@SUPPY concentrations of 20, 
50, 100, 200, 350µg/ml and for FE@SUPPY:2 concentrations of 5, 10, 20, 50, 200, 350µg/ml 
turned out to be most useful. Incubations of the substrates were accomplished with 
constant quantity of porcine carboxylesterase: 80 I.U. in phosphate buffered saline (PBS) at 
37°C. Enzymatic reactions were stopped by adding twice the amount of 
acetonitrile/methanol (10:1) after 0, 60, 120, 180, 240, 360min, respectively. After 
centrifugation (10000rpm, 3min) of the reaction mixtures, the obtained supernatant (~80µl) 
was analyzed by HPLC (injecting volume 20µl; System1). 
Metabolite studies 
In-vivo experiments were approved by the Austrian law on animal experiments and  followed 
the protocol established in previous studies of our group [6]. Briefly, 42 male wild type rats 
(250-300g) were either injected with 17±1MBq of [18F]FE@SUPPY (n=21) or with 14±1MBq of 
[18F]FE@SUPPY:2 (n=21) through a tail vein. Subsequently, the rats were sacrificed after 2, 5, 
10, 15, 30, 60, 120 minutes (n=3).  
Blood samples (3ml) were collected from the abdominal aorta in sodium citrate buffered 
tubes and centrifuged (3000rpm, 5min) to separate cellular components. Sample clean-up 
was performed by vortexing plasma with the equivalent amount of methanol/acetonitrile 
(9:1) for 1min and by subsequent two step-centrifugation (3000rpm, 3min and 10000rpm, 
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3min) to remove precipitated proteins. The obtained supernatants were analyzed by HPLC 
(System2).  
Brains were collected, weighed, homogenized and washed twice with phosphate buffered 
saline. After centrifugation (15000rpm; 5min), sample clean-up was performed as described 
for blood samples. Statistical calculations were performed with Microsoft® Excel and Graph 
Pad Prism®. 
 
Results 
Radiochemistry 
The radiopreparations for both A3R radioligands were completed within 70-80min. Starting 
from 51±25GBq of [18F]fluoride, 9.4±3.6GBq ([18F]FE@SUPPY) and 5.1±4.2GBq 
([18F]FE@SUPPY:2) were formulated. Specific radioactivity (determined via radio-HPLC) was 
70±26GBq/µmol for [18F]FE@SUPPY and 340±140GBq/µmol for [18F]FE@SUPPY:2 at the end 
of synthesis (EOS). Radiochemical purities always exceeded 98%.  
Enzyme reactions 
Results are presented in figure 2. The in-vitro assays showed Michaelis-Menten constants 
(KM) of 20.15µM for FE@SUPPY and 13.11µM for FE@SUPPY:2. The limiting velocities (VMax) 
were 0.035µM/min for FE@SUPPY and 0.015µM/min for FE@SUPPY:2. FE@SUPPY was 
cleaved to DFE@SUPPY, while FE@SUPPY:2 was cleaved to FE@SUPPY:21 (see figure 1). The 
HPLC assay was capable to qualitatively and quantitatively separate and resolve the 
potential metabolites. The detected radioactive metabolites are co-eluting with the 
corresponding reference standards (see table 1).  
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Metabolite studies 
Extent of metabolism of [18F]FE@SUPPY and [18F]FE@SUPPY:2 in blood is presented in figure 
3A. Rate of metabolism was different for [18F]FE@SUPPY and [18F]FE@SUPPY:2. 47.7% of 
[18F]FE@SUPPY were intact 15min after injection compared to 33.1% of [18F]FE@SUPPY:2;  
30min p.i. 30.3% of intact [18F]FE@SUPPY were found compared to 15.6% of 
[18F]FE@SUPPY:2.  
The radiolabeled metabolites in brain are presented in figure 3B. The point of time of the 
first detection of metabolites was different for [18F]FE@SUPPY and [18F]FE@SUPPY:2.  
 
Discussion 
General  
It appears undisputed, that there is a demand for a suitable PET-ligand for the A3R both for 
in-vitro and in-vivo use. The molecules, based on a diacyl-pyridine structure [18F]FE@SUPPY 
and [18F]FE@SUPPY:2, and later, xanthine-derivatives (radiolabelled with bromine-76) have 
been introduced for that purpose [5-7, 9, 10, 12]. All these molecules did not yet find their 
way into human application. In preclinical experiments with [18F]FE@SUPPY and 
[18F]FE@SUPPY:2, so far, the results indicate to focus on these molecules [5, 6, 9, 10]: Both 
automated radiosyntheses were feasible; uptake was found in organs reliably expressing 
A3R mRNA and first brain autoradiographic slides showed good selectivity and specificity. 
The uptake pattern of [18F]FE@SUPPY and [18F]FE@SUPPY:2 was similar and comparable to 
that found by Kiesewetter et al. [7].  
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To find its way into clinical application a newly developed radiotracer has to show favourable 
metabolic characteristics: sufficient stability within the time period specified for the 
application and absence of excessive metabolites in the target tissue.  
Enzyme reactions 
Taking a closer look on the chemical structure of [18F]FE@SUPPY and [18F]FE@SUPPY:2, it can 
be expected, that, after passing the blood brain barrier or other tissue membranes, the 
molecules are cleaved by hydrolase (e.g. carboxylesterase) by forming 2-[18F]fluoroethanol 
and the respective corresponding acids (cf. figure 1). 2-[18F]Fluoroethanol would easily 
diffuse from tissue and would not contribute to receptor signal leading to lower non-specific 
accumulation compared to tracers keeping their radiolabel to their backbone. To obtain a 
first estimate of potential in-vivo degradation, in-vitro enzyme (e.g. CES) reactions can be a 
helpful tool. It can be derived from figure 2 and table 1, that the degradation paths of 
enzymatic cleavage of FE@SUPPY and FE@SUPPY:2 are similar: In both cases, cleavage was 
observed on the carboxylic function while the thiocarboxylic core remained intact. This 
observation cannot be explained by the fact that carboxylesterases only address carboxylic 
functions (and not thiocarboxylic cores) - as probably inspired by its name. Since it is well 
known, that carboxylesterases contribute to cleavage on both ester functions [14], this 
observation has to be due to different stability properties of the thio- and carboxylic core 
within our molecules.  
Metabolite studies 
Sometimes, tracers, radiolabelled with fluorine-18 tend to show defluorination. In case of 
[18F]FE@SUPPY and [18F]FE@SUPPY:2, the minimum uptake in bone, shown in our precedent 
biodistribution studies, revealed no separation of [18F]fluoride from the parent molecules 
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[6,10]. In both, blood and brain, one hydrophilic metabolite was detected for [18F]FE@SUPPY 
and [18F]FE@SUPPY:2. As evident from figure 3A, differences in blood are between the time 
period of 15 and 30 minutes p.i. In this time period, [18F]FE@SUPPY is more stable (after 15 
minutes a factor of 1.42, after 30 minutes a factor of 1.93). This higher stability is in 
agreement with our in-vitro findings (difference in KM: factor 1.54). In brain, we found major 
differences: [18F]FE@SUPPY:2 formed an early hydrophilic metabolite, whereas metabolism 
of [18F]FE@SUPPY was not observed before 30 minutes p.i. A possible explanation for these 
findings could be the differences in metabolic pathways as observed in our previous 
carboxylesterase experiments.   
Comparison of enzyme reactions and ex-vivo metabolite studies 
Comparing the findings of carboxylesterase experiments with the ex-vivo studies, one has to 
remark, that [18F]FE@SUPPY:2 would be expected to form a radioactive hydrophilic 
metabolite ([18F]FE@SUPPY:21), potentially interacting with the target. In contrast, from the 
carboxylesterase path, [18F]FE@SUPPY forms DFE@SUPPY – a non-radioactive metabolite. 
Hence, from this point of view, [18F]FE@SUPPY, forming no radioactive hydrophilic derivative 
by CES path, would be favourable for potential applications in the central nervous system. 
 
Conclusion 
Aim of the present study was the assessment of the in-vitro and in-vivo stability of 
[18F]FE@SUPPY and [18F]FE@SUPPY:2. Although being structurally closely related, the way of 
CES degradation was different. Metabolic characteristics both in rodent blood and brain 
were different, too: for [18F]FE@SUPPY, brain metabolites were not observed before 30 
minutes p.i, and its metabolism in blood was more slowly. Knowing, that metabolism in rats 
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is several times faster than in human, we conclude that [18F]FE@SUPPY should be stable for 
the typical time span of a clinical investigation. Hence, from a metabolic point of view, for 
imaging of the density of the A3R one would tend to decide in favour of [18F]FE@SUPPY. 
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Figure 1 
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Figure 2 
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Figure 3 
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Table 1 
 
A3R defluoroethylated fluoroethylated final expected found 
Ligands metabolite metabolite metabolite metabolite 
FE@SUPPY DFE@SUPPY FE@SUPPY:11 SUPPY:0 DFE@SUPPY 
11.03±0.02 3.76±0.01 3.16±0.01 9.69±0.02 3.78±0.02 
FE@SUPPY:2 DFE@SUPPY:2 FE@SUPPY:21 SUPPY:0 FE@SUPPY:21 
10.70±0.01 16.94±0.02 2.86±0.01 9.69±0.02 2.86±0.01 
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Captions 
 
 
Figure 1: Potential metabolic pathways of [18F]FE@SUPPY and [18F]FE@SUPPY:2 cleaved by 
carboxylesterase (CES). Metabolites found in the CES experiments are in bold letters. 
Figure 2: Michaelis-Menten kinetics and schematic Lineweaver-Burk illustration of (A) 
FE@SUPPY and (B) FE@SUPPY:2 – each single point represents the mean value of triplicate 
analyses. vmax is the limiting velocity and KM is the Michaelis-Menten constant. 
Figure 3: Scheme showing [18F]FE@SUPPY and [18F]FE@SUPPY:2 and their respective 
metabolites 
A) in blood 
B) in brain 
Table 1: Retention times [min] of [18F]FE@SUPPY and [18F]FE@SUPPY:2 and their 
metabolites. Data represent arithmetic means ± SD. 
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2.2.6. PAPER 5 
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Abstract 
Purpose: Since the late 1980s, cocaine analogues based on the phenyltropane structure, 
such as [11C]CFT and [123I]ß-CIT have been used for the imaging of the dopamine transporter. 
Fe@CIT (fluoropropyl ester) and FP-CIT (N-fluoropropyl derivative) are further analogues. 
Aim of this study was to (1) evaluate and compare the metabolic stability of ß-CIT, FP-CIT 
and FE@CIT against carboxyl esterases and (2) evaluate selectivity of [18F]FE@CIT compared 
to [123I]ß-CIT and [123I]FP-CIT using autoradiography. 
Methods: In-vitro enzymatic hydrolysis assays were performed using different 
concentrations of ß-CIT, FE@CIT and FP-CIT with constant concentrations of carboxyl 
esterase. Autoradiography was performed on coronal 20 µm rat brain sections incubated 
with different radioactivity concentrations of [123I]ß-CIT, [123I]FP-CIT or [18F]FE@CIT and 
additionally with DASB (SERT) and nisoxetine (NET) for blocking experiments. 
Results: In-vitro assays showed Michaelis-Menten constants of 175 µmol (ß-CIT), 183 µmol 
(FE@CIT) and 521 µmol (FP-CIT). Limiting velocities were 0.1005 µmol/min (ß-CIT), 0.1418 
µmol/min (FE@CIT) and 0.1308 µmol/min (FP-CIT). This indicates a significantly increased 
stability of FP-CIT, whereas carboxyl esterase stability of ß-CIT and FE@CIT showed no 
significant difference. Autoradiographic analyses revealed a good correlation between DAT-
rich regions and the uptake pattern of FE@CIT. Blocking experiments showed a higher DAT 
selectivity for [18F]FE@CIT than for the other two tracers. 
Conclusion: We found, that (1) the metabolic stability of FE@CIT was comparable to that of 
ß-CIT, whereas FP-CIT showed higher resistance to enzymatic hydrolysis; and (2) the overall 
uptake pattern of [18F]FE@CIT on brain slices was comparable to that of [123I]ß-CIT and 
[123I]FPCIT. After blocking of NET and SERT-binding, a significantly higher DAT-selectivity was 
observed for [18F]FE@CIT. Hence, [18F]FE@CIT may be of interest for further clinical 
application. 
 
Key words: FE@CIT, DAT, Metabolism, Autoradiography 
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Introduction 
Alterations in the dopamine transporter (DAT) are associated with a variety of neurological 
and psychiatric diseases. Hence, the imaging of the DAT is undisputedly valuable for the 
diagnosis of these diseases. So far, a series of DAT-ligands - both for SPECT and PET - have 
been investigated with varying specificities and selectivities. [123I]ß-CIT (2ß-carbomethoxy-
3ß-(4-[123I]iodophenyl)tropane) and [123I]FP-CIT (N-(3-fluoropropyl)-3ß-(4-[123I]iodophenyl) 
nortropane-2ß-carboxylic acid methyl ester) have been established for routine SPECT. 
[11C]PE2I ([O-methyl-11C]N-(3-iodoprop-2E-enyl)-2ß-carbomethoxy-3ß-(4-methylphenyl) 
nortropane) was so far discussed as the carbon-11 labelled ligand of choice for PET. 
However, recent data revealed the formation of interfering metabolites and slow kinetics in 
humans hampering its applicability [1]. Furthermore, no fluorine-18 labelled radioligand has 
prevailed so far. We recently presented [18F]FE@CIT (2-[18F]fluoroethyl 3ß-(4-
iodophenyl)tropane 2ß-carboxylate) which offers favourable binding characteristics 
compared to FE-CIT, CFT, FECT, FETT, ß-CIT or FP-CIT and PE2I [1-5]. However, the molecules 
were compared on a cellular level. Another important parameter influencing the suitability 
of a radioligand is its metabolic behaviour. Therefore, the aim of the present study was the 
comparative evaluation of (1) the metabolic stability of ß-CIT, FP-CIT and FE@CIT (figure 1) 
against carboxyl esterases and (2) the autoradiographic binding pattern of [123I]ß-CIT, 
[123I]FP-CIT and [18F]FE@CIT, respectively. 
 
Materials and Methods 
Radiochemistry. [18F]FE@CIT was synthesized by reacting 3-β-(4-Iodophenyl)tropane-2-β-
carboxylic acid with 2-bromo-1-[18F]fluoroethane as reported elsewhere [2]. The 
radiosynthesis evinced radiochemical yields of > 90% (based on [18F]BFE), the specific 
radioactivity was > 416 GBq/µmol. An average 30 µAh cyclotron irradiation yielded more 
than 2.5 GBq [18F]FE@CIT. Radiochemical purity of [18F]FE@CIT exceeded 96% and total 
amounts of radioactivity up to 2.5 GBq were achieved. 
Enzyme reactions. Experiments were performed in triplicate (n=3), using different amounts 
of ß-CIT, FE@CIT and FP-CIT (ABX GmbH, Radeberg, Germany; 60, 120, 180, 240 and 360 
µmol) with a constant concentration of carboxyl esterase (porcine, E-3019, Sigma-Aldrich, 
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Steinheim, Germany; 24 Units/mg; 80 I.U., 36°C in 500 µl phosphate buffered saline). The 
reactions were stopped by adding the double amount of ice-cold methanol at 0, 60, 120, 
180, 240, 300 and 360 minutes, respectively. After centrifugation (10000 rpm, 3 min) of the 
reaction mixtures, the obtained supernatant was subjected to HPLC analysis (Agilent 1100 
system, Agilent diode array UV detector at 235 nm and 240 nm and a Raytest NaI Socket; 
stationary phase: Merck LiChrospher 100 RP-18 column (5 µm, 250 x 4 mm); mobile phase: 
63% ammonium acetate buffer (0.03M pH 3.5), 30% acetonitrile and 7% ethanol at a flow 
rate of 1 ml/min).  
Autoradiography. In vitro autoradiography was performed on 20 µm coronal brain sections 
(Interaural 7.12mm, Bregma -1.88mm) from male Wistar rats (30 days, 300 g). Frozen brain 
slices were thawed in binding buffer (Tris – HCl 50 mM, pH 7.4) and dried. Subsequently, 
brain sections were incubated with a mixture of 2 nM [123I]ß-CIT, 15 nM [123I]FP-CIT or 2 nM 
[18F]FE@CIT, respectively, in binding buffer. For blocking experiments 7 nM DASB (3-Amino-
4-(2-dimethylaminomethyl-phenylsulfanyl)-benzonitrile; ABX GmbH, Radeberg, Germany) 
and 10 nM nisoxetine (N-151, Sigma-Aldrich) were added to the incubation mixture. 
Incubation was performed for 90 min with activities ranging from 10 to 80 kBq/slice. After 
washing with ice-cold binding buffer and ice-cold water, the dried slices were subjected to 
imaging. Images were analyzed on a Canberra Packard instant imager (Canberra Packard 
Perkin Elmer, Waltham, MA, USA). Semi quantitative analysis was performed with two 
regions of interest (ROIs), one inside (DAT-rich, region 1) and one outside the striatum (DAT-
poor, region 2). Correct location of the ROIs was verified by histochemical counterstaining of 
the vicinal slices. Each obtained value represented the net counts per minute per mm2 for 
each ROI. Calculated ratios were the quotients of the corresponding region 1 and region 2 
for each slice. Thereafter, arithmetic means ± standard deviations were derived for baseline 
and blocked values.  
Statistical calculations were performed with Microsoft Excel 2000, Microsoft Corporation 
(2-tailed unpaired t-test) and Michaelis-Menten kinetics (Michaelis-Menten constants, KM, 
and limiting velocities, vmax) were calculated with GraphPad Prism
 (GraphPad software Inc. 
San Diego, CA, USA) Version 3.00. 
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Results 
Enzyme reactions. Results are presented in figure 2. The in-vitro assays showed Michaelis-
Menten constants of 175 µmol for ß-CIT, 183 µmol for FE@CIT and 521 µmol for FP-CIT, 
respectively. The limiting velocities were comparable: 0.1005 µmol/min (ß-CIT), 0.1418 
µmol/min (FE@CIT) and 0.1308 µmol/min (FP-CIT), respectively.  
Autoradiography. Single values of each experiment of the semi quantitative analysis are 
presented in table 1. Mean values range from 2.0 ± 0.3 (ratio [123I]FP-CIT, blocked) up to 2.4 
± 0.3 (ratio [18F]FE@CIT, baseline) and are also presented in figure 3. Representative 
autoradiographic images for different amounts of [18F]FE@CIT comprising the ROIs are 
shown in figure 4. 
 
Discussion 
General. The history of the evaluation and clinical application of DAT-ligands ranges back to 
the late 1980s [6], and a broad variety of radioligands have been introduced so far for PET 
and SPECT [7]. DAT-ligands mostly base on a tropane structure and exhibit different affinities 
for the central monoamine transporters DAT, SERT (serotonin transporter) and NET 
(norepinephrine transporter). However, for distinct imaging of the DAT, a high affinity for 
the DAT and selectivity DAT over SERT and DAT over NET is a prerequisite. [18F]FE@CIT, 
being one of the DAT-ligands displaying highest affinity and selectivity [3] radiolabelled with 
fluorine-18, has been introduced by our group recently [2]. Since a successful radioligand is 
characterized by (1) its affinity for the target (pharmacodynamics) and (2) its fate through 
the organism on its way to the target (pharmacokinetics and metabolism), these 
characteristics have to be resolved prior to clinical application. Since [123I]ß-CIT and [123I]FP-
CIT have found their way into routine clinical practice, we decided to evaluate [18F]FE@CIT in 
comparison to those well established radioligands. 
Enzyme reactions. Carboxyl esterases are prominent enzymes in vivo and are widely 
responsible for phase I metabolism of drugs [9]. Therefore, the estimation of the stability of 
drugs against these carboxyl esterases is desirable. It is well known, that carboxylesterases 
from different species show different quantitative behaviour (different Michaelis-Menten 
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constants with the same substrates) [10]. However, porcine carboxyl esterase used in these 
experiments – as compared to human carboxyl esterase – shows little qualitative deviation 
but operates significantly faster. Hosokawa et al found that porcine carboxyl esterases – due 
to similar catalytic properties of its isoenzymes – proved of value as a good model for human 
enzymatic hydrolysis [10]. Since we evaluated the stabilities of [123I]ß-CIT, [18F]FE@CIT and 
[123I]FP-CIT in a comparative manner and bearing short half-lives of positron emitters in mind 
we chose faster porcine carboxyl esterase for our purposes.  
Seibyl et al. showed acid cleavage as a major metabolic route for FP-CIT [11]. The Michaelis-
Menten constant represents the dissociation constant (affinity for substrate) of the enzyme-
substrate complex. Low values indicate that the enzyme-substrate complex is held together 
very tightly and rarely dissociates without the substrate first reacting to form product. The 
method used in the present experiments is a well established tool for the estimation of the 
stability of drugs against these enzymes [12] already introduced for PET tracers as well [13]. 
As shown in figure 2, the carboxyl esterase stabilities of [123I]ß-CIT and [18F]FE@CIT are 
comparable, whereas [123I]FP-CIT displays significantly increased carboxyl esterase stability 
compared to ß-CIT (p < 0.01) and FE@CIT (p < 0.05). One explanation could be the fact that 
in the FP-CIT molecule a more bulky fluoropropyl moiety is attached at the tropane 
substructure which could obstruct carboxylesterases from approaching to the ester bond. An 
even bulkier moiety is attached to the tropane in the PE2I structure, but there, it was shown 
recently that the para-methyl group is the primary target for metabolism (figure 1, number 
(4)) [1]. Since these radioactive metabolites were also found in brain, kinetic modelling could 
be complicated. Hence, an optimized DAT-ligand should not carry a methyl group in the para 
position of the phenyl ring. The method presented here using carboxyl esterases could 
facilitate the future design of PET tracers carrying ester functions by simply mimicking the 
main metabolic in-vivo route by a fast in-vitro method. Comparative knowledge of the 
metabolic pattern in-vitro could influence the schedule of forthcoming animal experiments. 
Autoradiography. The selectivity of DAT ligands versus SERT and NET is an important 
prerequisite for clinical appropriateness and “some degree of selectivity could be assumed 
from ratios of β-CIT and FP-CIT binding sites in the striatum and the cortex” [14]. From the 
obtained ratios, selectivity DAT/SERT and DAT/NET can be estimated. Amounts of 
radioactivity were selected in a range from 10 kBq up to 80 kBq per slice to measure the 
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influence of activity concentration on the binding characteristics. Single values presented in 
table 1 explicitly exclude that our results are biased by amount of radioactivity. On our semi-
quantitative analysis we observed comparable ratios for baseline experiments (see figure 3): 
Comparing [18F]FE@CIT with [123I]ß-CIT yielded a p-level of 0.45, comparing [18F]FE@CIT with 
[123I]FP-CIT yielded a p-level of 0.83. Based on these findings, selectivity advantages of 
neither ligand could be predicted. Calculating ratios obtained after blocking NET and SERT, 
the values of [18F]FE@CIT were significantly higher than those of [123I]ß-CIT (p = 0.02) and 
[123I]FP-CIT (p = 0.01). Therefore, our experiments revealed a significantly higher DAT-
selectivity of [18F]FE@CIT using autoradiography which is in line with the findings presented 
by Gu et al [3] using an in-vitro binding assay. The authors described there a higher affinity of 
FE@CIT for DAT (Ki 0.93 nM) versus ß-CIT (Ki 1.33 nM) and FP-CIT (Ki 8.29 nM) and a higher 
DAT/SERT and DAT/NET selectivity for FE@CIT. This higher selectivity of FE@CIT compared 
to the other DAT-ligands was reproduced by our experiments using semi quantitative 
autoradiography.  
 
Conclusion 
We found, that (1) the metabolic stability of FE@CIT was comparable to that of ß-CIT, 
whereas FP-CIT showed a significantly higher stability against carboxylesterases; and (2) the 
overall uptake pattern of [18F]FE@CIT on native rat brain slices was comparable to that of 
[123I]ß-CIT and [123I]FP-CIT. After blocking of NET and SERT-binding, a significantly higher 
DAT-selectivity was observed for [18F]FE@CIT. The chemical structure of [18F]FE@CIT avoids 
the formation of radioactive metabolites passing the blood-brain-barrier. Hence, 
[18F]FE@CIT may be of value for further clinical application. 
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Captions 
 
Figure 1. Chemical structures of (1) ß-CIT, (2) FE@CIT and (3) FP-CIT. Red arrows indicate the 
ester bond to be cleaved by carboxylesterase, green arrow indicates the found major 
metabolic route for PE2I. 
Figure 2. Michaelis-Menten kinetics of (A) FE@CIT, (B) ß-CIT and (C) FP-CIT: Points represent 
the mean values of triplicate analyses. vmax is the limiting velocity and KM is the Michaelis-
Menten constant. 
Figure 3. Target/non-target binding ratios of native (red bars) and blocked (yellow bars) rat 
brain slices after semi quantitative autoradiographic analysis (ratio of net counts/mm2). 
Columns represent arithmetic means, error bars represent standard deviations. Significance 
levels are indicated by grey brackets. 
Figure 4. Representative autoradiographic images of [18F]FE@CIT comprising the ROIs for 
semi quantitative analysis. Autoradiographies were developed simultaneously under the 
same conditions. Colour code represents relative intensity levels as given by the 
autoradiograph (linear scale). 
Table 1. Semi quantitative analysis of autoradiographies of [18F]FE@CIT, [123I]ß-CIT and 
[123I]FP-CIT. Each value represents the net counts per minute per mm2 for each ROI (mean 
value ± SD). Ratios are the quotients of the corresponding DAT-rich and DAT-poor Regions 
for each slice. 
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Figure 1. Chemical structures of (1) ß-CIT, (2) FE@CIT, (3) FP-CIT and (4) PE2I. Red arrows 
indicate the ester bond to be cleaved by carboxylesterase, green arrow indicates the found 
major metabolic route for PE2I. 
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Figure 2. Michaelis-Menten kinetics of (A) FE@CIT, (B) ß-CIT and (C) FP-CIT: Points represent 
the mean values of triplicate analyses. vmax is the limiting velocity and KM is the Michaelis-
Menten constant. 
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Figure 3. Target/non-target binding ratios of native (red bars) and blocked (yellow bars) rat 
brain slices after semi quantitative autoradiographic analysis (ratio of net counts/mm2). 
Columns represent arithmetic means, error bars represent standard deviations. Significance 
levels are indicated by grey brackets. 
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Figure 4. Representative autoradiographic images of [18F]FE@CIT comprising the ROIs for 
semi quantitative analysis. Autoradiographies were developed simultaneously under the 
same conditions. Colour code represents relative intensity levels as given by the 
autoradiograph (linear scale). 
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Table 1. Semi quantitative analysis of autoradiographies of [18F]FE@CIT, [123I]ß-CIT and 
[123I]FP-CIT. Each value represents the net counts per minute per mm2 for each ROI (mean 
value ± SD). Ratios are the quotients of the corresponding DAT-rich and DAT-poor Regions 
for each slice. 
 
NET CPM/mm
2 DAT-rich region DAT-poor region ratio 
activity [MBq] baseline blocked baseline blocked baseline blocked 
0.01 41±4 29.5±1.4 17.4±5.4 11.8±2.6 2.4±0.5 2.6±0.4 
0.04 166±14 91.6±9.7 76±11 39.3±7.3 2.2±0.5 2.4±0.2 
0.08 312±24 218±24 121.2±3.0 103±23 2.6±0.1 2.2±0.5 
mean mean [1
8
F]
-F
E
@
C
IT
 
 
2.4 ± 0.3 2.4 ±0.3 
 
0.01 2.1±0.2 1.7±0.6 1.2±0.1 0.9±0.2 1.8±0.1 1.9±0.4 
0.04 6.8±0.8 4.3±1.0 3.2±0.4 2.2±0.3 2.2±0.4 2.0±0.3 
0.08 13.4±1.5 11.3±2.1 5.1±1.4 5.5±1.3 2.7±0.5 2.1±0.4 
mean mean [1
2
3
I]
-ß
-C
IT
 
 
2.2 ± 0.5 2.0 ±0.4 
 
0.01 1.9±0.9 2.4±1.4 1.0±0.4 1.4±1.1 1.8±0.3 1.9±0.3 
0.04 10.6±4.9 5.2±2.1 4.5±2.4 2.6±1.0 2.5±0.7 2.0±0.2 
0.08 17.1±4.8 12.2±6.2 6.1±1.6 6.7±4.5 2.8±0.3 2.0±0.6 
mean mean [1
2
3
I]
-F
P
-C
IT
 
 
2.4 ± 0.6 2.0 ±0.3 
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2.3. DISCUSSION 
PET is the first choice technology for the visualization and quantification of receptors and 
transporters, allowing observation of physiological and pathophysiological conditions on a 
molecular level. New and innovative PET-radiopharmaceuticals need to be developed, to get 
further insights into the biochemical mechanisms involved in pathological changes. A 
suitable PET-tracer requires different parameters as e.g. high affinity and high specificity 
towards the dedicated target site, low lipophilicity and preferably also low unspecific 
binding. In addition, the degree of metabolization and degradation of the desired PET-tracer 
is of highest importance: radioactive metabolites might interfere with the target itself, and 
would lead to undesirable enhanced binding signal. Moreover, the binding kinetics of the 
investigated molecule has a major impact on the suitability of the tracer. So, in fact, all these 
prerequisites have to be considered and validated in the development and evaluation 
process of new PET-tracers.  
Hence, two major tools are crucial in the development process of new PET-tracers:  
1) a reliable production method and, even more important, an automated set-up, to assure 
save and reliable radiochemical preparation of the PET-radiopharmaceutical, and to keep the 
radiation burden of the operator to a minimum. Moreover, an automated radiosynthesis 
also serves as a prerequisite for the save and reliable routine production for the preclinical 
evaluation process, which leads to point 2:  
2) proof of tracer suitability (high affinity, high selectivity and specificity, beside low 
unspecific binding) through preclinical evaluation in an animal model, prior to human 
application.  
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1) Reliable production method/automatisation: 
In the thesis, both radionuclides, C-11 and F-18, were used for the description of the PET-
tracer development process: On the one hand, the short half-lived nuclide C-11 (20.3min), 
which requires quick handling, and an indirect synthetic route using gasous methyliodide, 
leading to an automated preparation method described in paper 1 ([11C]DASB), was used. On 
the other hand, the longer half-lived nuclide F-18 (109.2min), which allows longer synthetic 
procedures, including liquid chemistry, was used for the production of [18F]FE@SUPPY and 
[18F]FE@SUPPY:2 via direct fluorination methods, and was further used for a fluorination 
method via synthon ([18F]FE@CIT).  
A) [18F]FE@SUPPY-derivatives 
[18F]FE@SUPPY:2, a completely new potential [18F]fluoroethylated radiotracer for the A3R, 
has been successfully prepared (paper 2) and, furthermore, even an automated method for 
this tracer has been presented in this thesis. [18F]FE@SUPPY was introduced as the first A3R 
PET tracer recently, and the automation of its radiosynthesis was also covered in this thesis. 
Both automations, and, moreover, also a comparison of the parameters of the two tracers 
were described in paper 3 in the scientific topic section. In summary, both radiotracers were 
prepared in a feasible and reliable manner via direct radiofluorination. Automated 
preparations were performed on a GE TRACERlab FxFN synthesizer module within 70-80 
minutes. The radiochemical purities exceeded 97% in accordance with the regulations of the 
European pharmacopoeia. Sufficient overall yields and radiochemical purity for preclinical 
and potential future clinical investigations were achieved.  
Differences were observed concerning the amount of precursor molecules: [18F]FE@SUPPY:2 
needed higher amounts (about a double) of precursor, leading to 3-fold lower radiochemical 
yields, in comparison to [18F]FE@SUPPY. Interestingly, specific radioactivity of 
[18F]FE@SUPPY:2 was 5-fold higher than for [18F]FE@SUPPY. This fact seems very promising, 
since for investigations concerning receptors and transporters, high specific radioactivity is 
important. On the other hand, [18F]FE@SUPPY:2 showed sluggish behaviour in the 
radiochemical preparation procedure, which seems not so favourable.  
B) [18F]FE@CIT 
Radiochemical preparation of [18F]FE@CIT was not yet automated. 
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C) [11C]DASB 
Concerning the first manuscript, the radiosynthesis of the innovative SERT PET-tracer 
[11C]DASB was optimized towards a fully-automated, rapid and simple preparation, in order 
to provide this tracer for the neuroimaging of SERT-associated psychiatric disorders as e.g. 
depression. For routine application, the production of a radiotracer has to fulfil more 
requirements than just high yields and purity, therefore, a fully-automated synthetic 
procedure was developed, which also reduces the radiation burden for the operator. 
Although, this method was still prepared in a short overall production time, the failed 
syntheses rate remained extremely low.  
According to the successfull implementation of the fully-automated set-up, clinical and 
scientific studies were conducted with [11C]DASB at the PET-Center of Vienna in cooperation 
with the neuroimaging-group of Doz. Lanzenberger. First baseline results revealed, after 
injected radioactivity between 158 and 510 MBq of [11C]DASB, high serotonin transporter 
density in the striatum, thalamus, midbrain, raphe region (see figure 38). Medium serotonin 
transporter levels were found in the cingulate cortex. 
 
Figure 38: Distribution of the serotonin transporter in the human brain. Triplanar view (sagittal, 
coronal, axial sections), the blue cross indicates corresponding slices. The color table indicates the 
binding potential value. 
First results of a clinical study with [11C]DASB, where depressive patients were treated with 
SSRIs, are given in figure 39.  
It is satisfying to observe that the very methodical approach in the synthesis lab allows for 
the successful application in a clinical trial. Even more pleasant, if the clinical study allows for 
general answers in clinical questions.  
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Figure 39: SERT occupancy during treatment with SSRIs: the SERT binding is given before treatment 
(baseline), 6 hours after a single therapeutic dose, and after a treatment period of several weeks 
(multiple doses) in patients suffering from major depression (the parametric data are mean values 
of 18 patients). 
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2) Proof of tracer suitability - preclinical evaluation: 
Biodistribution 
A) [18F]FE@SUPPY-derivatives 
Highest uptake of [18F]FE@SUPPY was found in liver, pronounced uptake in kidney, lung and 
heart, whereas in brain only intermediate to low uptake was observed. Highest uptake of 
[18F]FE@SUPPY:2 was found in bowels and liver, pronounced uptake in kidney and heart, low 
uptake in fat, lung, spleen and brain. Biodistribution of these two tracers showed good 
correlations in brain, muscle and testes. The blood to brain ratio remained stable over time 
for [18F]FE@SUPPY:2 and increased over time for [18F]FE@SUPPY.  
B) [18F]FE@CIT & C) [11C]DASB 
Biodistribution experiments have not been conducted with these two tracers. 
Metabolic stability 
A) [18F]FE@SUPPY-derivatives 
Regarding the metabolic characterisation, both [18F]FE@SUPPY-derivatives belong to the 
class of dialkylpyridines, and comprise two ester functions within one molecule. Therefore, 
carboxylesterases were expected to significantly contribute to cleavage and degradation. 
The expected increased stability of the derivative [18F]FE@SUPPY:2, the isomer with the 18F-
label at the thiocarboxylic ester function, was not observed. Both, in in-vitro 
carboxylesterase studies, as well as in ex-vivo metabolite studies in rat blood and brain, 
revealed higher stability of [18F]FE@SUPPY. In blood, 15 minutes p.i. 50% of [18F]FE@SUPPY 
and 30% of [18F]FE@SUPPY:2 were intact; and 30 minutes p.i. 30% of [18F]FE@SUPPY and 
15% of [18F]FE@SUPPY:2 were still intact. In brain an early hydrophilic metabolite was 
observed for [18F]FE@SUPPY:2. For [18F]FE@SUPPY a radioactive metabolite in brain was not 
observed before 30 min p.i. Altough, structurally closely related, the pathway of CES 
degradation was different for the tracers. Enzyme reaction studies revealed cleavage of 
FE@SUPPY to DFE@SUPPY, and cleavage of FE@SUPPY:2 to FE@SUPPY:21.  
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B) [18F]FE@CIT  
In-vitro enzymatic assays revealed comparable stability of FE@CIT and ß-CIT, whereas FP-CIT 
was significantly more stable. 
C) [11C]DASB 
Metabolic stability experiments have not been conducted with this tracer in our group. 
Autoradiographic studies 
A) [18F]FE@SUPPY-Derivatives 
For the autoradiographic studies with the two A3R tracers, a selection of commercially 
available adenosine receptor ligands was used, as listed in table 3. 
 Compound Receptor-
subtype 
Ligand Affinity [nM] Selectivity Species 
DPCPX  A1 Antagonist Ki=0.46 
152 740 fold vs A1 rat 
SCH442416  A2A Antagonist Ki=0.048 
153 
Ki=0.5 
23000 fold for 
hA2A vs hA1 
human 
rat 
MRS1754  A2B Antagonist Ki=1.13 
154   
2-Cl-IB-Meca A3 Agonist Ki=0.33 
155 2500 vs A1 
1400 vs A2A 
 
MRS1523  A3 Antagonist Ki=18.9 
156 
Ki=113 
 human 
rat 
MRS 1191  A3 Antagonist Ki=31.4 
157  rat & 
human 
[125I]AB-Meca  A3 Agonist Kd=0.59 
50  human 
 
Table 3: Selection of commercially available adenosine receptor ligands 
 172 
First preliminary results of the autoradiographic distribution of [18F]FE@SUPPY were 
presented recently54. Then, highest binding of [18F]FE@SUPPY was then found in nucleus 
accumbens and caudate putamen and little uptake was observed in cortical regions in rat 
brain slices. Highly selective binding of [18F]FE@SUPPY was shown by displacement of 2-Cl-
IB-MECA, a selective blocking agent for the A3R. According to E.E. Bennaroch, the A3R is 
distributed in hippocampus and cerebellum in low and medium abundance7, which we could 
partly confirm in further experiments on rat brain slices, so far (see figure 40, figure 41). 
Blockings were conducted with the adenosine ligands given in Table 3.  
 
 
Figure 40: First autoradiographic results of [18F]FE@SUPPY and [125I]AB-MECA on rat brain slices: 
a) shows the distribution of [18F]FE@SUPPY in baseline and under blocking conditions 
b) shows the distribution of [125I]AB-MECA in baseline and under blocking conditions 
 
 
 
 
Figure 41: Fusion of a [125I]AB-MECA distribution of the A3R (since blocked with the dedicated A1, 
A2A and A2B compounds) with the histological picture of a rat brain slice. 
a) 
b) 
 173 
In summary, first findings revealed that FE@SUPPY competed the well known A3R agonist 
[125I]AB-MECA completely, which is not true for the commercially available A3R antagonist 
MRS1523 (see figure 38b).  FE@SUPPY:2 also competed [125I]AB-MECA in a comparable 
range to FE@SUPPY (data not shown). Binding of [18F]FE@SUPPY revealed high uptake in the 
hippocampal formation and was competed with Cl-IB-MECA and FE@SUPPY. 
 
All in all, the two novel [18F]labelled ligands for the A3R displayed some very good and 
important properties as suitable A3R PET-tracers: e.g. high affinity and selectivity. On the 
other hand, the octanol/water partition coefficient (as a measure of lipophilicity of the 
tracers), was determined using an HPLC essay based on the work of Donovan and 
Pescatore158 and was found to be between 4 and 5 (HPLClogP=4 at a pH 7.4; clogP=5.81). This 
high lipophicity was also reflected in the observed high unspecific binding in a rat model. 
Hence, the two tracers seem (from the momentary point of view) not to be so favorable to 
apply them to humans in the future.  
But, since the A3R shows large interspecies differences, especially between rodents and 
human, rats don´t seem to be a very suitable animal model for the examination of A3R 
studies. It also has to be pointed out that many authors state, one amongst them K.A. 
Jacobson, that, since the A3R appears only in low densities and in a disease specific manner, 
it is especially challenging to asses them in-vivo159. Moreover, Prof. Schubiger showed in a 
rat model, that the well known imaging agent [18F]FDG, which is widely used for brain 
imaging of various conditions in humans, didn´t show uptake in the brain of wild-type rats 
(see figure 42). Since, [18F]FE@SUPPY displays much lower affinity towards the rat A3R 
(Ki=600nM) than towards the human A3R subtype (Ki=4.2nM), there is still hope and a lot to 
explore in humanized animal models and e.g. post-mortem human brain slice 
autoradiography.  
 
 
 
 174 
 
 
Figure 42: Stunning observation, that [18F]FDG uptake was found in the brain of Wistar rats (a) , but 
not in the brain of Brown-Norway rats (b).160  
 
B) [18F]FE@CIT  
Baseline uptake of [18F]FE@CIT on rat brain slices was comparable with the uptake of [123I]ß-
CIT and [123I]FP-CIT. Under blocking conditions, [18F]FE@CIT revealed significant higher DAT-
selectivity than the other two tracers. Detailed results of the autoradiographic analyisis of 
[18F]FE@CIT are given in the specific topic section in paper 5. In summary, the high selectivity 
of [18F]FE@CIT over SERT and NET was confirmed in this study, and furthermore, this 
selectivity was significantly higher than selectivity of the well known tracers [123I]ß-CIT and 
[123I]FP-CIT. 
C) [11C]DASB 
Autoradiographic experiments have not been conducted with this tracer by our group.  
 
b) a) 
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3. CONCLUSION AND OUTLOOK 
The development and preclinical evaluation of 4 different PET-tracers for 3 targets, the DAT, 
the SERT and the A3R, respectively, were covered in the present thesis. The presented 
method for a fast and reliable radiosynthesis of [11C]DASB will facilitate further clinical 
investigations with this tracer. [18F]FE@SUPPY:2 was prepared successfully and in a feasible 
and reliable manner. Preclinical evaluations of the two novel [18F]labelled ligands for the A3R 
were conducted and the evinced parameters allowed a first estimate upon their suitability as 
A3R PET-tracers. [18F]FE@CIT was successfully evaluated in terms of metabolic stability 
against CES and autoradiographic distribution on rat brain slices.  
Future implementations and investigations  
 [11C]DASB will be rapidly prepared according to the presented method in the first 
manuscript, and is currently used for neuroimaging of the 5-HTT in scientific and clinical 
psychiatric trials with special interest in e.g. patients with attention-deficit hyperactivity 
disorder (ADHD) and serotonin transporter changes in steroid hormone treatment (e.g. high-
level long-term administration of opposite sex steroid hormones in transsexuals).  
Regarding the results of the manuscripts 2-4, [18F]FE@SUPPY and [18F]FE@SUPPY:2 served as 
PET-tracers for the A3R and revealed valuable results for ongoing in-vitro studies concerning 
the visualization and quantification of the A3R. From the present point of view, a clinical 
application of these two PET-tracers in humans cannot be seen. However, results are only 
evinced from rodents and due to the large interspecies differences of the A3R (especially 
between human and rats), there is a lot left to discover in e.g. post mortem human tissue 
slices or other humanized models. 
Future emphasis will be on the reduction of the high lipophilicity of our title compounds: 
more hydrophilic structural analogues, [18F]FE@SUPPY:11 and [18F]FE@SUPPY:21, are at the 
present in radiochemical preparation and will come into the preclinical evaluation process as 
soon as possible. Simultaneously we are working on improvements of the radiosyntheses via 
microfluidics and on improvements of the autoradiographic and micro-PET experiments.  
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Based on the results of the fifth paper, we aim for the future diagnostic application of 
[18F]FE@CIT in humans with neurological and psychiatric diseases caused by changes in the 
dopaminergic system (e.g. Parkinson’s disease, depression, drug abuse). The broad field of 
application of this tracer and its excellent DAT over SERT selectivity will provide an essential 
benefit for patients and medical research focused on drug development in this field. 
 
 
 178 
 
 
 
 
 
 
 
 
 
 
PART 4 
 
APPENDIX 
 
 
 
 
 
 
 179 
4. APPENDIX 
 
4.1. CURRICULUM VITAE 
 
Mag. pharm. Daniela Häusler 
Personal Information 
Nationality: Austria 
Date & Place of Birth: 04.12.1982, Vienna 
Email: daniela.haeusler@meduniwien.ac.at 
Education 
2006-2010 PhD-thesis, University of Vienna & Medical University of Vienna 
2000-2006  Study of Pharmacy at the University of Vienna; passed with distinction 
1992-2000  High School “Realgymnasium Perchtoldsdorf”, diploma passed with distinction 
1988-1992  Elementary School, Vienna 
Internships and professional experience 
2009   tutor for “Pharmazeutisches Grundpraktikum” at the Department of 
Pharmaceutical Technology and Biopharmaceutics, Vienna 
2007   Introductory Course in Laboratory Animal Science, Veterinary Medicine of 
Vienna 
  Practical training at the Institute of Brain Research, University of Vienna 
2003   Clinical traineeship in acupuncture at the Chinese-Japan Friendship Hospital, 
Beijing, China 
2001-2005  Practical training at the Pharmacy “Birkenapotheke”, Vienna 
1998-2006  Sports trainer at the “Sport Union Perchtodsdorf” and “VHS Liesing” 
Scholarship 
2007-2009  DOC-fFORTE, Austrian Academy of Sciences 
 180 
Award 
2009  4th THP award of the Austrian Society of Nuclear Medicine and Molecular 
Imaging for Basic Sciences in the field of nuclear medicine 
Memberships 
European Association of Nuclear Medicine (EANM) 
Österreichische Gesellschaft für Nuklearmedizin (OGN) 
Practical supervision of diploma theses: 
Practical supervision of the diploma thesis of Ms. Hoda El Samahi for the study project 
“Biopharmazeutische Aspekte bei der Evaluierung von FE@SUPPY”, of the diploma thesis of 
Ms. Stefanie Pupeter for the study project “Zell-Bindungsstudien zur präklinischen 
Evaluierung von PET-Tracern am Beispiel des Adenosin A3 Rezeptor Liganden 18F-
FE@SUPPY”and of the diploma thesis of Ms. Elisabeth Szerencsics for the study project 
“Präklinische Evaluierungen von [18F]FE@SUPPY and [18F]FE@SUPPY:2 anhand von 
Autoradiographien”. 
Personal Interests 
Kundalini-Yoga, Dancing, Swimming, Rock climbing, Sailing, Kayaking, Skiing 
Scientific publications 
Peer reviewed research articles: 
D. Haeusler, L.Nics, L.-K. Mien, J. Ungersboeck, R. R. Lanzenberger, K.Shanab, K. M. Sindelar, 
H. Viernstein, K.-H.Wagner, R. Dudczak, K.Kletter, W.Wadsak, M.Mitterhauser. [18F] 
FE@SUPPY and [18F]FE@SUPPY:2 - Metabolic considerations. Nucl Med Biol 2010, in press  
D. Haeusler, M. Mitterhauser, L.-K. Mien, K. Shanab, R. R. Lanzenberger, E. Schirmer, J. 
Ungersboeck,  L. Nics, H. Spreitzer, H. Viernstein, R. Dudczak, K. Kletter, W. Wadsak. 
Radiosynthesis of a novel potential adenosine A3 receptor ligand 5-ethyl 2,4-diethyl-3-((2-
[18F]fluoroethyl) sulfanylcarbonyl)-6-phenylpyridine-5-carboxylate ([18F]FE@SUPPY:2). 
Radiochim Acta 2009; 97: 753-758 
D. Haeusler, L.-K. Mien, L. Nics, J. Ungersboeck, C. Philippe, R.R. Lanzenberger, K. Kletter, R. 
Dudczak, M. Mitterhauser, W. Wadsak. Simple and rapid preparation of [11C]DASB with high 
quality and reliability for routine applications. Appl Radiat Isot 2009 Mar; 67: 1654-1660  
M. Mitterhauser, D. Haeusler, L.-K. Mien, J. Ungersboeck, L. Nics, R. R. Lanzenberger, K. 
Sindelar, H. Viernstein, R. Dudczak, K. Kletter, H. Spreitzer, W. Wadsak. Automatisation and 
first evaluation of [18F]FE@SUPPY:2, an alternative PET-Tracer for the Adenosine A3 
Receptor: A Comparison with [18F]FE@SUPPY. TO Nucl Med J 2009 May;1: 15-23 
D. E. Ettlinger, D. Haeusler, W. Wadsak, F. Girschele, K. M. Sindelar, L. K. Mien, J. 
Ungersböck, H. Viernstein, K. Kletter, R. Dudczak, M. Mitterhauser. Metabolism and 
Autoradiographic Evaluation of [18F]FE@CIT: A Comparison with [123I]ß-CIT and [123I]FP-CIT. 
Nucl Med Biol 2008 May;35(4):475-9. 
 181 
Wadsak W., Mien L. K., Shanab K., Weber K., Schmidt B., Sindelar K.M., Ettlinger D.E., 
Haeusler D., Spreitzer H., Keppler B.K., Viernstein H., Dudczak R., Kletter K., Mitterhauser M. 
The radiosynthesis of the adenosine A3 receptor ligand 5-(2-[18F]fluoroethyl) 2,4-diethyl-3-
(ethylsulfanylcarbonyl)-6-phenylpyridine-5-carboxylate ([18F]FE@SUPPY). Radiochim Acta 
2008;96:119-24. 
W. Wadsak, L. K. Mien, K. Shanab, D. E. Ettlinger, D. Haeusler, K. Sindelar, R. R. 
Lanzenberger, H. Spreitzer, H. Viernstein, B. K. Keppler, R. Dudczak, K. Kletter, M. 
Mitterhauser. Preparation and first evaluation of [18F]FE@SUPPY: a new PET-Tracer for the 
Adenosine A3 Receptor. Nucl Med Biol. 2008 Jan;35(1):61-6 
Toegel S., Wadsak W., Mien L.K., Viernstein H., Kluger R., Eidherr H., Haeusler D., Kletter K., 
Dudczak R., Mitterhauser M. Preparation and pre-vivo evaluation of no-carrier-added, 
carrier-added and cross-complexed [68Ga]-EDTMP formulations. Eur. J. Pharm. Biopharm. 
2008 Feb;68(2):406-12 
Wadsak W., Mien L.K., Ettlinger D.E., Eidherr H., Haeusler D., Sindelar K.M., Keppler B.K., 
Dudczak R., Kletter K., Mitterhauser M. [18F]Fluoroethylations: Different strategies for the 
rapid translation of [11C]methylated Radiotracers. Nucl Med Biol 2007;34:1019-28. 
Wadsak W., Mien L.K., Ettlinger D. E., Lanzenberger R. R., Haeusler D., Dudczak R., Kletter K., 
Mitterhauser M. Simple and fully automated preparation of [carbonyl-11C]WAY-100635. 
Radiochim Acta 2007; 95:417-422. 
Oral presentations :  
D.Haeusler, L.K.Mien, L.. Nics, J. Ungersboeck, W. Wadsak, C. Kuntner, T. Wanek, R. R. 
Lanzenberger, H. Viernstein, R. Dudczak, K. Kletter, M. Mitterhauser. The adenosine A3 
receptor PET-tracers, [18F]FE@SUPPY and [18F]FE@SUPPY:2 –the story goes on! 
Nuklearmedizin 2009; 48: 215-242, S. A142 
D. Haeusler, L.K. Mien, L. Nics, J. Ungersboeck, W. Wadsak, F. Girschele, C. Kuntner, T. 
Wanek, R. R. Lanzenberger, H. Viernstein, R. Dudczak, K. Kletter, M. Mitterhauser. 
[18F]FE@SUPPY – the first PET tracer for the Adenosine A3 receptor. Eur J Nucl Med 2009, in 
press 
D. Haeusler, K.M. Sindelar, L-K. Mien, J. Ungersboeck, L. Nics, F. Girschele, C. Kuntner, T. 
Wanek, H. Viernstein, R. Duczak, K. Kletter, W. Wadsak, M. Mitterhauser. [18F]FE@SUPPY:2 - 
ex-vivo Metaboliten. Nuklearmedizin 2008; 47: 225-274, S. A152 
D. Haeusler, W. Wadsak, L.K. Mien, D.E. Ettlinger, K.M. Sindelar, R.R. Lanzenberger, C. 
Kuntner, H. Viernstein, R. Dudczak, K. Kletter, M. Mitterhauser. In vivo and in vitro 
evaluation of [18F]FE@SUPPY. Nuklearmedizin 2007; 46:233-301, S. A148 
 
 182 
4.2. REFERENCES 
                                                      
1 Poulsen SA. Quinn RJ. Adenosine receptors: New opportunities for Future Drugs. 1998 Bioorg Med 
Chem.6:619-641. 
2 Müller CE., Scior T. Adenosine receptors and their modulators. 1993 Pharma Acta Helv. 68:77-111 
3 George SR. Twenty Questions. 2004 Nature drug discovery; 3:577-626. 
4 Morris AJ. Malbon CC. Physiological Regulation of G Protein-Linked Signaling. 1999 Physiol. Rev; 
79:1373-1430. 
5 Armstrong JM. et al. Gene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in 
murine T-lymphocytes: Studies of cells from A2A-receptor-gene-deficient mice. 2001 Biochem J; 
354(Pt.1):123-130. 
6 http://phylogenomics.berkeley.edu/AnimalProteome/gpcr_banner.jpg (28.01.2010) 
7 Benarroch EE. Adenosine and its receptors: Multiple modulatory functions and potential 
therapeutic targets for neurologic disease. 2008 Neurology; 70:231-236. 
8 Fredholm BB. et al. Structure and function of adenosine receptors and their genes. 2000 Arch 
Pharmacol; 326:364-374. 
9 Klotz KN. Adenosine receptors and their ligands. 2000 Arch Pharmacol; 362:382-391. 
10 Zhao Z et al. Characterisation of the mouse A3 adenosine receptor gene: exon/intron organization 
and promotor activiy. 1999 Genomics; 57:152-155.  
11 Fredholm BB. et al. Nomenclature and classification of purinoceptors. 1994 Pharmacol Rev; 46:143-
156. 
12 Fredholm BB. et al. Towards a revised nomenclature for P1 and P2 receptors. 1997 Trends 
Pharmacol Sci; 18:79-82. 
13 Fredholm B.B. et al. International Union of Pharmacology.XXV.Nomenclature and Classification of 
Adenosine Receptors. 2001 Pharmacol Rev; 53:527-552. 
14 Drury AN., Szent-Györgyi A. The physiological activity of adenine compounds with especial 
reference to their action upon the mammalian heart. 1929 J Physiol; 68:213-237. 
 183 
                                                                                                                                                                      
15 Sattin A., Rall TW. The effect of adenosine and adenine nucleotides on the cyclic adenosine 3`, 5`-
phosphate content of guinea pig cerebral cortex slices. 1970 Mol Pharmacol; 6:13-23. 
16 Ralevic V, Burnstock G. Receptors for purines and pyrimidines. 1998 Pharmacol Rev; 50:413-492. 
17 Wilson CN., Mustafa SJ. Adenosine receptors in health and disease. Handbook of experimental 
Pharmacology 193. 2009 Springer-Verlag Berlin Heidelberg; 1-24. 
18 Fredholm BB. et al. Actions of caffeine in the brain with special reference to factors that contribute 
to its widespread use. 1999 Pharm Rev; 51:83-133. 
19 Mobbs C. Caffeine and the adenosine receptor: Genetics trumps pharmacology in understanding 
pharmacology. 2005 Cellscience; 2:1-6. 
20 Dunwiddie TV., Masino SA. The role and regulation of adenosine in the central nervous system. 
2001 Annu Rev Neurosci; 24: 31-55. 
21 Cerqueira MD. Advances in pharmacologic agents imaging new A2A receptor agonists. 2006 Curr 
Cardiol Rep; 8:119-122. 
22 Jacobson KA., Gao ZG. Adenosine receptors as therapeutic targets. 2006 Nature rev drug discovery; 
5: 247-264. 
23 Meyerhof W. et al. Molecular cloningof a novel putative G-protein coupled receptor expressed 
during rat spermiogenesis. 1991 FEBS Lett; 284:162-172. 
24 Linden J. et al. Molecular cloning and functional expression of a sheep A3 adenosine receptor with 
widespread tissue distribution. 1993 Mol Pharmacol; 44:524-532. 
25 Sajjadi FG., Firestein GS. cDNA cloning and sequence analysis of the human A3 adenosine receptor. 
1993 Biochim Biophys Acta; 1179:105-107. 
26 Salvatore CA. et al. Molebular imaging and characterization of the human A3 adenosine receptor. 
1993 Proc Natl Acad Sci USA; 90:10365-10369. 
27 Monitto CL. et al. Localization of the A3 adenosine receptor gene (ADORA3) to human 
chromosome 1p. 1995 Genomics; 26:637-638. 
28 Atkinson MR. et al. Cloning, characterisation and chromosomal assignment of the human 
adenosine A3 receptor (ADORA3) gene. 1997 Neuroscience Research; 29:73-79. 
 184 
                                                                                                                                                                      
29 www.ncbi.nlm.gov/nuccore/ 
NC_000001.10?from=112021939&to=112110628&strand=true&report=graph (28.01.2010) 
30 Gessi S. et al. Pharmacological and biochemical characterization of A3 adenosine receptors in Jurkat 
T cells. 2001 Br J Pharmacol; 134:116-26. 
31 Merighi S. et al. Pharmacological and biochemical characterization of adenosine receptors in the 
human malignant melanoma A375. 2001 Br J Pharmacol; 134:1215-26. 
32 Suh BC. et al. Pharmacological characterization of adenosine receptors in PGT-beta mouse pineal 
gland tumour cells. 2001 Br J Pharmacol; 134:132-42. 
33 Gessi S. et al. A3 adenosine receptors in human neutrophils and promyelocytic HL60 cells: a 
pharmacological and biochemical study. 2002 Mol Pharmacol; 61:415-24. 
34 Fishman P. et al. A3 adenosine receptor as a target for cancer therapy. 2002 Anticancer Drugs; 
13:1-8. 
35 Fishman P. et al. Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate 
carcinoma cell growth by A3AR agonist. 2003 Anticancer Res; 23:2077-83. 
36 Christofi FL. et al. Differential gene expression of adenosine A1, A2A, A2B, and A3 receptors in the 
human enteric nervous system. 2001 J Comp Neurol; 439:46-64. 
37 Fishman P. et al. A3 adenosine receptor as a target for cancer therapy. 2002 Anticancer Drugs; 
13:1-8. 
38 Liang BT., Jacobson K. A. A Physiological role of the adenosine A3 receptor: Sustained 
cardioprotection. 1998 Proc Natl Acad Sci U.S.A.; 95:6995-6999. 
39 von Lubitz DK.et al. Stimulation of adenosine A3 receptors in cerebral ischemia. Neuronal death, 
recovery, or both? 1999 Ann. N.Y. Acad. Sci.; 890:93-106. 
40 Avila MY. et al. Knockout of A3 adenosine receptors reduces mouse intraocular pressure. Invest. 
2002 Opthalmol. Visual Sci.; 43:3021-3026. 
41 von Lubitz DK. et al. Right thing at a wrong time? Adenosine A3 receptors and cerebroprotection in 
stroke. 2001 Ann N Y Acad Sci.; 939:85-96. 
42 Laudadio MA., Psarrapoulou. The A3 receptor agonist 2-Cl-IB-MECA facilitates epileptiform 
discharges in the CA3 area of immature rat hippocampal slices. 2004 Epilepsy Res; 59:83-94. 
 185 
                                                                                                                                                                      
43 Lopes LV. et al. Adenosine A3 receptors are located in neurons of the rat hippocampus. 2003 
Neuroreport.; 26:1645-8. 
44 Okada M. et al. Effects of adenosine receptor subtypes on hippocampal extracellular serotonin 
level and serotonin reuptake activity. 1997 J Neurochem; 69:2581-8. 
45 Sawynok J. Adenosine receptor activation and nociception. 1998 Eur J Pharmacol; 347:1-11. 
46 Zhu CB. et al. Adenosine receptor, protein kinase G, and p38 mitogen-activated protein kinase-
dependent up-regulation of serotonin transporters involves both transporter trafficking and 
activation. 2004 Mol Pharmacol.; 65:1462-74. 
47 Di Chiara G. Dopamine in the CNS II. Handbook of experimental pharmacology 154/II. 2002 
SpringerVerlag Berlin Heidelberg New York; 135-150. 
48 Macek TA. et al. Protein kinase C and A3 adenosine receptor activation inhibit presynaptic 
metabotropic glutamate receptor (mGluR) function and uncouple mGluRs from GTP-binding proteins. 
1998 J Neurosci.; 18:6138-46. 
49 Baraldi PG. et al. Adenosine receptor antagonists: Translating medicinal chemistry and 
pharmacology into clinical utility. 2008 Chem Rev; 108:238-263. 
50 Olah ME. et al. 125I-4-Aminobenzyl-5´-N-methylcarboxamidoadenosine, a high affinity radioligand 
for the rat A3 adenosine receptor. 1994 Mol Pharmacol; 45:978-982. 
51 Varani K. et al. [3H]MRE 3008F20: A novel antaonist radioligand for the pharmacological and 
biochemcial characterisation of human A3 adenosine receptors. 2000 Mol Pharmacol; 57:968-975. 
52 Li AH. et al. Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2, 4-dialkylpyridine 
derivatives as selective A3 adenosine receptor antagonists. 1999 J Med Chem; 42:706-21. 
53 Wadsak W. et al. The radiosynthesis of the adenosine A3 receptor ligand 5-(2-[18F]fluoroethyl)2,4-
diethyl-3-(ethylsulfanylcarbonyl)-6-phenylpyridine-5-carboxylate ([18F]FE@SUPPY). 2008 Radiochim 
Acta; 96:119-24. 
54 Wadsak W. et al. Preparation and first evaluation of [18F]FE@SUPPY: a new PET-Tracer for the 
Adenosine A3 Receptor. 2008 Nucl Med Biol; 35:61-6.  
55 Beuming T. et al. The binding sites for cocaine and dopamine in the dopamine overlap. 2008 
Nature Neuroscience; 11:780–789. 
 186 
                                                                                                                                                                      
56 Shih MC. et al. Parkinson´s disease and dopamine transporter neuroimaging- a critical review. 2006 
Sao Paulo Med J; 124: 168-75. 
57 Asanuma K. et al. Assessment of disease progression in parkinsonism. 2004 J Neurol; 251 Suppl 
7:vII4-8. 
58 Brooks DJ. et al. Assessment of neuroimaging techniques as biomarkers of the progression of 
Parkinson's disease. 2003 Exp Neurol; 184 Suppl 1:S68-79. 
59 Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how 
close is it? 2003 Mov Disord; 18 Suppl 7:S43-51. 
60 Meyer JH. et al. Lower dopamine transporter binding potential in striatum during depression. 2001 
Neuroreport; 12:4121-4125. 
61 Logan J. et al. Concentration and occupancy of dopamine transporters in cocaine abusers with 
[11C]cocaine and PET. 1997 Synapse; 27: 347-356. 
62 Piccini PP. Dopamine transporter: basic aspects and neuroimaging. 2003 Mov Disord; 18 Suppl 
7:S3-8. 
63 Wilcox KM. et al. Self-administration of cocaine and the cocaine analog RTI-113: relationship to 
dopamine transporter occupancy determined by PET neuroimaging in rhesus monkeys. 2002 
Synapse; 43:78-85. 
64 Fowler JS. et al. [11C]Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter 
availability and dopamine transporter occupancy. 2001 Nucl Med Biol; 28:561-572. 
65 Tupala E. et al. Dopamine D2 receptors and transporters in type 1 and 2 alcoholics measured with 
human whole hemisphere autoradiography. 2003 Hum Brain Mapp; 20:91-102. 
66 Volkow ND. et al. Mechanism of action of methylphenidate: insights from PET imaging studies. 
2002 J Atten Disord; 6 Suppl 1:S31-43. 
67 Volkow ND. et al. Relationship between blockade of dopamine transporters by oral 
methylphenidate and the increases in extracellular dopamine: therapeutic implications. 2002 
Synapse; 43:181-187. 
68 Learned-Coughlin SM. et al. In vivo activity of bupropion at the human dopamine transporter as 
measured by positron emission tomography. 2003 Biol Psychiatry; 54:800-805. 
 187 
                                                                                                                                                                      
69 Wilson AA. et al. [18F]fluoroalkyl analogues of the potent 5-HT1A antagonist WAY 100635: 
Radiosyntheses and in vivo evaluation 1996 Nucl Med Biol; 23:487–490. 
70 Lundkvist C. et al. [18F]β-CIT-FP is superior to [11C]β-CIT-FP for quantitation of the dopamine 
transporter 1997 Nucl Med Biol; 24:621-627. 
71 Wilson AA. et al. Synthesis of two radiofluorinated cocaine analogues using distilled 2-
[18F]fluoroethyl bromide 1993 Appl Radiat Isot; 46:765-770. 
72 Gu X-H. et al. Synthesis and biological evaluation of a series of novel N- or O-fluoroalkyl derivatives 
of tropane: potential positron emission tomography (PET) imaging agents for the dopamine 
transporter. 2001 Bioorg Med Chem Lett; 11:3049-3053. 
73 Günther I. et al. [125I]ß-CIT-FE and [125I]ß-CIT-FP are superior to [125I]ß-CIT for dopamine transporter 
visualization: autoradiographic evaluation in the human brain. 1997 Nucl Med Biol; 24:629-634. 
74 Kula NS. et al. [3H]beta-CIT: a radioligand for dopamine transporters in rat brain tissue  1999 Eur J 
Pharmacol; 385:291-4. 
75 Lavalaye J. et al. [123I]FP-CIT binding in rat brain after acute and sub-chronic administration of 
dopaminergic medication. 2000 Eur J Nucl Med; 27:346-349. 
76 Bergström KA. et al. The Metabolite Pattern of [123I]ß-CIT Determined with a Gradient HPLC 
Method. 1995 Nucl Med Biol; 22:971-976. 
77 Chaly T. et al. Radiosynthesis of [18F] N-3-Fluoropropyl-2-ß-Carbomethoxy-3-ß-(4-Iodophenyl) 
Nortropane and the First Human Study with Positron Emission Tomography. 1996 Nucl Med Biol; 
23:999-1004. 
78 Coenen HH. et al. N.c.a. radiosynthesis of [123,124I]ß-CIT, plasma analysis and pharmacokinetic 
studies with SPECT and PET. 1995 Nucl Med Biol; 22:977-984. 
79 Mitterhauser M. et al. In vivo and in vitro evaluation of [18F]FETO with respect to the 
adrenocortical and GABAergic system in rats. 2003 Eur J Nucl Med Mol Imaging; 30:1398-1401. 
80 Mitterhauser M. et al. Biological evaluation of 2´-[18F]fluoro flumazenil ([18F]FFMZ), a potential 
GABA receptor ligand for PET. 2004 Nucl Med Biol; 31:291-295. 
81 Mitterhauser M. et al. Synthesis and Biodistribution of [18F]FE@CIT, a new potential tracer for the 
Dopamine Transporter. 2005 Synapse, 55:73-79. 
 188 
                                                                                                                                                                      
82 Emond P. et al. PE2I: a radiopharmaceutical for in vivo exploration of the dopamine transporter. 
2008 CNS Neurosci Ther; 14:47-64. 
83 Shih MC. et al. Parkinson´s desease and dopamine transporter neuroimaging- a critical review. 
2006 Sao Paulo Med J; 124:168-75. 
84 Pavese N., Brooks DJ. Imaging neurodegeneration in Parkinson´s disease. 2009 Biochim Biophys 
Acta; 1972:722-729. 
85 De Bruyne S. et al. Synthesis, radiosynthesis and in vivo evaluation of [123I]-4-(2-(bis(4-
fluorophenyl)methoxy)ethyl)-1-(4-iodobenzyl)piperidine as a selective tracer for imaging the 
dopamine transporter. 2009 J Labelled Comp Radiopharm; 52:304-311. 
86 Frazer A., Hensler JG. "Chapter 13: Serotonin Receptors". From: Siegel GJ et al (eds) Basic 
Neurochemistry: Molecular, Cellular, and Medical Aspects. 1999 Philadelphia: Lippincott-Raven. pp. 
263–292. 
87 Murphy DL., Lesch K-P. Targeting the murine serotonin transporter: insights into human 
neurobiology. 2008 Nature Review Neuroscience; 9:85-96. 
88 Akimova E. et al. The serotonin-1A receptor in anxiety disorders. 2009 Biol Psychiatry;66(7):627-
635. 
89 Hurlemann R. et al. 5-HT2A receptor density is decreased in the at-risk mental state. 2008 
Psychopharmacology;195(4):579-590. 
90 Joyce J N. et al. Serotonin uptake sites and serotonin receptors are altered in the limbic system of 
schizophrenics. 1993 Neuropsychopharmacol; 4:315-36. 
91 Ichimiya T. et al. Serotonin transporter binding in patients with mood disorders: a PET study with 
[11C](+)McN5652. 2002 Biol Psychiatry; 9:715-22. 
92 Owens MJ. et al. Role of serotonin in the pathophysiology of depression: focus on the serotonin 
transporter. 1994 Clin Chem; 2:288-95. 
93 Meyer J H. et al. Occupancy of serotonin transporters by paroxetine and citalopram during 
treatment of depression: a [11C]DASB PET imaging study. 2001 Am J Psychiatry; 11: 1843-9. 
94 Reivich M. et al. PET brain imaging with [11C](+)McN5652 shows increased serotonin transporter 
availability in major depression. 2004 J Affect Disord; 2: 321-7. 
 189 
                                                                                                                                                                      
95 Meyer JH. et al. Brain serotonin transporter binding potential measured with carbon 11-labeled 
DASB positron emission tomography: effects of major depressive episodes and severity of 
dysfunctional attitudes. 2004 Arch Gen Psychiatry; 12:1271-9. 
96 Parsey RV. et al. Lower serotonin transporter binding potential in the human brain during major 
depressive episodes. 2006 Am J Psychiatry; 1:52-8. 
97 Jarret ME. et al. Relationship of SERT polymorphisms to depressive and anxiety symtoms in 
irritable bowel syndrome. 2007 Biol Res Nurs; 2:161-9. 
98 Suehiro M. et al. A PET radiotracer for studying serotonin uptake sites: carbon-11-McN-5652Z. 
1993 J Nucl Med; 1:120-7. 
99 Wilson A A. et al. Novel radiotracers for imaging the serotonin transporter by positron emission 
tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-
(phenylthio)araalkylamines. 2000 J Med Chem; 16:3103-10. 
100 Tarkiainen J. et al. Carbon-11 labelling of MADAM in two different positions: a highly selective PET 
radioligand for the serotonin transporter. 2001 J Labelled Cpd Radiopharm; 44:113–120. 
101 Solbach C. et al. Determination of reaction parameters for the synthesis of the serotonin 
transporter ligand [11C]DASB: Application to a remotely controlled high yield synthesis. 2004 
Radiochim Acta;92: 341-344.  
102 Meyer JH. et al. Brain serotonin transporter binding potential measured with carbon 11-labeled 
DASB positron emission tomography: effects of major depressive episodes and severity of 
dysfunctional attitudes. 2004 Arch Gen Psychiatry; 12:1271-9. 
103 Meyer JH. et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at 
different doses: an [11C]DASB positron emission tomography study. 2004 Am J Psychiatry; 5:826-35.  
104 Meyer JH. et al. Occupancy of serotonin transporters by paroxetine and citalopram during 
treatment of depression: a [11C]DASB PET imaging study. 2001 Am J Psychiatry; 11:1843-9. 
105 Parsey RV. et al. Metabolite considerations in the in vivo quantification of serotonin transporters 
using 11C-DASB and PET in humans. 2006 J Nucl Med; 11:1796-802. 
106 Parsey RV. et al. Lower serotonin transporter binding potential in the human brain during major 
depressive episodes. 2006 Am J Psychiatry; 1:52-8. 
 190 
                                                                                                                                                                      
107 Schonbachler R. et al. Synthesis and 11C-Radiolabelling of a Tropane Derivative Lacking the 2beta-
Ester Group: a Potential PET Tracer for the Dopamine Transporter. 1999 J Labelled Cpd Radiopharm;  
42:447-456  
108 Larsen P. et al. Synthesis of [11C]iodomethane by iodination of [11C]methane. 1997 Appl Radiat 
Isot; 48:153-157. 
109 van Dort ME, Tluczek L. Synthesis and carbon-11 labeling of the stereoisomers of meta-
hydroxyephedrine (HED) and meta-hydroxypseudoephedrine (HPED) 2000 J Label Cpd Radiopharm; 
43(6): 603-612. 
110 Langer O, Gulyás B. et al. Radiochemical labelling of the dopamine D3 receptor ligand RGH-1756. 
2000 J Label Cpd Radiopharm; 43:1069 - 1074. 
111 Coenen HH.et al. Preparation of N.C.A. [18F]-CH2BrF via aminopolyether supported nucleophilic 
substitution. 1986 J Label Compd Radiopharm; 23:587. 
112 Bergman J. et al. Automated synthesis and purification of [18F]bromofluoromethane at high 
specific radioactivity 2001 Appl Rad Isot; 54: 927-933. 
113 Zheng L, Berridge MS. Synthesis of [18F]fluoromethyl iodide, a synthetic precursor for 
fluoromethylation of radiopharmaceuticals 2000 Appl Rad Isot; 52:55-61. 
114 Elsinga PH. et al. Synthesis and evaluation of [18F]fluoroethyl SA4503 and SA5845 as PET ligands 
for the sigma receptor. 2001 J Label Compd Radiopharm; 44:S4 (poster session). 
115 Block D. et al. N.c.a. 18F-fluoroacylation via fluorocarboxylic acid esters. 1987(1988) J Label 
Compd Radiopharm; 25:185–200. 
116 Skaddan MB.et al. Synthesis, [18F]labelling, and biological evaluation of piperidyl and pyrrolidyl 
benzylates as in vivo ligands for muscarinic acetylcholine receptors. 2000 J Med Chem; 43: 4552-62. 
117 Oh SJ.et al. Re-evaluation of 3-bromopropyltriflate as the precursor in the preparation of 3-
[18F]fluoropropylbromide. 1999 Appl Rad Isot; 51:293-97. 
118 Lundkvist C. et al. [18F]beta-CIT-FP is superior to [11C]beta-CIT-FP for quantitation of the 
dopamine transporter. 1997 Nucl Med Biol; 24:621-7. 
119 Chesis PL, Welsh MJ. Comparison of bromo- and iodoalkytriflates for 18F-labelling of amines. 1990 
Appl Rad Isot; 41: 259-265. 
 191 
                                                                                                                                                                      
120 S. Zijlstra, T.J. de Groot, L.P. Kok, G.M. Visser and W. Vaalburg, N-[18F]-Fluoroalkylation of 
noraporphines: microwave versus thermal treatment, Eur J Morphol 33 (1995), pp. 154–157 
121 de Groot TJ. et al. 1-[18F]Fluoro-2-propanol-p-toluenesulfonate: a synthon for the 
preparation of N-([18F]fluoroisopropyl)amines . 1992 Appl Rad Isot; 43:1335-1339.  
122 Goodman MM. et al.  18F-labeled FECNT: a selective radioligand for PET imaging of brain 
dopamine transporters  2000 Nucl Med Biol; 27:1-12. 
123 Gründer G. et al. [18F]Fluoroflumazenil: a novel tracer for PET imaging of human benzodiazepine 
receptors. 2001 Eur J Nucl Med; 28:1463-1470. 
124 Satyamurthy N. et al. (2´-[18F]fluoroethyl)spiperone, a potent dopamine antagonist: Synthesis, 
structural analysis and in-vivo utilization in humans. 1990 Appl Radiat Isot; 41:113-129. 
125 Satyamurthy N. et al. No-carrier-added 3-(2´-[18F]fluoroethyl)spiperone, a new dopamine 
receptor-binding tracer for positron emission tomography 1986 Nucl Med Biol; 13:617-624 
126 Chi DY. et al. Synthesis of no-carrier-added N-([18F]fluoroalkyl)spiperone derivatives. 1986 Int J 
Rad Appl Instr Part A; 37:1173-1180. 
127 Zijlstra S. et al. Synthesis and in vivo distribution in the rat of several fluorine-18 labelled N-
fluoroalkylaporphines. 1993 Appl Radiat Isot; 44:651-658. 
128 Wester HJ. et al. 6-O-(2-[18F]Fluoroethyl)-6-O-Desmethyldiprenorphine ([18F]DPN): Synthesis, 
biologic evaluation, and comparison with [11C]DPN in humans. 2000 J Nucl Med; 41:1279-1286. 
129 Hamacher K, Coenen HH. Efficient routine production of the 18F-labelled amino acid O-(2-
[18F]fluoroethyl)-L-tyrosine. 2002 Appl Radiat Isot; 57:853-856. 
130 Suehiro M. et al. Radiosynthesis and biodistribution of the S-[18F]fluoroethyl analog of McN5652. 
1996 Nucl Med Biol; 23:407-412. 
131 Tang G. et al. Pharmacokinetics and radiation dosimetry estimation of O-(2-[18F]fluoroethyl)-L-
tyrosine as oncologic PET tracer. 2003 Appl Radiat Isot; 58: 219-225. 
132 Chin FT. et al.  Syntheses and applications of three 18F-fluoroalkylating agents in a commercial 
automated radiosynthesis apparatus 2003 J Label Compd Radiopharm; 46:S172. 
133 Skaddan MB.et al. Synthesis, [18F]labelling, and biological evaluation of piperidyl and pyrrolidyl 
benzylates as in vivo ligands for muscarinic acetylcholine receptors. 2000 J Med Chem; 43:4552-62. 
 192 
                                                                                                                                                                      
134 Zhang MR. et al. How to increase the reactivity of [18F]fluoroethylbromide: [18F]fluoroethylation of 
amine, phenol and amide functional groups with [18F]FEtBr, [18F]FEtBr/NaI and [18F]FetOTf. 2003 J 
Label Comp Radiopharm; 46: 587-598. 
135 Schirrmacher R. et al. Syntheses of novel N-([18F]fluoroalkyl)-N-nitroso-4-methyl-
benzenesulfonamides and decomposition studies of corresponding 19F-and bromo-analogues: 
potential new compounds for the 18F-labelling of radiopharmaceuticals. 2003 J Label Compd 
Radiopharm; 46: 959-977. 
136 Lu SY. et al. Efficient O- and N-(fluoroethylations) with NCA [18F]fluoroethyl tosylate under 
microwave-enhanced conditions. 2004 J Label Compd Radiopharm; 47: 289-297. 
137 Comagic S. et al. Efficient synthesis of 2-bromo-1-[18F]fluoroethane and its application in the 
automated preparation of 18F-fluoroethylated compounds. 2002 Appl Radiat Isot; 56: 847-851. 
138 Zhang MR. et al. Development of an automated system for synthesizing 18F-labelled compounds 
using [18F]fluoroethylbromide as a synthetic precursor. 2002 Appl Radiat Isot; 57:335-342. 
139 Wadsak w. et al. [18F]-fluoroethylations: different strategies for the rapid translation of 11C-
methylated radiotracers. 2007 Nucl Med Biol; 34:1019-1028. 
140 http://www.abx.de/ (ABX Radeberg, Germany) 
141 Shanab K. et al. Synthesis of in vivo metabolites of the new adenosine A3 receptor PET-radiotracer 
[18F]FE@SUPPY. 2008 Heterocycles; 75:77-86. 
142 http://www.abx.de/ (ABX Radeberg, Germany) 
143 Wadsak W. et al. Radiosynthesis of the adenosine A3 receptor ligand 5-(2-[
18F]fluoroethyl)2,4-
diethyl-3-(ehtylsulfanylcarbonyl)-6-phenylpyridine-5-carboxylate ([18F]FE@SUPPY). 2008 Radiochim. 
Acta; 96:119-24 .  
144 Radiopharmaceutical Preparations (Radiopharmaceutica, 5.0/0125). In: European Pharmacopoeia 
(Europäisches Arzneibuch). 5th edition (5. Ausgabe Grundwerk), official Austrian version. 2005b 
Vienna:Verlag Österreich GmbH; p.823-831. 
145 Bergström M. et al. Autoradiography with Positron Emitting Isotopes in Postitron Emission 
Tomography Tracer Discovery. 2003 Mol Imag Biol; 3(6):390-396. 
146 Mitterhauser M. et al. Synthesis and biodistribution of [18F]FE@CIT, a potential tracer for the 
dopamine transporter. 2005 Synapse; 55:73-79 
 193 
                                                                                                                                                                      
147 Mitterhauser M. et al. In vivo and in vitro evaluation of [18F]FETO with respect to the 
adrenocortical and GABAergic system in rats. 2003 Eur J Nuc Med Mol Imaging; 30:1398-1401. 
148 Pawelke B. Metabolite analysis in positron emission tomography studies: examples from food 
sciences. 2005 Amino Acids; 29:377-388. 
149 Ishiwata et al. Metabolite analysis of [11C]flumazenil in human plasma: assessment as the 
standardized value for quantitative PET studies. 1998 Ann Nucl Med; 12:55-59. 
150 Picture taken from a presentation of Dr. M. Berger 
151 Pictures taken from a presentation of Dr. M. Berger 
152 Bruns RF. et al. Binding of the A1-selective adenosine antagonist 8-cyclopentyl-1,3-
dipropylxanthine to rat brain membranes. 1987 Arch Pharmacol; 335(1):59-63. 
153 Toddle et al. Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in 
vivo imaging of the adenosine A2A receptor system using positron emission tomography. 2000 J Med 
Chem; 43:4359. 
154 Kim Y-C. et al. Anilide derivatives o fan 8-Phenylxanthine carboxylic congener are highly potent 
and selective antagonists at human A2B adenosine receptors. 2000 J Med Chem; 43: 1165-1172. 
155 Kim H.O. et al. 2-Substitution of N6-benzyladenosine-5´-uronamides enhances selectivity for A3 
adenosine receptors. 1994 J Med Chem; 37:3614−3621. 
156 Li AH. et al. Structure-activity relatonships and molecular modeling of 3,5-diacyl-2,4-
dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. 1998 J Med Chem; 
41:3186-3201. 
157 Jiang JL. et al. 6-phenyl-1,4-dihydropyridine derivatives as potent and selective A3 adenosine 
receptor antagonists. 1996 J Med Chem; 39:4667-4675. 
158 Donovan SF, Pescatore MC. Method for measuring the logarithm of the octanol-water partition 
coefficient by using short octadecyl-poly(vinyl alcohol) high-performance liquid chromatography 
columns. 2002 J Chromatogr A; 952:47-61. 
159 Wilson CN., Mustafa SJ. Adenosine receptors in health and disease. Handbook of experimental 
Pharmacology 193. 2009 Springer-Verlag Berlin Heidelberg; 635. 
160 Picture thankfully received from Prof. Schubiger 
